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Abstract
Pharmacological therapy of anal fissures reduces maximum resting pressure (MRP), 
allowing healing by promoting anodermal vascular perfusion. In this thesis the clinical 
and manometric responses to diltiazem and botulinum toxin and the therapeutic potential 
of indoramin and salbutamol were investigated. A porcine internal anal sphincter model 
was developed to validate the responses to pharmacological agents.
Of 33 patients with anal fissures with higher MRP than in 20 controls [110 (77-227) vs. 
88 (46-175) cmH20 , P<0.05], the fissures healed in 19 (58%) after a two-month course 
of diltiazem, [110 (77-195) vs. 81 (53-147) cmH20, PO.OOOl]. Those with unhealed 
fissures [111 (77-227) vs. 92 (56-136) cmH20, PO.Ol] received another course. At four 
months in 18 (75%) of 20 the fissures healed; 12 [114 (88-195) vs. 113 (51-142) cmH20, 
P=0.07] that had healed initially and 6 [102 (77-227) vs. 109 (47-134) cmH20, P=0.50] 
of 8 after a second course. At six months the fissures healed in 13 (90%) of 15 patients 
[110 (77-144) vs. 125 (53-161) cmH20, P=0.63]. While 58% of fissures with high MRP 
healed with diltiazem, 42% did not despite reduction in MRP; a subgroup with normal 
MRP healed although MRP remained unchanged.
A “no-needle” delivery, evaluated by injecting methylene blue in porcine anal sphincters 
allowed maximal instillation into the IAS at 60% to the horizontal axis, was employed to 
inject 25 Units botulinum toxin on either side of the fissure in 10 patients. At one week 
MRP [99 (71-185) vs. 81 (37-166) cmH20, PO.01] and pain scores [6 (3-8) vs. 4 (1-8), 
P<0.001] were reduced. At three months 5 (50%) fissures healed.
Oral indoramin (20mg) reduced MRP at one hour in 10 volunteers [85 (46-136) vs. 63 
(36-117) cmH20 , P<0.005] and 10 patients with anal fissures [131 (94-227) vs. 88 (57- 
169) cmH20, P<0.0001] and the reduction was sustained for three hours. The results 
were similar with oral salbutamol (4mg) [94 (47-175) vs. 65 (44-101) cmH20, PO.01] 
and [144 (97-194) vs. 101 (78-181) cmH20, P<0.005]. Salbutamol caused tremors in 9
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subjects and was not investigated further. In 8 volunteers topical indoramin in paraffin 
base (lOmg, 20mg, 30mg and 40mg) applying each dose on different days, like placebo 
had no effect after one or three hours [P=NS, ANOVA].
Porcine IAS muscle tissue was morphologically similar to human tissue and maintained a 
spontaneous tone. Histamine and phenylephrine induced concentration-dependent 
contractions; isoprenaline induced relaxation. Glyceryl trinitrate (GTN) at a 
concentration of 2.2x1 O'4, 6.6x1 O'4 and 2.2x1 O'3 M caused mean relaxation of 14.9%, 
28.7% and 35.3%. L-NAME (N(G)-nitro-L-arginine methyl ester) abolished 
acetylcholine mediated relaxation due to muscarinic relaxation with nitric oxide. 
Adenosine triphosphate-induced relaxation was enhanced by the purinoceptor antagonist 
suramin. Indoramin reduced phenylephrine induced contraction suggesting an effect on 
<xi adrenoceptors. Prazosin reduced histamine induced IAS contraction. Nitric oxide was 
the predominant but not the sole neurotransmitter for inducing relaxation, as there was 
some relaxation on electrical field stimulation (EFS) after the addition of L-NAME. The 
EFS responses in hypertonic in vitro porcine IAS caused by phenylephrine, were 
investigated to explain failure of fissures to heal with agents that reduce sphincter tone. 
The residual tone, i.e. the level of tone after EFS in 10 IAS strips was proportional and 
correlated with the level of tone before EFS, (r2 = 0.90, P<0.001, d.f. =120) and after 
GTN [2.2x1 O'4, 6.6 xlO-4, 2.2x10-3 M] and diltiazem [lxl0*4 M] was also proportional to 
the tone before treatment [r^=0.95, d.f.=21; r2=0.87, d.f.=20; f*=0.72, d.f.=20; r*=0.90', 
d.f.=25 respectively]. Hence fissures do not heal despite reduced MRP because the 
ischaemic threshold, above which there is inadequate perfusion of the anoderm is not 
reached.
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CHAPTER ONE
INTRODUCTION
1.1. DEFINITION AND AETIOLOGY OF AN ANAL FISSURE
An anal fissure is a split in the skin of the distal anal canal. It is a lesion of comparatively 
minor pathological importance and its underlying cause remains a clinical curiosity. 
Young adults of both sexes are equally affected [Bennett and Goligher, 1962] and show a 
varied clinical presentation. Petros et al. (1993) in a retrospective study of 172 patients 
noted that anterior fissures and sentinel piles were more common in women; pruritis and 
rectal drainage mostly occurred in men and patients with a longer duration of symptoms 
and those with pruritis and drainage were more likely to have a fistula. Younger patients 
frequently reported rectal bleeding.
Whilst acute fissures heal spontaneously or with simple therapeutic measures a 
proportion progress to form a chronic linear ulcer [Lund and Scholefield, 1996]. This 
chronicity is perpetuated by hypertonicity of the internal anal sphincter, the underlying 
genesis of which is poorly understood. The difference between an acute and chronic anal 
fissure may be defined in both temporal and pathological terms, although the latter are 
more robust. The features of a chronic anal fissure include the presence of a sentinel 
“pile” distally, a fibroepithelial polyp at the apex, rolled edges and visible fibres of the 
internal anal sphincter at the base of the fissure.
Most anal fissures are idiopathic with no identifiable underlying disease process [Lund 
and Scholefield, 1996; Schouten et al., 1996a] and there is no simple and unified theory 
to explain their genesis. Ball (1908) believed that the anal canal mucosa tears from a
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shearing force exerted by a constipated stool leaving a linear laceration of the anoderm 
extending from the dentate line to the anal verge. However not all patients who develop 
fissures have experienced constipation [Keighley and Williams, 1993]. Ball stated the 
tearing down of an anal valve is important, but this is not true as an intact valve is seen at 
the proximal end of a fissure [Motson, 1985]. Jensen (1988) interviewed 174 patients in 
order to identify dietary risk factors, and noted significantly decreased risk with frequent 
consumption of raw fruits, vegetables, and wholegrain bread whilst an increased risk was 
noted with foods with little dietary fibre. Oh et al (1995) investigated the aetiological 
factors in 1,391 patients of whom 1,313 had idiopathic fissures thought to arise from 
underlying inflammation. They speculated that as it was common to find stool trapped in 
the perianal folds, ammonia generated from the entrapped stool with chloride from sweat 
caused skin irritation and inflammation around the anus, and the passage of stool through 
the inflamed anal canal lead to tearing of the anal skin. Other aetiological factors in this 
study included surgery, trauma and subluxation of the anus. Whilst Oh et al. (1995) 
proposed inflammation in genesis of fissures, the progression of acute to chronic fissures 
was not clear. Shafik (1982) hypothesised that fissures became chronic only in patients in 
whom the epithelial remnants of the anorectal sinus were present in the subdermal layer 
of the anal canal. He proposed these remnants resulted in epithelial sequestra that 
harboured infection and prevented healing.
The majority of fissures occur in the posterior midline. Lock and Thomson (1977) 
investigated 188 patients with idiopathic fissures and noted posterior fissures in 142 
(75.6%), anterior fissures in 26 (13.8%), whilst 15 (8%) had posterior and anterior
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fissures and 5 (2.6%) had lateral fissures. Shafik (1982) suggested that there is lack of 
tissue support posteriorly within the anal canal, where a Y-shaped configuration is created 
by the decussation of fibres accounting for the preponderance of posterior fissures. Oh et 
al. (1995) showed that although posterior fissures are more common than anterior ones, 
anterior midline fissures were more common in females where the sphincter muscular 
support was deficient.
Current opinion regarding chronicity of fissures is based on Schouten’s studies (1994, 
1996 a, b, c) on the vasculature of the anoderm. Schouten et al. (1994) described an 
inverse relationship between anal pressure and anodermal blood flow. The perfusion of 
the anoderm at the posterior midline was significantly lower than at the sides of the anal 
canal. Klosterhalfen et al. (1989) and Schouten et al. (1996b) provided evidence to 
demonstrate that the posterior anoderm is a poorly perfused area of the anal canal, which 
perpetuates the chronicity of fissures although there is no firm evidence to demonstrate 
that ischaemia is the sole aetiological factor.
The relationship between pregnancy, childbirth and fissures is unique and is not 
completely understood. Abramowitz et al. (2002) followed 165 patients in the postpartum 
period and identified 25 with anal fissures; dyschezia being the most important risk 
factor. Whilst these patients have fissures that are commonly located anteriorly they are 
often associated with low anal canal pressures [Corby et al., 1997]. Other causes of 
fissures include Crohn’s disease, syphilis, human immunodeficiency virus (HIV), or
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tuberculosis. These are secondary fissures and are most appropriately treated by 
addressing the underlying disease process.
1.2. PHYSIOLOGICAL FEATURES ASSOCIATED WITH AN ANAL 
FISSURE
It is now generally agreed that recognised features common to most chronic anal fissures 
include a high resting anal canal pressure due to hypertonicity of the internal anal 
sphincter (IAS), the presence of “ultraslow” pressure wave activity in the IAS, and 
reduced vascular perfusion index at the site of the anal fissure.
1.2.1. INTERNAL ANAL SPHINCTER ACTIVITY
Early manometric studies of patients with fissures failed to demonstrate high resting 
pressures. Graham-Stewart et al (1961) used a large latex balloon which filled the anal 
canal to investigate 6 subjects and noticed unsteadiness of the pressure compared with 
controls and no significant difference in resting pressure. Duthie and Bennett (1964) 
using a manometric pull through technique with open-end water filled tubes also found 
no difference between patients with fissures and their controls.
Nothmann and Schuster (1974) studied 7 patients with fissures, 10 normal subjects and 7 
patients with irritable bowel syndrome using a triple balloon system. The anal canal
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balloon, representing the IAS tone, showed the resting pressure was twice in patients with 
fissures (85mmHg, range 75 to 100) than in controls (50mmHg, range 25 to 75). There 
was no difference in pressures in the balloon placed to represent the external anal 
sphincter. Hancock (1977) used a small water-filled balloon built into a hollow perspex 
rod and measured anal canal pressure in steps of 1cm from the anal verge in 12 patients 
with anal fissures. The mean maximum resting anal pressure in patients with anal 
fissures (116.8 ± 21.8, s.d., cmH20) was significantly higher than in controls (85.0 ± 
20.5, s.d., cmH20; PO.Ol).
The discrepancies of earlier studies that failed to identify raised anal canal pressure could 
in part be explained by the recording methods used. Graham-Stewart et al. (1961) failed 
to get steady readings in patients with fissures, and Duthie and Bennett (1964) may have 
not used a sufficient perfusion pressure in their recording equipment. Hancock (1976) 
had shown that in a fine perfused recording system the speed of perfusion does influence 
the pressure and motility pattern recorded. Gibbons and Read (1986) attempted to 
eliminate recording bias by investigating the effects of different diameters of probes on 
resting anal canal pressure. The results in 6 patients with fissures exceeded the normal 
range as compared with 14 controls irrespective of the probe size. With the smallest 
probe (0.4cm diameter) the resting pressure in patients was 114 ± 17.1 cmH20 (mean, 
s.d.) compared to 73.1 ± 27.0 cmH20 in controls (mean, s.d.). These results suggested 
that high resting pressures were recordable in patients with fissures even when small 
probes were used and were unlikely to be due to spasm; therefore they probably 
represented a true increase in basal sphincter tone. Lin (1989) examined resting,
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voluntary contraction pressures and sphincter length in 29 patients with chronic anal 
fissures, 50 patients with Grade III or IV haemorrhoids and 36 controls with no anorectal 
symptoms or pathology. The maximal basal pressures in chronic anal fissures, 
haemorrhoids, and controls were 87.4 ± 38.8, 85.3 ± 27.7, and 71.2 ± 24.9 mmHg; the 
maximal contraction pressures were 162.1 ± 64.5, 158.8 ± 58.0, and 132.9 ± 44.9 
mmHg; the lengths of the functional sphincter of the three groups were 3.9 ± 0.6, 3.8 ± 
0.8, and 3.7 ± 0.5 cm. The maximal basal pressures and maximal contraction pressures in 
patients with fissures or haemorrhoids were significantly greater than in the control 
group; whereas the functional sphincter lengths in the three groups showed no significant 
difference.
Hancock (1977) noted that IAS activity in the presence of fissures was abnormal. He 
classified the motility pattern of the IAS during recording into one of three groups: Flat -  
steady anal pressure showing only slow waves; Irregular -  resting pressure unsteady, 
sometimes with marked fluctuations in pressure; Ultra-slow waves -  regular pressure 
waves of amplitude greater than 25 cmH20 and frequency less than 2/min. In the 12 
patients with fissures examined ultraslow pressure waves were present in 10, but only in 
2 of 40 controls fPO.OOl). These waves were thought to represent the chronic 
overactivity of the IAS in association with a fissure. Schouten and Blankensteijn (1992) 
investigated these ultra-slow waves and demonstrated these waves were present in 29 of 
58 patients with fissures and in 2 of 20 controls. The median value of maximum anal 
canal pressure in those patients and volunteers with ultra-slow waves was higher than 
those subjects who did not (158 v 138 cmH20, P<0.05 and 181.5 v 92 cmH20, PO.OOl
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respectively). Two weeks after surgical treatment these ultra-slow waves had disappeared 
in half of the patients, with a reduction in maximum anal canal pressure to the levels in 
control subjects without these waves. The pressure reduction was significantly greater 
than in patients with persistent ultra-slow waves (40% v 15%, P<0.02). The authors 
concluded that these waves were the manifestation of increased activity of the IAS. Keck 
et al (1995) also demonstrated ultraslow wave activity in 11 of 12 patients with chronic 
anal fissures and showed greater amplitude of ultra-slow wave activity as compared with 
controls (31 mmHg v 15 mmHg). They also investigated the high pressure zone/ 
sphincter length ratio in patients and controls and showed this ratio was 58% compared 
with 48% in controls. Interestingly the elevated pressure was not confined to the site of 
the fissure; this led the authors to conclude that the primary abnormality in fissures is 
persistent hypertonia affecting the entire internal sphincter.
Farouk et al. (1994) investigated internal sphincter activity in 30 patients with anal 
fissures, 22 patients with haemorrhoids and 33 controls with ambulatory anal sphincter 
fine-needle electromyography and anorectal manometry. The median internal sphincter 
electromyography frequency was similar in the fissure group, the haemorrhoid group and 
the control group (0.49 Hz, 0.46 Hz (P>0.05), and 0.44 Hz (P>0.05) respectively). The 
median anal resting pressures were similar in the fissure group (132 cmH2 0 ) and the 
haemorrhoid group (116 cmH20, P>0.05), but significantly greater than in the control 
group (94 cmH20, P<0.05). The median number of transient relaxations of the internal 
anal sphincter with an associated rise in rectal pressure was 1 (range, 0-4) per hour in the 
fissure group, 6 (range, 4-7) per hour in the haemorrhoid group, and 4 (range, 3-6) per
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hour in the control group. The investigators were able to only investigate 6 patients with 
fissures following lateral internal sphincterotomy, between 12 and 18 months 
postoperatively. All these fissures had healed. The median anal canal pressure was 102 
cm of H2O (P>0.1 vs. controls) and the number of internal sphincter relaxations increased 
to 4 per hour (P < 0.01 vs. preoperative number). The authors concluded that IAS 
relaxation was less frequent in patients with chronic anal fissures that have failed to heal 
in comparison to patients with haemorrhoids and normal controls. This evidence further 
supported the hypothesis that internal sphincter hypertonia may be relevant to the 
pathogenesis of this disorder.
Kuypers (1983) and later Jost et al. (1995a) have shown the IAS in healthy volunteers 
relaxed in response to rectal distension; the recto-anal inhibitory reflex. Nothmann and 
Schuster (1974) recorded abnormalities of IAS reflex effects in response to rectal 
distension. Whilst there was an initial relaxant response as in controls, in 90% patients 
with fissures as compared with 26% of controls a rebound or “overshoot” contraction was 
noted. There were no changes seen in the external anal sphincter at the time of this 
“overshoot”. The significance of this abnormal response of the IAS was unclear at this 
stage. However this was not a consistent finding as Keck et al. (1995) demonstrated in 
12 patients with chronic anal fissures a normal rectoanal reflex without “overshoot”. 
Reissman et al (1995) evaluated this “overshoot” phenomenon in 37 HIV +ve patients, 
28 of whom were homosexual, 9 who were bisexual, and 7 control HIV -ve patients. It 
was not stated whether the control patients were homosexual or bisexual. All had a 
single posterior fissure except 6 of the 37 HIV +ve patients who had multiple and/or
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lateral fissures. The “overshoot” was absent in 35 (95%) of 37 of HTV +ve patients but 
was present in all HIV -ve patients. The aetiology in 19 patients was determined to be 
due to HIV, cytomegalovirus, herpes simplex virus or from a leukaemic infiltrate. Two 
patients who were HIV +ve and demonstrated the “overshoot” contraction benefited from 
division of the IAS. In the remaining 16 patients no aetiological factors were identified 
and were treated conservatively with debridement, and anal hygiene. The authors 
concluded that the majority of fissures noted in HIV +ve patients are not associated with 
IAS hypertonia or overshoot contraction of the IAS in response to rectal distension. After 
infections have been excluded patients should undergo anorectal manometry to determine 
the truly benign fissures; these may benefit from surgery.
1.2.2. ISCHAEMIC NATURE OF ANAL FISSURES
Klosterhafen et al. (1989) conducted postmortem angiographical analyses of the 
vasculature of the posterior commissure of the anal canal. They demonstrated in 85% of 
nonselected autopsies that the posterior commissure was the end of the capillary system 
of the inferior rectal artery. Schouten et al. (1994) demonstrated an inverse relationship 
between anal pressure and blood flow. They performed doppler laser flowmetry of the 
anoderm combined with anorectal manometry in 178 subjects, consisting of 31 healthy 
volunteers, 23 with fecal incontinence, 17 with haemorrhoids, 9 with anal fissure, and 98 
with other colorectal disorders. They examined anodermal blood flow, flux represented 
as V, in the four quadrants of the anal canal in 16 controls and showed that perfusion of 
the anoderm at the posterior midline was significantly lower than in the other three
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segments (posterior midline: 0.74 ± 0.26 V; left lateral side: 1.68 ± 0.81 V; right lateral 
side: 1.57 ± 0.52 V; anterior midline: 1.48 ± 0.69 V, PO.OOl). Overall they found a 
significant inverse correlation between maximum anal resting pressure and anodermal 
blood flow at the posterior midline (r = -0.616, PO.OOl). In the 9 patients with chronic 
anal fissure, the mean maximum anal resting pressure was 125 ± 26 mmHg, which was 
significantly higher than in patients with haemorrhoids (82 ± 15 mmHg), controls (66 ± 
19 mmHg), and patients with fecal incontinence (42 ± 14 mmHg, PO.OOl), whereas the 
blood flow at the base of the fissure was significantly lower (0.43 ± 0.10 V v 0.57 ±0.19 
V vs. 0.75 ± 0.26 v 1.03 ± 0.34 V). They also demonstrated in 10 patients that during 
anaesthesia the anal pressure dropped from 63 ± 21 mmHg to 32 ± 15 mmHg (P < 0.001), 
whereas the anodermal blood flow at the posterior midline increased from 0.79 ± 0.22 V 
to 1.31 ± 0.35 V (PO.OOl). The authors concluded that anodermal blood flow at the 
posterior midline was less than in the other segments of the anal canal and the perfusion 
of the anoderm at the posterior commissure was strongly related to anal pressure. The 
higher the pressure, the lower the flow. These conclusions led Schouten et al. (1996b) to 
propose that chronic anal fissures were ischaemic ulcers. These ideas were further 
investigated in a recent postmortem topographical count of arteriole density in anal canals 
from 8 cadavers by Lund et al. (1999). They showed a paucity of vessels in the posterior 
quadrant. This helped to bolster Schouten’s ideas on the ischaemic nature of anal 
fissures.
1.2.3. THE EXTERNAL ANAL SPHINCTER
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Few studies have investigated the role of the external anal sphincter in the pathogenesis 
or treatment of chronic anal fissures. Nothmann and Schuster (1974) showed no 
abnormal manometry from a balloon placed to measure the pressure of subcutaneous 
external anal sphincter. Gibbons and Read (1986) also demonstrated no significant 
difference in maximum squeeze pressure between 6 patients with fissures and 14 controls 
(272.8 ± 92.2 v 284.8 ± 59.5 cmFfeO). However Jost et al (1995a) investigating the 
external anal sphincter electromyographically found in 9 of 12 patients studied there was 
overactivity of the external anal sphincter and argued that as a contribution of the resting 
anal pressure arose from the external sphincter treatment directed against this muscle was 
also necessary.
1.3. HISTOPATHOLOGY OF THE INTERNAL SPHINCTER IN AN ANAL 
FISSURE
Miles (1919) in his anatomical studies of haemorrhoids described an area of circular 
fibrosis at the lower end of the anal canal that he coined with the term “pecten band” that 
was not present in a healthy anal canal. He failed to recognise this band as the IAS fibres 
and felt that division of this band was necessary for treatment. We now know that a 
hypertonic IAS is associated with both internal haemorrhoids and fissures and as such this 
“pecten band” is present in both conditions. The “pecten” was initially described by 
Stroud (1896) as an area in the middle third of the anal canal and marked the junction of 
the proctodeum and the hind gut. Abel (1932) sought to clarify the histological nature of
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the “pecten band” associated with anal disease. He agreed that hypertonicity or spasm 
occurring in the alimentary canal produced local passive congestion, which resulted in 
fibrous tissue deposition and that pectenotomy was a curative procedure for treatment of 
this band, but failed to recognise that this band was IAS fibres. Fine and Laws (1940) 
demonstrated the presence of smooth muscle fibres only in biopsies from the region in 
normal volunteers. It was Goligher (1961) who realised that the pecten band was the 
IAS. Petrozzi et al (1967) histologically analysed tissue from 24 resected anal fissures 
and noted loss of substance in the mucosa and in the deeper layers, with an intense 
chronic inflammatory process and acute activity. Brown et al. (1989) sought to clarify the 
histopathology of the IAS in patients with chronic anal fissures. In all 18 patients studied 
fibrosis was evident in the IAS compared with 4 control specimens, and in 16 fibrosis 
was more prominent in the base of the fissure rather than laterally in the IAS. The 
authors suggested that the myositis that is associated with chronic anal fissures may 
explain the spasm and fibrosis.
1.4. TREATMENT OF ANAL FISSURES: CONSERVATIVE MEASURES
The initial approach in the treatment of anal fissures is non-operative. Sharp (1996) 
suggested that an acute anal fissure will heal spontaneously or in response to medical 
therapy with warm baths, stool softeners, bulk laxatives, analgesics, topical anaesthetics 
and reassurance. The severe, constant, commanding pain of a chronic fissure is a more 
difficult to treat. In order to treat the initiating event in the development of fissures, the
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avoidance of constipation has been emphasised. Jensen (1986, 1988) found that 
consumption of certain foods increased the risk of developing a fissure, and that dietary 
bran supplements and warm sitz baths were superior to topically applied local anaesthetic 
or hydrocortisone cream. Jensen (1987) also investigated the maintenance therapy with 
unprocessed bran in the prevention of acute anal fissure recurrence. Patients were 
randomised to either receive placebo, 2.5mg or 5g thrice daily for one year. The 
recurrence rates were 68%, 60% and 16% respectively, and significantly fewer 
recurrences occurred in patients receiving higher dose of dietry bran.
Fries and Reitz (1964) investigated whether medical therapy should be reserved for anal 
fissures of short duration. In 18 patients with fissures of 3 months or less duration 
healing occurred in 9 (50%), whilst in 61 patients with a mean duration of symptoms of 
26.4 months the healing rate was 39.3%. The difference was not significant to reserve 
conservative for fissures of short history only. They reinforced the notion that the 
duration of symptoms did not influence the healing rate; as fissures healed in 15 (38.5%) 
of 39 patients with a history less than 6 months compared with 18 (45%) of 40 with 
symptoms of more than 6 months duration.
Gabriel (1930) recommended practice of regular anal dilatation for the treatment of anal 
fissures. Lock and Thomson (1977) conducted a study in 133 patients who were treated 
with anal dilatation and topical local anaesthetic gel. Healing occurred in 71 (53.4%) 
who were then discharged from further attendance. 58 of these healed patients replied to 
long-term follow-up questionnaires and 33 (56.9%) remained symptom free. The
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presence of a sentinel tag or fibrous anal polyp was the only significant predictor of 
failure to respond to conservative treatment. Gough and Lewis (1983) established a 
randomised clinical trial in 82 patients to assess the value of regular anal dilatation in 
combination with topical local anaesthetic. After 1 month’s treatment 17 (43.6%) of 39 
in the lignocaine gel group had healed compared with 18 (41.9%) of 43 in the group that 
used lignocaine gel and anal dilatation. There was no significant difference in these 
treatment modalities and anal dilatation could therefore not be advocated. However they 
found that a sentinel tag was present in 18 (54.5%) of 33 whose fissures healed on 
conservative therapy compared with 23 (50%) of 46 whose fissure persisted despite 
treatment. Furthermore they suggested abandoning the use of a dilator in favour of 
topical local anaesthetic agents and early lateral sphincterotomy.
McDonald et al. (1983) randomised 81 patients with acute anal fissures for treatment with 
either lignocaine gel and “Normacol” granules or an anal dilator. Of those that returned 
for follow up at 6 weeks 11 (31.4%) in the group that used the dilator compared with 12 
(38.7%) that did not had failed treatment. This difference was not statistically significant 
and reinforced the idea that an anal dilator was of no added value to medical therapy.
Other simple therapeutic measures such as silver nitrate cautery to the fissure, sitz baths, 
and anal dilators have been disappointing. Shub et al. (1978) studied 393 patients treated 
with cautery, suppositories and sitz baths; 44.4% of healed in the short term but 27.2% 
developed recurrent anal fissures over a 5-year follow up period.
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1.5. TREATMENT OF ANAL FISSURES: OPERATIVE STRATEGIES
“Of all structures in the area, one stands out as the king. You can damage, deform, ruin, 
remove, abuse, amputate, maim or mutilate every structure in and around the anus except 
one. The structure is the sphincter ani” [Bomemeier, I960].
Current treatment has aimed at reducing resting anal pressure by diminishing sphincter 
tone and improving blood supply at the site of the fissure, thus promoting the healing rate. 
Hughes (1953) acknowledged that anal spasm prevented the fissure from healing, though 
he mistakenly stated that the base of the fissure was formed by the circular fibres of the 
subcutaneous portion of the external anal sphincter. We know now that these fibres are 
of the internal anal sphincter.
Early operative techniques for the treatment of fissures included lateral sphincterotomy 
(Boyer, 1818), the midline posterior sphincterotomy (Dupytren, 1833), excision of the 
fissure with a triangular piece of perianal skin (Gabriel, 1930), and the simplest of all an 
anal stretch (Recamier, 1838). Goodsall (1892) stated that open anal sphincterotomy 
through the base or near the fissure “invariably cured the fissure”. An early report by 
Martin (1922) recommending subcutaneous sphincterotomy performed blindly in the 
posterior quadrant was not received well. Miles’s (1939) “pectenotomy”, that is the 
division of what he called the pecten band in the lower part of the anal canal, was in fact 
internal anal sphincterotomy as the work by Eisenhammer (1951) and Goligher (1956)
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had shown this band to be the lower fibres of the internal sphincter. The word pecten 
arises from the latin translation of “a comb”.
Eisenhammer (1951) introduced the term “chronic anal contracture” with the misbelief 
that the chronic fissure syndrome became fully established only when the IAS underwent 
changes in contractility. Nevertheless he recognised the failure of anal dilators in treating 
anal fissures, and reintroduced the procedure of “linear internal anal sphincterotomy”, 
aware of the associated risk of incontinence. In his method sphincterotomy was 
combined with anal dilatation with an anal dilator (diameter of 1 7/8 inches) and excision 
of the fissure.
1.5.1. ANAL DILATATION
Manual dilatation of the anus is a simple procedure and previously a popular treatment 
option. Recamier first described it for the management of anal fissure in 1838. Its 
reintroduction by Goligher (1961) and its popularisation by Lord (1968) for third-degree 
haemorrhoids led to its acceptance. Watts et al. (1964) in an early comparison between 
dilatation and internal sphincterotomy recommended the former technique as the first line 
treatment. In MacDonald et a l ’s (1992) group of 46 patients treated by anal dilatation 
the fissures failed to heal in 26 (56.5%); 2 patients experienced major incontinence, 
whilst 9 experienced minor incontinence. The advent of endoanal ultrasonography 
provided an insight as to the degree of damage associated with this procedure. In 12 men 
with faecal incontinence with a mean resting anal canal pressure of 49 ± 3 cmfLO (mean
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± s.e.m.) Speakman et al. (1991) demonstrated by ultrasonography internal anal sphincter 
defects in 11 with a mean fragmentation of 153° of the circumference. There were also 
external anal sphincter defects in 3 patients. Nielsen et al (1993) demonstrated the risk 
of sphincter damage and anal incontinence in a study of 32 patients with a median follow 
up of 4 years (range 2 to 6 years). Anal dilatation resulted in incontinence in 12.5% of 
patients, although sphincteric defect was evident in 65% of 20 patients who underwent 
endoanal endosonography. Strugnell et al (1999) advocated gentle digital dilation of the 
anus (DDA) under total neuromuscular blockade. Over a 15-year period 273 who 
underwent DDA were followed up (median 7.8 years) by a questionnaire or telephone 
interview; none were incontinent; 15 patients had impaired control, 9 (3.8%) followed 
and 6 preceded the treatment. Twenty-three patients in this study who had experienced 
either temporary or permanent impairment, whether or not pre-existing, were invited to 
attend for ultrasonography and manometry. Of 18 examined no sphincteric damage was 
seen, and the manometric studies were normal. The authors advocated care when 
performed by an unsupervised trainee.
1.5.2. INTERNAL ANAL SPHINCTEROTOMY 
Introduction in the Twentieth Century
Eisenhammer (1951) had coined the term “chronic anal contracture” with certain anal 
conditions and for treatment of fissures recommended a 4/5 division of the muscle, and
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total division extending to the circular muscle of the rectum when there was pronounced 
contracture.
By 1959 the “standard internal sphincterotomy”, as described by Eisenhammer had been 
modified to comprise division of only half of the IAS to the dentate line in its lateral or 
posterolateral part. Further division was performed when proximal relaxation of the 
sphincters was required; and complete division of the IAS was deemed necessary in cases 
where pain and spasm were pronounced. Brossy (1965) believed that the chronicity of 
anal fissures was maintained by chronic spasm or contracture of the internal anal 
sphincter and advocated a complete sphincterotomy. Eisenhammer (1959) further 
proposed excision of the hypertrophied papillary polyp above and the external tag 
(sentinel pile) below the fissure and undermining the edges of the fissure to divide the 
tethering fibres. However, it was recognised that secondary chronic anal fissures were 
often associated with normal sphincter tone, and it was imperative to avoid division of the 
IAS in these cases. Quite correctly, Eisenhammer (1959) emphasised a degree of 
conservatism regarding surgery of the anal canal.
Recognition of postoperative functional results
Although internal sphincterotomy was recommended by Morgan and Thompson (1956), 
Lockhart-Mummery (1957) and Goligher (1961); Bennett and Goligher (1962) recognised 
the lack of information on the subsequent effect on anal function. Morgan and Thompson 
(1956) never commented on the functional result in their patients treated by
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sphincterotomy. Goligher (1961) demonstrated that although some patients developed 
impaired control for several weeks eventually anal function returned to normal. Bennett 
and Goligher (1962) reviewed 127 cases of anal fissure treated by sphincterotomy after 3 
months to 6 years. They noted that continence was defective frequently in the first few 
weeks after operation (34% for flatus, and 15% for faeces). This gradually improved 
although at time of interview there was still evidence of defective function (24% for 
flatus, 11% for faeces and 28% had faecal soiling). Whilst the median follow up time 
was not stated 105 cases had been followed for a year and 23 for more than 3 years. 
There was no clear correlation between functional disturbance and the extent of internal 
sphincter division, estimated by reference to the operation notes, and by palpation of the 
gap at the time of review, although only 20 patients had complete sphincterotomies. The 
recurrence rate in the series of 127, measured by recurrence of pain was 7%. It appeared 
that the recurrences occurred after one year. Interestingly Brossy (1965) claimed no 
lasting defect of continence with complete division of the sphincter.
Dilatation vs. sphincterotomy
Watts et al. (1964) compared prolonged (minimum four minutes) dilatation of the anus 
with lateral sphincterotomy in 241 patients (141 patients had lateral sphincterotomy, and 
had been previously reported by Bennett and Goligher (1962)). Follow up was available 
for 95 patients; anal dilatation produced rapid relief of pain, but with symptomatic 
recurrence in 16%. Defects in anal control, which comprised of either incontinence to 
flatus or faeces or soiling, occurred in 28 (31%) of 90 with dilatation as compared with
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43 (34%) of 127 after sphincterotomy. The authors concluded that anal dilatation was the 
procedure of choice and recommended internal anal sphincterotomy in the event of 
recurrence.
Outpatient sphincterotomy
Magee and Thompson (1966) reviewed the results of 139 patients who underwent internal 
anal sphincterotomy as an outpatient procedure with xylocaine local anaesthesia between 
1962 and 1963. In a posterior or posterolateral fissure the muscle incision was at the base 
of the fissure, but was made in the left posterolateral quadrant for an anterior fissure. The 
operation was successful in the majority, but 3% of patients had recurrent fissures on 
examination, and another 9% had pain on defaecation when the stool was hard. Imperfect 
control of faeces and flatus was noted in 3% and 17% respectively, and 41% of patients 
complained of soiling of their underwear. These results were comparable to later reports 
[Khubchandani et al., 1989; Oh et al., 1995].
Effects of posterior sphincterotomy
Hardy (1967) reviewed the results of posterior sphincterotomy in 59 patients. There were 
no recurrences but 9 (15%) patients had some form of incontinence, and 30 (51%) 
complained of some mucous discharge. On examination, 15 patients had a “keyhole 
deformity” posteriorly that was regarded as the cause of mucous discharge, of whom 9 
complained about. Hawley (1969) randomly allocated 18, 32 and 24 patients to anal
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stretch, posterior sphincterotomy or a lateral sphincterotomy respectively. The fissures 
healed in all patients who underwent lateral sphincterotomy, in 30 (92%) who had a 
posterior sphincterotomy and in 13 (72%) after anal stretch. The two patients that 
experienced soiling had a posterior sphincterotomy.
The lateral internal anal sphincterotomy
Parks (1967) in refining the technique of lateral sphincterotomy described dividing the 
lower part of the internal sphincter under vision through a short circumferential incision 
in the skin at the lateral anal verge that was closed by suturing. Notaras (1969) is credited 
for promoting the technique of lateral subcutaneous internal sphincterotomy that Riberio 
(1960) described initially in 112 patients. In this technique the lower part of the internal 
sphincter is divided as in performing a subcutaneous tenotomy by introducing the knife 
blade at the anal verge between the anal canal mucosa and the IAS, then directing the 
cutting edge laterally towards the IAS. Notaras treated 66 patients with immediate relief 
of pain and the fissures healed by 3 weeks. The incidence of faecal soiling was 6%, 
compared to 30% and 41% following posterior internal sphincterotomy reported by 
Bennett and Goligher (1962) and Magee and Thompson (1966) respectively. Hoffman 
and Goligher (1970) reviewed 99 patients who underwent lateral subcutaneous 
sphincterotomy, with a mean follow up period of 11 (range 3 to 24) months. The 
technique involved passing the blade between the internal and external sphincters and 
cutting medially, which differed from Notaras’ technique where the IAS was divided 
from within outwards. One patient had a brisk reactionary haemorrhage, and another
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developed a perianal abscess and subsequent fistula at the site of sphincterotomy. All but 
4 healed by one month. There were 3 (3%) recurrences; one had a further internal 
sphincterotomy, and the other two though completely relieved of anal pain, had 
persistently unhealed anal fissures. Twelve (12%) patients had impaired continence 
and/or soiling. Millar (1971) by incising the lower two-thirds of the internal sphincter in 
a series of 99 patients healed over 80% within two-weeks with no evidence of recurrences 
noted at a follow up period ranging from 3 months to 4 years. He concluded that at that 
time lateral anal sphincterotomy for chronic anal fissure was deemed to be the best 
available treatment.
Which technique of sphincterotomy?
Although there had not been a formal randomised clinical trial comparing the various 
operative techniques lateral internal sphincterotomy was adopted in preference to anal 
dilatation and posterior sphincterotomy. This was a pivotal point in the surgical 
management of anal fissures, as studies then sought to identify several important factors. 
These included either improvement in the operative technique or comparing outcome 
measured by rate of complications, resolution of symptoms, healing and recurrence rates, 
functional impairment and effect on sphincter pressure.
Notaras (1971) treated 82 patients by lateral sphincterotomy. All fissures but 2 (2.4%) 
healed by 3 weeks. At 6 months in a postal survey those that replied, 90% of the total 
group were pain free. Of 73, 4 (5.5%) patients complained of soiling of their
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underclothes 3 weeks after the operation and continued to complain of this symptom at 6 
months. Rudd (1975) carried out open lateral subcutaneous sphincterotomy with the 
patient in the prone jack-knife position, and under lidocaine local anaesthesia the IAS was 
divided with the radial skin incision left open. In a follow up of 3 to 24 months, with an 
undefined median period, there were no recurrences. The fissures healed in all 200 
patients except one, who subsequently was diagnosed with Crohn’s disease. No patient 
developed incontinence to flatus or stool. Bailey et al. (1978) investigated 418 patients 
with anal fissures, some with associated anal disease, who underwent open lateral 
sphincterotomies with a radial incision over a 3 year period. Complications occurred in 
22 (5.3%) patients that included urinary retention (0.2%), bleeding (1%), abscess 
formation (0.7%), fistulae in the sphincterotomy site (1.2%), and incontinence to gas or 
faeces (2.2%) that was minor in all but one who required a sphincteroplasty. Ravikumar 
et al. (1982) carried out subcutaneous lateral sphincterotomy in 60 patients, 45 (75%) of 
whom had posterior fissures. In 40 (67%) the fissures healed within 10 days, in 18 (30%) 
within 10 to 20 days, in the remaining 2 (3.3%) by 5 weeks, and 55 (91.7%) returned to 
work within 48 hours. Only 3 (5%) patients had minor soiling that resolved within three 
weeks. During a minimum of two years follow up there were no complications or 
recurrences. The authors suggested several operative guidelines. Firstly the 
sphincterotomy should be away from the fissure site so that intact mucosal bridges fill the 
gap between divided muscle fibres to allow rapid healing. Secondly the entire thickness 
of the lower internal sphincter must be divided, as any remaining intact fibres go into 
intense spasm to compensate for the divided fibres. Thirdly the upper one-third of the 
sphincter must remain intact for continence. Finally the mucosa over the sphincterotomy
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site should not be breached as this would predispose to infection. While excision of the 
sentinel pile was not addressed the authors observed that small skin tags regressed 
completely and larger ones regressed considerably after sphincterotomy and none of the 
patients treated wished to have the sentinel tag excised at a later date.
Whilst lateral subcutaneous sphincterotomy was increasingly accepted the recurrence rate 
when performed under local anaesthesia was of concern. Marby et al. (1979) reported a 
recurrence rate in 13 (29%) patients as compared to 4 (10%) patients in a group of 156 
treated by either subcutaneous sphincterotomy under local anaesthesia or anal dilatation 
under general anaesthesia. In those patients with recurrence, the maximum resting 
pressure (MRP) remained unchanged. Keighley et al. (1981) treated 71 patients with 
acute anal fissures by lateral sphincterotomy under either local or general anaesthesia. 
Although at one month the majority of patients were pain free, at four months the clinical 
picture changed considerably; in 14 (41%) of 34 patients who were treated under local 
anaesthetic the fissures recurred. All the fissures healed in the group treated under 
general anaesthesia. At four months the reduction (21%) in MRP was greater in patients 
treated under general anaesthesia (131 ± 25 to 104 ± 36 C111H2C), n=6) than the 13% 
reduction in those treated under local anaesthesia (124 ± 34 to 109 ± 31 cmffeO, n=5), but 
the numbers were too small to demonstrate statistical significance.
Boulos and Araujo (1984) investigated the adequacy of sphincterotomy by either a 
subcutaneous or an open technique in 28 patients with chronic anal fissures. Both groups 
were relieved of pain within a week, and the fissure healed in all subjects at one month.
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The reduction in MRP after subcutaneous sphincterotomy was 51%, and 50% after open 
sphincterotomy, with incontinence to flatus in 3 (21%) and 2 (14%) respectively, but on 
further follow up these patients regained full control. Complications included skin 
ecchymosis and discolouration at the site of the wound, particularly after subcutaneous 
sphincterotomy. One patient in each group developed sepsis, which did not require 
treatment. This study demonstrated that the extent of sphincter division and the resultant 
reduction in MRP was similar, and the subcutaneous sphincterotomy was of comparable 
efficacy to open sphincterotomy. The authors concluded that although the subcutaneous 
technique was similar, the open technique allowed better control of bleeding.
Long term effects of sphincterotomy
Chowcat et al. (1986) examined the long-term effect of either open or subcutaneous 
technique on MRP in 28 patients with anal fissures. Preoperatively the median MRP in 
patients with anal fissures was 98.0 cmH20, which was significantly higher than the median 
MRP of 72.6 cmH20  in 14 control patients. The reduction in MRP that was maintained at 12 
months was about 50%. Cerdan et al. (1982) studied 15 patients whose MRP was 95 cm 
H20, which was significantly higher than in controls, and was reduced to a normal anal canal 
pressure after sphincterotomy. Although MRP was reduced after sphincterotomy [Boulos 
and Araujo, 1984], Melange et al. (1992) were unable to demonstrate a correlation between 
preoperative and postoperative clinical symptoms and manometry. Garcia-Aguilar et al. 
(1996) analysed the data of 324 patients who underwent open sphincterotomy; and 225 
patients who underwent subcutaneous sphincterotomy, with an average follow up of 36
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months. Statistically significant differences were noted in difficulty in controlling flatus 
(30.3% vs. 23.6%), soiling (26.7% vs. 16.1%), and accidental bowel movements (11.8% 
vs. 3.1%). When patients were asked to express their degree of satisfaction 90% reported 
overall satisfaction, fewer patients who had undergone the open sphincterotomy than 
those who had closed technique were satisfied (49.7% vs. 64.4%). However, similar 
numbers of patients (1.2% vs. 1.3%) were very dissatisfied. The authors concluded that, 
although open and subcutaneous internal sphincterotomy were equally effective in 
controlling the symptoms of chronic fissures, the closed technique was preferable because 
it demonstrated less impairment of continence.
Although internal sphincterotomy allowed adequate division of the IAS with minimal 
morbidity, a high cure rate and low recurrence rate the long term sequelae were not 
addressed. Walker et al. (1985) conducted a retrospective review of 306 patients who 
underwent either closed or open sphincterotomy, alone or with other anal procedures 
including haemorrhoidectomy or fissurectomy. The follow up period ranged from three 
to five years (mean 4.3 years). They demonstrated that, although all patients were cured 
of anal fissure or stenosis, complications were observed in 110 (36%) patients. The 
complications after closed sphincterotomy alone occurred in 10 (22%) of 45 patients, 
after open sphincterotomy alone in 21 (55%) of 38 patients and in 79 (35.4%) of the 
remaining 223 patients who had sphincterotomies combined with other procedures.
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Though the authors did not state the period of short-term follow up, they indicated that 
that short term complications included an unhealed wound, pruritis, pain, incontinence to 
flatus, and bleeding. Among the 100 patients available for long term follow up (mean 4.3 
years (range 3 to 5 years)) 9 were incontinent to flatus, 6 complained of minor faecal 
soiling, 5 reported anal discharge and 4 complained of urgency. When different 
procedures were compared, closed sphincterotomy had fewer complications; though this 
comparison was without statistical qualification. The authors felt that patients ought to 
be warned of possible minor complications and impairment of continence. Lewis et al 
(1988) in an analysis of 247 closed and 103 open sphincterotomies reported a healing rate 
of 95.4% with an incidence of incontinence of 6.6% that was slightly higher after the 
closed 6.9% than the open 5.8% sphincterotomy. The minimum follow up period was 14 
months (mean 37 months).
The largest review of the sequelae of internal sphincterotomy for chronic fissure in ano 
involved 1355 patients, the majority of whom underwent open bilateral sphincterotomy. 
The follow up ranged from four to nine years [Khubchandani and Reed, 1989]. Of the 
1057 patients whose outcomes were recorded in the case notes the fissure healed in 1033 
(97.7%) patients. Responses were received from 829 (61.2%) patients and 1102 (81.3%) 
physicians, with a common subset of 717 (52.9%) subjects. Flatus incontinence, 
occurring “sometimes” to “infrequently” occurred in 255 (35.7%) of 715 subjects and 
was not related to gender. An alarming 35 (4.9%) of 716 complained of faecal urgency, 
whilst 152 (21.2%) of 716 described soiling. There were statistically no differences 
between the method of sphincterotomy an terms of incontinence to flatus, soiling or
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urgency. Only 56 patients were not satisfied with the outcome of their surgery. In a 
similar questionnaire survey by Nyam and Pemberton (1999) 10 years later showed that 
in 487 of 585 who responded whose mean follow up was 72 months the healing rate was 
96% and 98% of the patients were satisfied with the result. Episodes of faecal 
incontinence occurred in 219 (45%) of 487. Females were statistically significantly more 
prone to flatus incontinence and though males complained of soiling, this did not reach 
statistical significance. Only 3% of patients felt that incontinence affected their quality of 
life.
Pemikoff (1994) reappraised the technique of lateral internal sphincterotomy by 
examining the results, the morbidity and mortality in a retrospective review of 290 
patients who had an open sphincterotomy and 210 who had a closed sphincterotomy, with 
a mean follow up of 5.6 (range 1-11) years. Only 1% failed to heal. Long-term minor 
complications occurred in 55 (11%) patients. These included minor faecal soilage in 22 
(4.4%), incontinence to flatus in 14 (2.8%), bleeding in 7 (1.4%), urgency in 5 (1%) and 
pain in 10 (0.2%). Complications were noted in 43 (15%) of 290 of those who had an 
open sphincterotomy group compared with 17 (8%) of 210 in the closed sphincterotomy 
group; the incidence of complications in the former group were significantly greater. 
Sharp (1996) felt that a follow up of less than 10 years was unlikely to identify 
cumulative causal effects on incontinence.
Littlejohn and Newstead (1997) showed that when sphincterotomy was extended to the 
dentate line incontinence rates ranged from 0-35 %, with a healing rate of 93-100%, and a
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recurrence rate of 0-25%. They advocated a “tailored sphincterotomy” where the 
sphincter was divided to the length of the fissure. The healing was 99.65%, with 
complete resolution of symptoms in those that required a repeat sphincterotomy. 
Complications included one patient with faecal soiling (0.35%), four patients with flatus 
incontinence (1.4%), and two with faecal urgency (0.7%).
1.53 . FISSURECTOMY/ FISSURECTOMY AND SPHINCTEROTOMY
Gabriel (1930) made a square incision around the fissure with removal of any associated 
tags allowing drainage a fissure. The wound was left open. Though this was not a true 
fissurectomy the purpose of the procedure was to drain a deep ulcerated posterior fissure. 
No mention was made of dividing the IAS.
Hughes (1953) believed that the radical cure of an anal fissure entailed excision of the 
fissure, division of the subcutaneous sphincter muscle and application of a split skin graft to 
the area as to shorten convalescence. In his series 12 patients following excision of the 
fissure combined with primary skin grafting had a 100% “take” and left hospital within a 
week.
Abcarian (1980) compared 150 patients who had lateral internal sphincterotomy with an 
equal number who had fissurectomy-midline sphincterotomy. The fissurectomy was 
performed by making a 2cm U-shaped midline incision at the site of the fissure separating 
the skin from the external sphincter and dissecting the anal fissure from the scarred
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internal anal sphincter. The fissure and its accompanying abnormalities (i.e. hypertrophic 
anal papilla and sentinel pile) were then excised to the dentate line and a superficial 
midline sphincterotomy was made in the distal half of the internal anal sphincter. Finally, 
the cut edge of the rectal mucosa was sutured to the internal sphincter at the area of the 
dentate line. It was found that hospital stay (3-4 vs. 1-2 days), time for resolution of 
symptoms (2-3 weeks vs. 1-2 weeks) and wound healing (6-7 vs. 2-3 weeks) were 
doubled following fissurectomy-midline sphincterotomy compared to lateral 
sphincterotomy. Early and temporary loss of continence for flatus was fairly common in 
both groups (40% fissurectomy-sphincterotomy vs. 30% internal sphincterotomy). After 
two weeks these problems resolved in those following internal sphincterotomy, however 
occasional loss of flatus and faecal soilage were seen in 8 (5%) patients among the other 
group. This was attributed to a “key-hole” deformity due to scarring leaving a permanent 
gutter at the anal verge. In each group 2 (1.3%) recurred. Abcarian concluded although 
lateral internal sphincterotomy was the procedure of choice because of low risk of 
incontinence, fissurectomy had a role in midline fissures complicated by underlying 
fistula.
Bode et al (1984) reviewed 121 patients who underwent fissurectomy and midline 
sphincterotomy with a mean follow-up of 8.1 years. Minor incontinence occurred in 30 
(25%) patients in the immediate postoperative period that resolved by two months. Of 6 
(5.0%) recurrences, 5 (4.1%) were acute fissures in the fissurectomy scar that healed 
spontaneously. One patient (0.8%) developed recurrent ulcer-in-ano complete with a 
sentinel pile and a hypertrophied papilla 2 years after the original operation and
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underwent a second fissurectomy with superficial midline sphincterotomy. None of the 
patients developed incontinence, anal strictures, or keyhole deformity. Except 3 (2.5%) 
who had recurrences of their fissures, the remaining 118 (97.5%) were satisfied with the 
result.
Gingold (1987) described sphincterotomy with partial fissurectomy as an outpatient 
procedure under bupivicaine local anaesthesia and reported a series of 86 patients with a 
median follow-up of 2 years. Three patients had recurrence, giving a success rate of 96.4 
%, with no complications or disturbed continence.
Di Castro et al. (1997) reported on 195 patients who underwent fissurectomy with 
posterior midline sphincterotomy with anoplasty (FPSA). The fissure was excised with 
an elliptical incision until healthy tissue was exposed, and a sphincterotomy was made in 
the posterior midline. The cut edge of the rectal mucosa was then drawn downwards and 
sutured to the lower margin of the IAS. The wound healed satisfactorily in all patients 
after a mean time of 4 weeks.
Recent therapeutic agents in the conservative treatment of fissures have complemented 
surgical treatment. Engel et al. (2002) used topical isosorbide dinitrate after fissurectomy 
to enhance postoperative tissue perfusion and promote wound healing. In 17 patients 
with fissures not responding to conservative management fissurectomy was performed. 
There were no postoperative complications. All wounds had healed by 10 weeks and no 
fissure recurrence was seen after a median follow-up of 29 months.
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1.5.4. ANAL ADVANCEMENT FLAPS
Whilst the classic high-pressure fissure responds well to lateral internal sphincterotomy, 
the anal island advancement flap is advocated for patients with primary or recurrent 
fissures and for women with a complicated obstetric history with low resting anal canal 
pressure. This particular group of patients do not benefit from sphincterotomy as this is 
more likely to precipitate incontinence. In order to aid selection of suitable cases, 
manometric and endosonographic evaluation is often employed. This operation avoids 
further disruption to the internal sphincter, and avoids factors that might otherwise 
jeopardise continence. Skin flaps can either be triangular (Y-V), or a square-shaped 
sliding graft. Oh and Zinberg (1982) advocated the use of C-anoplasty as it extended the 
pedicle without compromising the vascular supply.
Samson and Stewart (1970) reported a Y-V anoplasty performed in 2072 patients from 
1964 to 1968. The infected fissure with crypt bearing haemorrhoidal tissue was excised 
and the defect closed with a broad based split skin graft. Though the authors did not state 
their success rate they reported few complications: 10 fissures recurred, and 7 patients 
had mild stenosis.
Nyam et al. (1995) performed an island advancement flap in 21 patients with anal fissures 
who had weak sphincters. The preoperative median resting anal pressure was 66 (range 
43-90) cmffeO, these values were significantly lower than controls. Endoanal
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ultrasonography demonstrated sphincter defects in 15 of these patients. All fissures 
healed and, at a median follow up of 18 (range 2-28) months continence was maintained.
Leong and Seow-Chen (1995) prospectively evaluated 40 patients who were randomised 
equally to either receive a lateral sphincterotomy or rhomboid anal advancement flap. 
They showed that whilst all those in the former group healed, three in the latter group did 
not. No anal incontinence was recorded in any patient from either group. Of the 
sphincterotomy group, three were dissatisfied as they developed skin tags or temporarily 
painful scars at the operation site. In the anal advancement group, three were not satisfied 
as the wounds failed to heal and two underwent subsequent lateral sphincterotomy. The 
follow up did not include anal manometry.
1.6. ENDOANAL ULTRASOUND IMAGING OF THE ANAL SPHINCTERS
Endoanal ultrasonography has identified the effect of anal dilatation and lateral 
sphincterotomy on the anal sphincters. Speakman et al. (1991) examined the structure 
and function of the anal sphincters in 12 male patients who were incontinent following 
anal dilatation. The mean resting pressure was 49 cmH20, and the mean voluntary 
contraction pressure was 93 cmH20. In 11 of the 12 patients the IAS was disrupted with 
a mean loss of 153° of the circumference. Anal dilatation resulted in fragmentation of 
the IAS, rather than an isolated defect. Three patients also had defects in the external 
anal sphincter and only one patient had a normal endosonographic appearance.
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Nielsen et al. (1993) studied 32 patients with a median age o f 48 (range, 19-78) years and 
a median follow up o f 4 (range, 2-6) years after anal dilatation performed for chronic anal 
fissures. Four patients (12.5%) developed minor incontinence. Of 20 who accepted 
endosonographic follow-up, sphincter defects were found in 13 (65%); 2 o f  the 4 
incontinent patients and 11 o f the 18 continent patients had IAS defects. In 4 continent 
patients, the IAS was fragmented and had disrupted at more than one site. There was no 
description o f  associated external anal sphincter injury. Anal dilatation can be regarded 
as an uncontrolled tearing procedure that does damage the sphincter muscles with 
considerable detriment to anal function (fig. 1.1.).
Figure 1.1. Endoanal ultrasound demonstrating the appearance of the internal anal 
sphincter (IAS) after manual dilatation for chronic anal fissure. The white arrows indicate 
the defects in the IAS.
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Sultan et al. (1994) carried out a prospective evaluation o f  the extent o f IAS division two 
months after open lateral sphincterotomy in 15 patients (mean age 39, range 26-67 years) 
with chronic anal fissure. The defect in the IAS corresponded to the site o f  surgical 
division, and was usually 20% o f  the circumference (fig. 1.2). The disruption in females 
was more extensive, as in 9 o f  10 females the defect involved the whole length o f  the 
IAS, presumably related to the shorter anal canal in females. The authors recommended 
that as division o f  the IAS in most females was more extensive than intended, a limited 
division to the length o f  the fissure should be sufficient as Sultan et al. (1993) had 
identified occult external sphincter defects in 35% o f primiparous and 44% o f  
multiparous females following vaginal delivery.
Figure 1.2. Endoanal ultrasound demonstrating the appearance of the internal anal 
sphincter (IAS) after lateral sphincterotomy for chronic anal fissure. The white arrow  
indicates the defect in the IAS.
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Such is the current concern regarding sphincterotomy that Farouk et al. (1998) advocated 
perioperative endoanal ultrasound scan for patients with anal fissures to identify those at 
high risk of incontinence in whom an anal advancement flap should be a safer option to a 
sphincterotomy. Although a sphincteric defect after dilatation does not necessarily cause 
disturbance of continence it may manifest clinically later in time as a consequence of 
idiopathic degeneration [Vaizey et al., 1997] or of childbirth [Burnett et al., 1991].
It has become evident from these observations that patients, particularly females, should 
be appropriately selected and any form of treatment that disrupts the sphincter mechanism 
should be considered carefully. Endoanal ultrasonography has also identified inadvertent 
division of the EAS or inadequate division as reasons for failure of a fissure to heal 
[Farouk et al., 1997; Garcia-Granero et al., 1998].
1.7. CHEMICAL SPHINCTEROTOMY
This term refers to pharmacological manipulation of anal sphincter tone as an alternative 
modality to surgery for the treatment of anal fissures. Lateral sphincterotomy diminishes 
IAS hypertonia and reduces anal canal pressure; this in turn improves anal mucosal blood 
low and promotes healing of anal fissures. However, sphincterotomy can be associated 
with long-term disturbances of sphincter function. The optimal treatment for anal 
fissures is to induce a temporary reduction of anal canal pressure to promote healing of 
the fissure without permanently disrupting normal sphincter function. Broader
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understanding of the intrinsic mechanisms controlling smooth muscle contraction has 
allowed pharmacological manipulation of anal sphincter tone [Lund and Scholefield, 
1996; Madoff, 1998]. A reduction in anal sphincter tone is achievable by enhancing IAS 
relaxation through direct action on internal anal sphincter smooth muscle cells. These 
mechanisms serve to reduce intracellular Ca2+, which reduces the tonic state of the 
muscle. These can occur through nitric oxide donation, direct intracellular Ca2+ 
depletion, muscarinic receptor stimulation, a-adrenergic inhibition, or p-adrenergic 
stimulation [Cook et al., 2001]. Manipulation of these mechanisms does not effect the 
contraction of the striated external anal sphincter whose contractile mechanisms function 
at the level of the neuromuscular junction.
1.7.1. NITRIC OXIDE DONORS
O’Kelly et al. (1993) recognised nitric oxide as the predominant neurotransmitter 
mediating neurogenic relaxation of the human IAS. They also demonstrated that sodium 
nitroprusside, an exogenous source of nitric oxide, mimicked the effect of electrical field 
stimulation in relaxing the human IAS in vitro. Glyceryl trinitrate (GTN) and isosorbide 
dinitrate have also been shown to act as nitric oxide donors, and are available as 
ointments for topical administration. Nitric oxide donors probably aid healing through an 
increase in local blood flow secondary to a reduction in intra-anal pressure and perhaps 
also by vasodilatation of the vessels supplying the anal musculature. Kua et al (2001) 
showed that application of 0.2% GTN ointment onto the anoderm increased the mean
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blood flow over the anal fissure region. This effect lasted throughout a one hour study 
period.
The optimal therapeutic dose
Loder et al (1994) investigated the feasibility of “reversible chemical sphincterotomy” by 
local application of GTN. Their study was conducted with 3 phases. In an initial 
investigation of two patients to establish the optimal drug concentration aliquots of 0.2%, 
0.5%, 1% and 2% were used. Headaches lasting several hours were reported in both 
patients with the 0.5%, 1% and 2% doses and in only one patient lasting 30 minutes with 
the 0.2% formulation. The second phase investigated the effect of 0.2% GTN in 10 
subjects, with a mean age of 39 years, two of whom were without anorectal conditions, 
two with pruritis ani, four with haemorrhoids, one with a fissure and the remaining one 
with anal pain. 0.2% GTN caused the maximum resting anal canal pressure to 
significantly decrease by 27% from a mean of 99 crn^O  to 73 cmH20. In a randomised 
trial 20 patients treated with 0.2% GTN the maximum resting anal canal pressure 
decreased significantly from a mean of 103 cmH20 to 79 cmH20, while in those treated 
with placebo the resting pressure change from a mean of 95 cmH20 to 88 cmH20 was not 
significant.
Gorfine (1995a) treated 15 patients, 11 who had acute posterior midline fissures, one with 
an acute anterior fissure, and three who had posterior midline ulcers, with 0.5-lg of 0.5%
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GTN ointment used four times daily. All patients reported relief of anal pain within 3 to 
4 minutes after application. Of the 12 patients with superficial anal fissures, 10 (83%) 
were healed within two weeks and the remaining 2 healed after four weeks of treatment. 
Of the patients with chronic anal ulcers though one had symptomatically improved after 
two weeks, requested sphincterotomy and healed. The remaining 2 patients had also 
improved symptomatically but failed to heal after two months. They refused 
sphincterotomy. Mild transient headaches were reported in 5 (33%) patients. Gorfme 
(1995b) used 0.3% GTN four times daily in 40 patients with anal fissures and 14 with 
anal ulcers. Compliance with therapy occurred in 30 and 11 patients respectively. In 
those with anal fissures 9 (30%) within two weeks, in 21 (70%) within four weeks or less 
and in 23 (77%) within eight weeks or less. In those with anal ulcers 2 (18%) healed 
within two weeks, 3 (27%) within four weeks or less and in 6 (54%) within eight weeks 
or less. Headaches occurred in 12 (22%) of 54 patients.
Watson et al. (1996) applied GTN in increasing concentrations from 0.2%-0.8% to the 
anal margin in 19 patients with anal fissures. If, after application of a dose of GTN, the 
anal canal pressure failed to decrease by 25% without side effects, the next higher 
concentration was used. Of 13 that attended follow up at 6 weeks the fissure healed in 9 
(69%), one healed with 0.2%, five with 0.3%, one with 0.4% and two required 0.8%. Five 
patients demonstrated tachyphylaxis to GTN.
Lund et al. (1996) found that while a dose of 0.4% in two subjects caused headaches 
whereas 0.2% caused no side effects in 4 volunteers. They then treated 21 patients
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suffering from chronic anal fissures with 0.2% GTN twice daily for 4-6 weeks. The mean 
± s.d. maximum resting anal canal pressure decreased significantly from 118.7 ± 45.0 
cmH20 to 70.3 ± 34.1 cml-kO over 20 minutes after application. Healing occurred in 11 
(52%) at 4 weeks and in 18 (86%) at 6 weeks. Lund and Scholefield (1997a) reaffirmed 
in a further study of 39 consecutive patients with chronic anal fissures, seven of whom 
had recurrences after previous surgery, the effectiveness of treatment with 0.2% GTN. 
The maximum anal canal pressure decreased significantly from 122.1 ± 44 to 72.5 ± 33.3 
cmH20 20 minutes after application. Healing occurred in 14 (36%) at four weeks and in 
33 (85%) at six weeks. All 7 patients with recurrent fissures healed with GTN ointment. 
Mild headaches occurred in 8 (24%) and 5 fissures that had healed at four weeks recurred, 
of these 4 were again successfully treated with GTN.
Carapeti et al. (1999a) investigated the optimal therapeutic dose with the least side effects 
and long-term benefit. In a double blind controlled trial, patients were randomised to 
receive placebo, 0.2% GTN, or increasing concentrations of GTN starting with 0.2% for 8 
weeks. After 10 weeks (which included 8 weeks of treatment) healing was observed in 7 
(32%) of 22 patients on placebo, 15 (65%) of 23 on 0.2% GTN, and 16 (70%) of 23 
patients on escalating doses of GTN. Nine (39%) of 23 fissures had healed after six 
weeks with high dose of GTN compared with 5 (22%) of 23 on 0.2% GTN. Headaches 
were reported by 33 (72%) of 46 patients on GTN compared with 6 (27%) of 22 on 
placebo. All groups described a significant reduction in mean pain scores after 2 weeks 
of therapy. There was a reduction in the maximum resting anal canal pressure from pre­
treatment baseline to 8 weeks and this was more pronounced after GTN, with a mean
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reduction of 32 ± 15 cml-feO as compared with placebo which resulted in a decrease of 19 
±19 cmH20. The median follow up was 9 (range 6-14) months during which recurrences 
were observed in 3 (43%) of 7 treated with placebo, 5 (33%) of 15 treated with 0.2% 
GTN and 4 (25%) of 16 treated with higher doses of GTN. This study affirmed that there 
was no advantage in using doses of GTN higher than 0.2%, as although higher doses 
healed the fissures more quickly, this did not prevent relapse. They attributed the high 
healing rate of placebo to the fact that many patients with chronic fissures could heal 
spontaneously.
Palazzo et al (2000) re-explored the use of 0.5% GTN in 45 patients. At 6 weeks, 73% 
of the fissures healed and at 3 months there were no recurrences; 84% had headaches, and 
11% discontinued treatment because of that. This study affirmed that high dose of GTN 
healed fissures, but with higher incidence of side effects. Ward et al (2000) using 0.5% 
GTN healed 12 (75%) of 16 fissures but 9 (56%) of the 16 had headaches. Ciccaglione et 
al (2000) have also shown that higher doses (2% as compared with 0.2%) of GTN are of 
no added benefit in the healing rate or the reduction in maximum resting anal canal 
pressure.
Scholefield et al (2003) conducted a double blind, multicentre, randomised controlled 
trial dose finding study with 0.1%, 0.2%, 0.4% GTN and placebo. Initial analysis showed 
that, after 8 weeks of treatment, the healing rate in the placebo group was 37.5% 
compared with 46.9% for 0.1%, 40.4% for 0.2% and 54.1% for 0.4% GTN. None was 
significantly better than the placebo response. After excluding fissures without secondary
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criteria for chronicity, the healing rate in the placebo group was 24%, compared with 50% 
for 0.1%, 36% for 0.2%, 57% for 0.4% GTN. These values were statistically 
significantly different for the placebo group compared with the 0.1% and 0.4% GTN 
groups. This apparent effect of GTN on the chronic anal fissures but not the acute 
fissures led the authors to conclude that perhaps the definition of chronicity related to 
fissures may need to be reviewed.
These few reports indicate that while GTN has a therapeutic role headaches constitute a 
major disadvantage in its use and patients’ compliance outside clinical trials is not 
sufficiently strict.
Comparative studies on the effectiveness of GTN
Lund and Scholefield (1997b) in the first randomised trial treated 80 consecutive patients 
with topical application of either 0.2% GTN or placebo twice daily. After 8 weeks 26 
(68%) of 38 treated with GTN healed as compared to 3 (8%) of 39 treated with placebo. 
Two patients from the fissure group were excluded because fissures were not identified at 
the time of inclusion. One patient from the placebo arm failed to attend. The maximum 
resting anal canal pressure fell significantly from 115.9 ± 31.6 to 75.9 ± 30.1 cmH20 after 
application of GTN compared to 118.1 ± 44.6 to 111.5 ± 42.0 cm H2O after placebo. The 
anodermal blood flow, measured by laser flowmetry, significantly increased from 32.4 ± 
27.5 to 42.8 ± 27.6 units after application of GTN but with placebo the change from 24.9 
± 11.1 to 28.1 ± 10.2 units was not significant.
60
Bacher et al. (1997) randomised 12 acute fissures, and 8 chronic fissures to GTN and 10 
acute and 5 chronic fissures to topical local anaesthetic. At 2 weeks GTN healed 60% of 
the fissures, 11 (92%) of 12 acute fissures and 1 (13%) of 8 chronic fissures; while none 
treated with local anaesthetic gel healed. At 4 weeks GTN healed 80% of cases, 11 
(92%) of 12 acute fissures and 5 (63%) of the 8 chronic fissures; while 40% healed with 
local anaesthetic gel, 5 (50%) of 10 acute fissures and 1 (20%) of 5 chronic fissures. 
Those who had healed by 2 weeks with GTN showed a significant reduction in maximum 
anal canal pressure from 110 (78-156) to 87 (60-120) cmffeO but in those that healed by 
4 weeks there was no significant decrease in maximum anal canal pressure. GTN caused 
headaches in 20% of patients.
Kennedy et al (1999) randomised 43 patients with chronic anal fissures, 24 for GTN and 
19 for placebo treatment thrice daily for three weeks. After four weeks if the fissures 
remained unhealed in the GTN group, treatment was continued until healing was 
achieved or lateral sphincterotomy was performed if symptoms were severe. At one week 
in the GTN group the maximum resting anal canal pressure reduced significantly from 
125 ± 8 cmfbO to 107 ± 7 cmtbO and had increased to 119 ± 8 cm H2O by 4 weeks. 
The reduction in anal canal pressure in the placebo group at one week (117 ± 4 cmtfeO) 
and 4 weeks (113 ± 5 cmH20) was not significant. At four weeks eleven had healed with 
GTN and three with placebo.
GTN in clinical practice
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Whilst GTN is advocated as first line treatment for chronic anal fissures with encouraging 
results, concerns about its effectiveness in clinical practice outside clinical trials emerged 
in other reports. Pitt et al (1999) published a report of a consecutive series of 45 patients 
with chronic anal fissures with a median duration of 6 months treated with 0.2% GTN 
and followed up for a median of 6(1-11) months. Patients were reviewed every 4 weeks 
and GTN treatment was continued if they were improving, otherwise they were advised to 
have internal sphincterotomy if the fissure did not heal after 12 weeks. Twenty-six (58%) 
developed headaches during treatment and 5 abandoned treatment in favour of surgery. 
Twenty-two (49%) healed, but 10 recurred and so only 12 (27%) of the original 45 
remained healed during the follow up period. The median time to healing of the fissure 
was 6 (range 2-12) weeks; recurrences started 7 weeks after stopping treatment. The 
authors concluded that GTN was a useful adjunct to therapy but internal anal 
sphincterotomy remained the mainstay of treatment.
Dorfman et al (1999) conducted a retrospective review of 31 patients with chronic anal 
fissures who were managed by twice-daily 0.2% GTN. Of 27 respondents 18 (67%) had 
complied with treatment and, of 15 (56%) who had complete symptomatic relief after 3 
to 10 weeks of therapy, 4 (27%) recurred after a median follow up of 6 months and 21 
(78%) of the 27 had headaches or light headedness, sufficiently severe for 2 (10%) 
patients to cease therapy.
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Jonas et al. (1999) evaluated the results of topical treatment with 0.2% GTN for 6 weeks 
in 49 consecutive patients; the fissures healed in 21 (43%), in 2 the fissures healed 
spontaneously after the patients discontinued their medication, and in 26 (53%) patients 
with persistent symptoms after completing treatment, the fissure healed after patients 
underwent a lateral internal sphincterotomy. The investigators concluded that despite 
increasing concerns about surgery it still had a valuable role in healing of chronic anal 
fissures.
Altomare et al (2000) conducted a multicentre, randomised, placebo-controlled, double 
blind trial where 132 consecutive patients received either 0.2% GTN or placebo twice 
daily for 4 weeks. One hundred and nineteen patients completed the trial and the two 
groups were matched for gender, age, duration of symptoms, site of fissure, and duration 
of treatment. 29 (49.2%) of 59 healed after GTN and 31 (51.7%) of 60 healed after 
placebo. The mean pain score after one week of GTN treatment decreased significantly 
from 7.56 ± 1.8 to 4.13 ± 2.7 and there was also a significant reduction from 6.91 ± 2.3 to 
3.97 ± 2.8 after one week of placebo. Anal manometry was available in 93 patients. The 
maximum resting anal canal pressure significantly fell from 97.3 ± 16 to 83.2 ± 16 mmHg 
in the GTN group and from 92.1 ± 14 to 82.4 ±17 mmHg in the placebo group. This trial 
reaffirmed clinical doubt of the superiority of 0.2% GTN over placebo.
Hasegawa et al. (2000) followed up 16 patients with acute fissures and 40 patients with 
chronic anal fissures after treatment with 0.2% GTN. Ten (63%) of 16 acute fissures 
healed at 4 weeks and 13 (81%) by 8 weeks, whilst of the chronic fissures 13 (33%)
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healed by 8 weeks and 20 (50%) by 12 weeks. Headaches were seen in 8 (14%), 7 
discontinued treatment; and 26 (46%) experienced mild headaches. Five (22%) patients 
had recurrences, 4 were treated successfully with a further course of GTN and the other 
patient required a lateral sphincterotomy, and healed.
GTN vs lateral sphincterotomy
Oettl6 (1997) randomised 24 patients to either GTN or sphincterotomy. All fissures 
healed by 4 weeks after sphincterotomy and, at a median follow up period of 22 (8-34) 
months, there were no recurrences and no patient developed incontinence. Of those 12 
patients treated with GTN, in 10 (83%) the fissures healed by 4 weeks and in the other 2 
patients the fissures failed to heal after two more weeks of treatment until they underwent 
sphincterotomy. At follow up, those fissures that had healed with GTN remained healed.
Two recent randomised controlled trials concluded that GTN was not superior to lateral 
sphincterotomy as treatment for chronic anal fissures. Richard et al (2000) presented a 
randomised study by the Canadian Colorectal Surgical Trials Group in which the fissure 
healed at 6 weeks in 34 (89.5%) of 38 patients in the sphincterotomy group, compared 
with 13 (29.5%) of 44 treated with GTN, of whom 5 (38.4%) of 13 relapsed. The 
respective healing rates at 6 months were 35 (92.1%) and 12 (27.2%); 20 (45.4%) treated 
with GTN required a sphincterotomy and 8 (23.2%) patients discontinued treatment 
because of a headaches. The group concluded that internal sphincterotomy was superior 
to GTN and would remain the treatment of choice for the treatment of chronic anal
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fissures. Evans et al. (2001) reported healing in 26 (97%) of 27 patients treated by 
sphincterotomy compared with 20 (60.6%) of 33 patients treated with GTN for 8 weeks; 
12 patients who failed GTN treatment underwent sphincterotomy.
Libertiny et al (2002) conducted randomised trial of 0.2% GTN and lateral internal 
sphincterotomy was conducted in 70 patients were randomised, with 35 in each group. 
Of those administered GTN, 19 (54%) of 35 healed and the remaining 16 were treated by 
sphincterotomy. Recurrences by six months were observed in three patients initially 
treated successfully with GTN, the other 16 that had initially healed had still healed by 24 
months. All those that were operated on had healed, but one patient’s fissure recurred 
after eight months.
The characteristics of the anal fissure and healing
Pitt et al. (2001a), concerned about the poor effectiveness of GTN, investigated 42 males 
and 22 females, mean age 37.5 years, with chronic anal fissures of a median duration of 7 
(range 3-180) months. The fissures were located anteriorly in 17 (27 %) and 19 (30 %) 
were associated with sentinel piles. Patients were treated with 0.2% GTN topically twice 
daily and reviewed 4 weekly, and remained on GTN if there was symptomatic relief, 
otherwise they were offered sphincterotomy. Sphincterotomy was also offered if after 12 
weeks treatment with GTN the fissure did not heal. The follow up period extended to 32 
weeks. Initially 26 (40.6%) healed, but 12 (46.2%) had a recurrence within 32 weeks, 
therefore 14 (21.9%) remained healed in the long term. By completion of the study 20
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patients underwent lateral internal sphincterotomy; the remaining patients who had not 
healed with GTN declined surgery. Headaches were observed in 41 (64 %); of these 10 
(15.6%) stopped therapy. According to a Cox model multivariate analysis of sex, age, 
duration and site of the fissure, presence of sentinel pile, presence of childbirth and 
constipation factors related to failed treatment were the duration of greater than 6 months 
and the presence of a sentinel pile. The authors suggested that these patients should be 
warned that topical GTN therapy was more likely to fail, and earlier sphincterotomy was 
advised.
Long term results of GTN treatment
Recent published reports have reaffirmed the poor long-term results in the treatment of 
chronic anal fissures. Lund and Scholefield (1998) then assessed long-term follow-up of 
patients with chronic anal fissures treated with GTN. 41 patients who had previously 
healed with GTN returned a questionnaire with a median follow up 28 (range 24-38) 
months. 30 had no further symptoms and 11 developed a symptomatic relapse. Of these 
latter patients, 3 underwent sphincterotomy, 6 healed with further GTN and 2 settled 
spontaneously.
Kennedy (1999) conducted a randomised, double-blind trial, placebo-controlled trial to 
test the effectiveness of GTN and showed that both groups had a significant reduction in 
pain scores by 4 weeks. Long-term follow-up was conducted in 17 patients with a mean 
time of 28.5 (range 26-31) months. Of 8 patients who had initially healed with GTN, 5
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recurred, a further course of GTN in these patients healed 2; 2 underwent sphincterotomy 
and 1 remained unhealed. Within the group of 17 a total of 10 (59%) had healed with 
GTN and 5 (29%) had undergone sphincterotomy.
Graziano et al (2001) compared 0.25% GTN treatment in 22 patients (16 chronic and 6 
acute fissures) with 21 (16 chronic and 5 acute fissures) who had received placebo 
treatment. The mean follow up was 39 weeks. The healing rate with GTN was 75% for 
chronic and 83% for acute fissures, and the recurrence rate for the chronic fissures at 9 
months was 67%. Only 1 (6%) of 16 of the chronic fissures healed with placebo. Whilst 
GTN was effective for both acute and chronic fissures, there was an appreciable rate of 
recurrence.
Systemic levels of GTN
Jonas et al. (2001a) investigated whether systemic levels of GTN following topical 
application correlated with the measured reduction in anal pressure. 30 healthy 
volunteers underwent static anal manometry for 10 minutes before and 2 hours after 
application of 0.2% GTN to the anoderm. Blood samples were taken regularly for 3 
hours post-application. The MRP was significantly reduced after 10 minutes but had 
returned to pre-treatment values by 3 hours. Whilst the pulse was statistically unchanged 
during the study, the systolic blood pressure was significantly lower 20-90 minutes after 
application, and diastolic pressure was decreased throughout the study. Headaches were 
experienced by 14 of 30 volunteers after a median (range) of 41 (4-120) minutes,
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persisting for 74 (30-176) minutes, with an intensity score of 19 (5-30) mm represented 
on a 100-mm visual analogue scale. There was no correlation between plasma GTN 
concentration, MRP, and the onset, duration or intensity of headaches.
Isosorbide Dinitrate
Isosorbide dinitrate (ISDN) is an alternative nitric oxide donor that has been used 
successfully in the treatment of anal fissures. Schouten et al (1996c) treated 34 patients 
with 1% ISDN ointment applied 3 hourly to the anoderm. All patients reported mild 
transient headaches during the first 2 days that ceased by 10 days, but no patient stopped 
treatment. At 6, 9 and 12 weeks the fissures healed in 14 (41%), 22 (65%) and 30 (88%) 
patients respectively. The mean maximum resting anal pressure was reduced from 111 
mmHg to 86 mmHg at 3 weeks and to 96 mmHg at 6 weeks. The mean duration of 
follow up was 11 months and during this period in 2 (7%) the fissure recurred. Of the 
four patients that had a persistent fissure after 12 weeks of treatment, two were treated by 
lateral sphincterotomy and two by fissurectomy and anoplasty.
Lysy et al (1998) used Isoket® spray, isosorbide dinitrate, to treat 41 patients with chronic 
anal fissure in a dose of 1.25mg or 2.5mg thrice daily for 4 weeks. Of 41 patients 34 
(83%) healed within 4 weeks. The average time for symptoms to resolve was 6.5 ± 0.7 
days. In 6 (15%) the fissures did not heal after a further 4 weeks of treatment; they 
underwent lateral sphincterotomy. One patient discontinued treatment because of 
headaches, and overall seven patients had mild headaches during treatment. Six of the 34
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that had initially healed suffered recurrence, but responded to a further 4 weeks of 
treatment. In patients whose treatment was successful, the reduction in mean resting 
pressure was 32.5% (from 110.6 ± 2 to 70.6 ± 1.3 mmHg), whereas the decrease in those 
that did not respond was 16% (105 ± 2 to 90 ± 2.6 mmHg).
Were et al. (2001) randomised 20 patients to ISDN and 17 to a placebo. Both groups 
were treated for a median duration of 5 (1-10) weeks. In the ISDN group the fissures 
healed in 17 (85%) compared with 6 (35%) controls with two recurrences in each group. 
Headaches occurred in 9 (45%) treated with ISDN and in 3 (18%) who had a placebo.
Engel et al (2002) hypothesised that chronic anal fissures unresponsive to conservative 
treatment was due to the fact that the fissure was an unstable scar tissue. The 
investigators selected 17 patients whose mean age was 46 (29-78) years with painful 
fissures who had failed to heal with 1% ISDN. These patients were treated by 
fissurectomy followed by topical ISDN. The aim was to create a fresh surgical wound 
and to promote its healing by improving tissue perfusion with a nitric oxide donor. At six 
weeks healing was complete in all except one who required treatment until 10 weeks. At 
a median follow-up of 29 (23-36) months there were no recurrences and none complained 
of incontinence to solid, liquid faeces, or gas.
1.7.2. CALCIUM ANTAGONISTS
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Nifedipine is a dihydropyridine calcium-channel blocker; less correctly referred a 
‘calcium-antagonist,’ which inhibits calcium ion entry through voltage-sensitive areas of 
vascular smooth muscle and myocardium. It reduces myocardial contractility, depresses 
the formation and propagation of electrical impulses within the heart, and decreases 
coronary and systemic vascular tone. Nifedipine is used for the treatment of angina and 
hypertension. Its side effects are associated with vasodilatation and include flushing and 
headache (which become less obtrusive after a few days), and ankle swelling (which may 
respond only partially to diuretics).
Chrysos et al (1996) conducted the first clinical study of the role of calcium antagonists 
on anal canal pressure based on the rationale that nifedipine, a calcium channel 
antagonist, decreased lower oesophageal sphincter pressure in achalasia. Ten patients 
with non-prolapsing haemorrhoids and/or anal fissures, mean (s.d.) age 52 ± 11 years; and 
10 controls, mean (s.d.) age 45 ± 9 years underwent anal manometiy before and 30 
minutes after sublingual administration of 20mg nifedipine. The maximum resting anal 
canal pressure decreased significantly in both groups, in patients from 119.5 ± 15.7 
cmfbO (mean, s.d.) to 82.4 ± 12.9 cmt^O, and in controls from 87.5 ± 8.4 cmt^O to 
66.8 ± 11.9 C111H2O, a reduction of resting pressure noted for patients and controls was 
32% and 24% respectively. The mean maximum squeeze pressure in both groups was 
unchanged. This was as expected as the external anal sphincter is striated muscle and as 
such is unaffected by nifedipine. The investigators noted that nifedipine also influenced 
the frequency and amplitude of slow waves in both groups; the presence, frequency and 
amplitude of ultra-slow waves in patients, but not in controls; and the frequency of anal
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sampling events in the patient group. These results indicated that nifedipine also had an 
inhibitory effect on the phasic activity of the IAS. Nifedipine did not influence the blood 
pressure and heart rate significantly. None reported any dizziness, fatigue or nausea, but 
2 controls and one patient reported transient headache or showed flashing of the face that 
settled within 30 minutes.
Antropoli et al (1999) in a randomised, double-blind, multicentre trial, investigated the 
efficacy of local application of 0.2% nifedipine gel twice daily for 3 weeks in healing 
acute fissures in 141 patients compared to a control group of 142 patients treated with 1% 
lidocaine and 1% hydrocortisone gel. At three weeks 134 (95%) healed with nifedipine 
compared to 71 (50%) in the control group. The maximum resting anal canal pressure 
decreased significantly by 30% in the nifedipine group from a mean of 72.5 ± 10.1 
mmHg to 50.5 ± 10  mmHg after three weeks, and the squeeze pressures also reduced 
significantly by 16.8 % from 130.5 ± 19.2 mmHg to 108.5 ± 18.6 mmHg. In the control 
group the reductions in resting pressure (from 70.5 ±9.1 mmHg to 63.5 ± 9.0 mmHg) and 
squeeze pressure (from 129.5 ± 20.1 to 119.5 ± 17.3 mmHg) were not significant. No 
patient treated with nifedipine showed any systemic side effect, probably due to lower 
systemic absorption than that seen with sublingual nifedipine.
Cook et al. (1999a) evaluated oral nifedipine on resting anal pressure and on fissure 
healing. The authors felt that an oral preparation would overcome some of the confusion 
that existed with the site of application and dose of topical preparations, and that it might 
improve patient compliance. Eight volunteers of median age 31 (range 20 to 35) years
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and 15 patients of median age 34 (range 20 to 60) years with chronic anal fissures were 
treated with 20mg nifedipine orally twice daily. In the volunteers, the mean maximum 
resting anal canal pressure fell significantly by 35% from 85 to 54 cmFbO after the initial 
dose and after five days by 28% to 62 cmffeO. There was no significant change in the 
squeeze pressure before (122 cmFbO) or after the initial dose (121 cmtfeO) or at 5 days 
(128 cmFbO). The diastolic blood pressure did not change significantly. In the 15 
patients the initial dose of nifedipine caused a 36% significant fall in the maximum 
resting anal canal pressure from 102 to 65 cmFfeO. There was no change in the 
maximum squeeze pressure (from 93 vs. 95 cmFkO). The diastolic blood pressure fell 
significantly after the first dose, but this was not sustained. Five patients developed 
headaches, 10 noted flushing and one developed ankle oedema. No patients developed 
postural hypertension or incontinence. In three (20%) patients the fissures healed by six 
weeks and in nine (60%) after eight weeks. Another three patients were asymptomatic 
and declined further treatment, one patient healed with topical GTN and one underwent a 
sphincterotomy, one patient recurred within the first month, but responded to topical 
GTN treatment. Cook and Mortensen (2000) commented on the reduction of squeeze 
pressure reported by Antropoli et al. (1999) that has not been reported in other studies 
and were unable to offer an explanation.
Diltiazem, a non-dihydropyridine calcium-channel blocker, also effects vascular smooth 
muscle relaxation and dilatation. Its clinical use is similar to nifedipine but it has cardiac- 
depressant activity, slowing automaticity and conduction through the atrioventricular 
node but it induces less vasodilatation.
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Carapeti et al (1998a, 1998b, 1999b) demonstrated that a single dose of oral diltiazem 
significantly lowered the mean resting anal sphincter pressure by 21%, from 97 ± 17 to 77 
±11 cmFbO and in a twice-daily dose by 17%, from 97 ± 17 to 80 ± 14 cmFfeO; two 
(20%) of 10 subjects described postural dizziness. The investigators sought to achieve a 
similar effect with a topical dose of diltiazem gel. A maximal effect was produced by 2% 
diltiazem. The mean resting anal pressure was reduced by 28%, from 105 ± 12 to 76 ± 11 
cmthO. This effect lasted three to five hours after application, and no side effects were 
observed in the 10 subjects that were studied. Higher concentrations of 5% and 10% 
topical diltiazem produced no additional effect. It was noted that neither the oral nor the 
topical preparations of diltiazem caused an increase in the anodermal blood flow 
measured using a laser doppler flowmeter. These encouraging reports offered an 
alternative to GTN in the treatment of chronic anal fissures.
Carapeti et al (2000) proceeded to examine the effectiveness of 2% topical diltiazem gel 
applied thrice daily for eight weeks in 15 patients with chronic anal fissures whose 
median age was 37 (range 26 to 66) years. The starting resting anal pressure was elevated 
in 14 patients (>120 cmH20); one patient had a normal resting pressure of 85 cmH20. At 
eight weeks 10 (67%) of 15 the fissures had healed. Of the remaining five, one was 
asymptomatic and had a normal resting pressure, despite persistence of the fissure, and 
four remained symptomatic and opted for internal anal sphincterotomy. There was no 
significant difference in the pre-treatment maximum resting anal canal pressure between 
responders (median 120; range, 85-156 cmH20) and nonresponders (median 136; range,
73
110-140 cmt^O) or in the post-treatment maximum resting anal pressure between 
responders (median 88; range, 80-104 cmFfeO) and nonresponders (median 94; range, 82- 
142 cmthO). No headaches or side effects were reported. In the whole group there was 
an overall significant reduction in mean maximum resting anal canal pressure of 24.4% 
and median pain scores after treatment. This study also demonstrated that there was no 
significant difference in anodermal blood flow before and during treatment measured by 
laser doppler flowmetry.
Knight et al. (2001) reported on a prospective assessment of 71 patients, median age 39 
(range 12-76) years with chronic anal fissures, treated with 2% topical diltiazem gel twice 
daily. At the first review, after an eight week course, 47 (73%) of 64 who attended the 
first review healed, 17 with an unhealed fissure were given the option of a further course 
of diltiazem, topical 0.2% GTN or internal sphincterotomy. Of these, 12 had a second 
course of diltiazem, of whom 8 healed after a further course of treatment. At median 
follow up of 32 (range 14-67) weeks 27 (66%) of 41 assessed remained asymptomatic, 
seven had mild symptoms with healed fissures and seven had a fissure recurrence of 
whom three healed with further topical diltiazem gel, three healed with topical GTN and 
one underwent internal sphincterotomy.
Jonas et al. (2001b) investigated the role of oral diltiazem as a potential treatment for anal 
fissures and randomly assigned 24 patients, median age 35 (range 18-61) years, to receive 
oral (60mg) diltiazem and 26 patients, median age 35 (20-80) years to have topical 2% 
diltiazem twice daily for eight weeks. The maximum anal resting pressure fell
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significantly after the first dose in both groups; by 15% from a mean of 95 to 81 cmt^O 
on oral treatment and by 23% from a mean of 102 to 79 cmFfeO on topical treatment. At 
eight weeks the fissure healed in 9 (38%) who were on oral diltiazem and in 17 (65%) 
who had topical diltiazem. Oral diltiazem caused side effects in 8 patients; headaches in 
two, nausea or vomiting in three, a generalised rash in two, and a reduced sense of smell 
and taste in one patient. Seven of these patients did not complete the 8 weeks prescribed 
course of treatment. No patient on topical diltiazem reported side effects. There were no 
changes in pulse or blood pressure which may be due to the low oral dosage and to 
negligible systemic absorption of the topical preparation.
Kocher et al. (2002) randomly allocated 29 patients with fissures, median age of 39 
(range 21-73) years, to receive 0.2% topical GTN twice daily and 31 patients, median age 
of 45 (21-73) years, to receive 2% topical diltiazem also twice daily. After 6-8 weeks, 21 
(72%) in the GTN group experienced side effects (mainly headaches) compared with 13 
(42%) in the diltiazem group. Three patients treated with diltiazem reported perianal 
itching or pruritis severe enough to discontinue treatment, but no patient reported 
incontinence. Symptomatic relief was achieved in 25 (86%) patients at 8 weeks in the 
GTN group, of these 12 healed and 13 improved. Similar relief was achieved in 24 
(77%) patients in the diltiazem group, of whom eight healed and 16 improved. Thus, as 
the efficacy of topical diltiazem is similar to GTN with lesser side effects it was 
recommended as a first line for treatment for chronic anal fissures.
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Jonas et al. (2002) have presented evidence that topical diltiazem healed GTN-resistant 
fissures. In 39 patients, median age 42 (range 20-80) years, with chronic anal fissures 
that had failed to heal on 0.2% GTN, 2% diltiazem gel was administered topically twice 
daily for 8 weeks. The 39 patients comprised 27 who had completed a course of GTN but 
had not healed. Of these, 12 (44%) healed with diltiazem and there were 12 who could 
not complete their GTN course due to headaches; of these 7 (58%) healed.
DasGupta et al. (2002) reported on 23 patients, median age of 45 (range 22-80) years who 
had symptoms for a median of 6 (range 2-36) months and were treated by 2% topical 
diltiazem as a thrice-daily application. The fissure healed in 11 (48%) of the group, 
usually by 8 weeks; the 12 remaining patients either underwent lateral sphincterotomy, 
used GTN or declined further intervention. This study reaffirmed the increasing 
acceptance for topical diltiazem and suggested using it to control symptoms while 
patients were waiting for internal sphincterotomy.
Griffin et al. (2002) contacted 35 of 50 patients, median follow-up period of 31 (range 
27-37) months that had been treated by Jonas et al. (2001). Of those 17 responders, seven 
(41%) reported recurrent symptoms after a median duration of 6 (range 1 to 35) months 
with episodes lasting from 3 days to 2 weeks. Of these seven with symptomatic 
recurrence, four required further treatment with GTN, two of whom healed with GTN and 
two received injections of botulinum toxin and healed. None of the patients in the 
original responding group required surgery. The long term healing rate for GTN reported 
by Lund and Scholfield (1998) was 73% at a median follow up of 28 months and in
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Kennedy’s series (1999) 59% remained healed at a mean follow up of 28.5 months. 
These studies confirm that, whilst topical agents heal chronic fissures, there is an 
appreciable recurrence rate.
1.7.3. MUSCARINIC AGONISTS
Few studies have involved topical muscarinic agonists. Carapeti et al. (1999b) 
investigated 10 volunteers, median age 36 (range 21-49) years in whom 0.05%, 0.1%, and 
1% bethanecol gel was applied to the anal verge. There was a dose-dependent reduction 
in the maximum resting anal canal pressure with a 24% significant reduction from a mean 
of 108 to 82 cmFkO sustained for 4 (range 3-5) hours that was achieved with 0.1%; 
higher doses did not produce a greater effect. Carapeti et al. (2000) then went on to 
report the use of 0.1 % bethanecol gel in 15 patients with chronic anal fissures, median 
age 34 (range 20-75) years. After 8 weeks 10 (66%) were asymptomatic, in 9 (60%) the 
fissure had healed with relief of symptoms; in one asymptomatic patient the fissure 
persisted, 4 with unhealed fissures underwent sphincterotomy and the last patient 
withdrew because she was pregnant. There was a significant reduction in the maximum 
resting anal canal pressure, from a mean of 118 to 99 cmFfeO; and in the pain scores, 
from a median (range) of 5.5 (4.5-8) to 0.5 (0-3) after 8 weeks treatment. No headaches 
or side effects were reported. There was no significant change in the anodermal blood 
flow measured by laser doppler flowmetry before and during treatment.
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1.7.4. SYMPATHETIC NEUROMODULATORS
Hieble and Ruffolo Jr. (1996) described the use of a-i adrenoceptor antagonists in the 
management of symptomatic urethral obstruction caused by a-adrenoceptor-mediated 
contraction of the stromal smooth muscle of benign prostatic hypertrophy. Eckardt et al. 
(1996) reported that inhaled salbutamol, a P2-agonist, shortened attacks of severe pain in 
patients with proctalgia fugax.
Pitt et al. (2000) investigated the effect of indoramin, as an a -1 adrenoceptor antagonist, 
on the internal anal sphincter in seven patients with chronic anal fissures, mean age 38 
(range 24-48) years and six healthy volunteers, mean age 52.2 (range 30-71) years. 
Following a single 20 mg oral dose of indoramin, anal manometry was performed using a 
water-filled microballoon by a station pull-through method at one cm intervals, with 
equilibration of the pressure before a reading was taken. The measurements were 
repeated at one, two and three hours post ingestion. The mean maximum resting anal 
canal pressure reduced significantly from 106.9 to 68.6 cmtfeO, a 35.8% reduction in the 
patient group and from 84.2 to 52.2 cmt^O, a 39.9% reduction in controls at one hour. 
These significant reductions were maintained at two and three hours in both groups. No 
adverse cardiovascular or other effects were experienced by any subjects in the study. 
The heart rate increased from a mean of 82.3 beats per minute to a maximum of 87.5 
beats per minute after two hours and reduced to 84.7 after three hours. The mean blood 
pressure reduced significantly from 156.3 mmHg to 138.3 mmHg after 2 hours and
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increased to 145.3 mmHg after 3 hours. The maximum resting anal canal pressure in 
both controls and patients with anal fissures was at 1 to 2 cm from the anal verge; this 
profile was not altered by indoramin. This initial study prompted further investigation 
into indoramin as a therapeutic agent for chronic anal fissures.
Ojo-Aromokudo et al. (1998) conducted a pilot study in volunteers and patients with 
chronic fissures using a dose of 4mg oral salbutamol. Combining Pitt et al. ’s (2000) data 
with his results he noted that whilst there was no apparent difference in the a- 
adrenoceptors in the IAS of patients with anal fissures compared with controls, as 
measured by the reduction in anal canal pressure after the administration of indoramin, 
the p-adrenoceptors are probably up-regulated in patients with anal fissures, as the 
reduction in anal canal pressure was higher in patients with fissures than in controls. 
Regadas et al. (1993) have also demonstrated up-regulated P-adrenoceptors in vitro 
where supersensitivity to relaxation by isoproterenol, a P-adrenoceptor agonist, was 
demonstrated in IAS strips removed from patients undergoing lateral sphincterotomy, as 
compared with IAS strips removed from patients with third-degree haemorrhoids.
Pitt et al. (2001b) proceeded to conduct a double-blind randomised placebo-controlled 
trial of oral indoramin to treat 23 patients with chronic anal fissure. They treated 14, 
mean age 37 years, with 20mg oral indoramin; and nine, mean age 39 years with a 
placebo; seven patients in the indoramin group and two patients in the placebo group 
withdrew within the first 2 weeks of treatment due to side effects that included fatigue, 
dizziness, headache, dry mouth, nasal congestion, and retrograde ejaculation. At six
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weeks the fissure healed in only one (7%) compared with two (22%) in the placebo 
group. The fissure that healed with indoramin recurred at three months. The 
investigators felt, on the basis of these results, that it was ethically inappropriate to 
continue with the study. Given that other similar agents that reduced resting anal canal 
pressure went on to heal chronic anal fissures it was not clear why indoramin had failed.
The conclusions of Ojo-Aromokudo et al (1998) and Regadas et al (1993) are in direct 
conflict with recent work by Acheson et al (2002) who investigated 15 volunteers in a 
randomised, double-blind, placebo-controlled, cross-over trial of 4mg oral salbutamol. 
They showed that there were no significant differences between salbutamol and placebo 
when the fall in resting anal canal pressure at each time point were compared. Two hours 
after ingestion, the mean resting anal pressure was reduced by 3.0 % in the salbutamol 
group and 12.2 % in the placebo group and there were no significant changes in squeeze 
pressures. Blood pressure and heart rate all increased but did not reach statistical 
significance. Two volunteers developed a minor tremor and one had palpitations with the 
active drug. The investigators were doubtful whether sympathetic modulators could yield 
a therapeutic benefit for chronic anal fissures.
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1.7.5. BOTULINUM TOXIN
Clostridium botulinum produces several toxins, of which types A, B and E have been 
linked to cases of botulism in humans. Botulinum toxin type A is of therapeutic value in 
various neurological and opthalmological disorders. Brooks in the 1950’s suggested that 
botulinum neurotoxin type A might be used to reduce muscle hyperactivity [Schantz, 
1994]. Botulinum neurotoxin type A (BoNT/A) was first used clinically by Scott (1980) 
as an injection into the extraocular muscles to treat strabismus.
Schiano et al. (1998) described the first use of botulinum toxin in the gastrointestinal tract 
in the treatment of achalasia. BoNT/A acts presynaptically by blocking acetylcholine 
release at the neuromuscular junction [Mandal and Robinson, 2001].
The first account of botulinum toxin in the treatment of an anorectal condition was for the 
treatment of 7 patients with anismus [Hallan et al., 1988]. After injection of botulinum 
toxin into the striated muscle complex the symptom scores improved significantly and 
correlated with a significant reduction in the maximum voluntary and canal squeeze 
pressures. Joo et al. (1996) injected 6 units of botulinum toxin into either side of the 
paradoxically contracting muscle (at either the external anal sphincter (EAS) or the 
puborectalis muscle) in 4 patients with anismus that had failed treatment with 
biofeedback. All improved within 1 and 3 months after injection and 2 had sustained 
improvement for a period of 3 months to 1 year.
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Jost (1997a) investigated the neurophysiological effect of Botox (botulinum toxin) on the 
EAS and demonstrated a temporary reduction of the amplitude of the optimum response 
after stimulation of the pudendal nerve without a change of nerve latency. This 
phenomenon via inhibition of acetylcholine release is translated clinically into incomplete 
contraction of the muscle. The mechanism of action on the IAS has only recently become 
apparent. Jones et al (2002a, 2003) demonstrated that the contraction of isolated porcine 
IAS in an organ bath was inhibited by guanethidine consistent with this being mediated 
by sympathetic noradrenergic nerves. Although treatment with botulinum toxin increased 
myogenic tone by 38%, it reduced electrically field stimulated contraction. The 
investigators concluded that when botulinum toxin was used in the treatment of anal 
fissures the blockade of the sympathetic output probably outweighed its effect on 
increasing myogenic tone. Jones et al. (2002b) proposed that as the sympathetic drive on 
IAS in patients with chronic anal fissures was increased, botulinum toxin was a more 
specific pharmacological agent.
Jost and Schimrigk (1993) first described the use of botulinum toxin in the treatment of 
anal fissures. They injected 2.5 units of Botox (Allergan Pharmaceuticals, Irvine, Ca, 
USA) into the EAS on both sides of a chronic anal fissure in a 42-year old woman where 
attempts at conservative management had failed. Pain resolved after one day, the 
sphincter tone was reduced by the third day. The fissure healed and the sphincter tone 
returned to normal by 12 weeks. Jost and Schimrigk (1994) reported that 10 (83%) of 12 
patients treated in the same manner healed by 3 months with no disturbance in continence 
or change in manometric measurements.
82
Gui et al (1994) described the effect of three injections of 5 units of botulinum toxin into 
the internal sphincter in 10 patients. At one week pain disappeared in 7 patients and 
diminished in one. The resting pressure was reduced by 23.9%, whilst the voluntary 
squeeze pressure was unchanged. After 2 months the fissure healed in 7 (70%) patients, 
while the resting pressure remained low and the maximum voluntary pressure was 
unaffected.
Jost and Schimrigk (1995) reported their experience from 1992 in treating 26 patients 
with chronic anal fissures of average duration of 15 months. On the first day after 
injection in 19 (73%) the pain resolved and at 3 months 21 (81%) healed, with one case 
of mild incontinence that recovered completely. There were no recurrences in 19 patients 
assessed at six months and in 14 assessed at one year. Jost and Schimrigk collating their 
results in a pooled series of 50 patients with anal fissures, reported that, apart from 
temporary incontinence, an additional unwanted side effect of perianal thrombosis in 
19.2% of 26 female patients treated.
Mason et al (1996) demonstrated that either one or two injections of 0.125 ng or two 
injections of 0.5 ng of botulinum toxin into the lower fibres of the IAS in five male 
patients lowered the resting anal canal pressure without adversely affecting other 
anorectal physiological variables. The maximal resting anal canal pressure decreased 
from a mean (s.d.) of 146.6 (5.2) cm H2O by 23.2 (5.6) cm H2O. In two patients this was 
maintained for three months, in two patients the resting pressure was higher than pre­
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treatment levels, while the voluntary squeeze pressure did not significantly change, and 
the last patient refused manometry.
Jost (1997b) injected either 2.5 or 5 units of botulinum toxin into the EAS in 100 patients 
with chronic anal fissures at one week 78% were pain-free. The fissures healed in 82% at 
three months and in 79% at six months, seven complained of incontinence for flatus for 
less than two weeks, and two female patients experienced faecal incontinence for one 
week. All with unhealed fissures had an internal sphincterotomy.
Espi et al. (1998) injected 20 patients with 5 units of Botox on either side of an anal 
fissure, and 16 patients with an additional 5 units below the fissure. The healing was 
65% and 81% respectively at 6 months.
Maria et al. (1998a) in a double blind randomised trial compared 20 units of botulinum 
toxin injected into the internal anal sphincter with saline injections in 30 patients. The 
healing rates at 2 months were 73% in the treatment group compared with 13% in the 
control group. The reduction in resting anal canal pressure was 25%, in those injected 
with botulinum toxin, and was insignificant in the control group, while the voluntary 
pressure was unaltered in both groups. Maria et al. (1998b) investigated the 
effectiveness of larger doses of Botox injected into the IAS. The first group of patients 
with fissures received 15 units injected into the internal sphincter; the second group 
received higher doses of 20 and 25 units respectively. In a direct comparison it was 
found that whilst both 15 units and 20 units of Botox reduced resting pressure at one
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month, only the higher dose caused in a sustained reduction at 2 months. Once again the 
maximum voluntary pressure was unchanged in both groups.
Brisinda et al. (1999) compared the effectiveness of 20 units of botulinum toxin injected 
into the IAS and topical nitroglycerin in 25 patients in each group. Healing of the fissure 
at one month was shown in 24 (96%) and 15 (60%) patients with a reduction in resting 
pressure of 26% compared with 17% respectively.
Jost and Schrank (1999a) treated 50 patients with an alternative form of botulinum toxin 
type A, Dysport (Ipsen Pharmaceuticals, Dublin, Ireland), in doses of 10 units or 20 units 
injected adjacent to the fissure margins, with a comparable healing rate of 78% by 3 
months. The external sphincter tone as measured manometrically was reduced as well as 
the puborectalis tone, although the authors did not mention how the tone of the latter 
muscle was measured.
Minguez et al. (1999) examined 3 different doses (10 units, 15 units and 21 units) of 
Botox in 69 consecutive patients (groups I, II, III) with chronic anal fissures. After one 
month pain relief was more evident in the second and third than in the first group (74%, 
100%, and 48% respectively). There was a significant reduction of MRP only in groups 
II and III, but the squeeze pressure decreased significantly in all three groups. The need 
for reinjection due to persistence of symptoms or early relapse in the individual groups 
was 52%, 30%, and 37% and for subsequent internal sphincterotomy which occurred 
from two to six months was and 17%, 19%, and 5% respectively.
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Jost and Schrank (1999b) investigated the effect of repeated injections in anal fissures 
that relapsed or where initial treatment was ineffective. In the fissures that recurred and 
were treated with the same 5 unit dose, 14 (70%) of 20 healed and, of 30 that had failed 
initial treatment, 19 (63%) healed when treated with 10 units. This reaffirmed botulinum 
toxin as an effective treatment for recurring anal fissure as well as in therapeutic failure of 
prior toxin injections.
Maria et al. (2000) treated 50 patients with chronic posterior anal fissures by injection of 
20 units of botulinum toxin either into each side of the posterior (group 1) or the anterior 
(group 2) midline. At 2 months the fissures in 15 (60%) patients in group 1 healed 
compared with 22 (88%) in group 2. Injection into the anterior midline also resulted in 
lower of resting pressures and produced early healed scars. The authors suggested that 
the poorer response when the injection was directed to the posterior midline could be due 
to destruction of myenteric nerve fibres associated with the fibrosis or ischaemia 
associated with posterior chronic fissures.
Lysy et al. (2001) randomly assigned 30 patients with chronic anal fissures that did not 
respond to topical isosorbide dinitrate were to either a single injection of 20 units of 
botulinum toxin followed by 2.5 mg topical isosorbide dinitrate thrice daily for three 
months or botulinum toxin alone. At six weeks the fissures healed in 10 (66%) of 15 of 
the former group and 3 (20%) in the latter group. The reduction in maximum resting anal 
canal pressure after isosorbide dinitrate was significantly greater when applied after than
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before. The authors suggested that the improved potency of isorbide dinitrate on 
maximum resting anal pressure after botulinum toxin injection suggested a primary 
cholinergic tonus dominance in some patients and not as previously claimed anal 
sphincter insensitivity to nitrates.
As with other forms of combination therapy the optimal dosage of botulinum toxin in 
combination with topical nitrates was unclear. Madalinski et al. (2001) administered 50 
to 100 units of botulinum toxin in 13 patients with fissures previously treated with topical 
nitrates and 25 units of botulinum toxin; seven (54%) of 13 healed, and one patient 
required 100 units before the fissure healed.
Brisinda et al. (2002) examined the effectiveness of increasing doses of botulinum toxin 
injected into the IAS in promoting healing in 150 patients with chronic anal fissure. 
Group 1 received 20 units initially and a repeat 30 units injection if the fissure persisted; 
group 2 had 30 units injected initially and retreatment with 50 units if necessary. One 
month after injection 55 (73%) in group 1 and 65 (87%) in group 2 healed; five patients 
in group 2 reported incontinence of flatus that resolved spontaneously after two weeks. 
At two months there were 67 (89%) in group 1 and 72 (96%) in group 2 with healed 
fissure scars. In group 1 six (8%) fissures recurred after they had healed at one month, 
the fissure persisted in three patients in group 2, and never healed in two other patients.
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1.7.6. OTHER POTENTIAL AGENTS
The expansion of novel therapies to modulate anal sphincter tone is based on the 
understanding of the innervation of the IAS. Trimebutine (3,4,5-trimethoxybenzoic acid 
2-(dimethylamino)-2-phenylbutylester) causes the release and modulation of peptides and 
has actions mediated through opiate receptors [Delvaux and Wingate, 1997]. 
Trimebutine 200mg thrice daily was more effective than a daily dose of 400mg of 
mebeverine in reducing the frequency, duration and intensity of pain attacks in patients 
with irritable bowel syndrome [Schaffstein et al., 1990]. Ho et al. (1997) investigated the 
role of trimebutine, reducing anal sphincter spasm and thus in relieving pain after 
haemorrhoidectomy. In a randomised trial 80 patients who received trimebutine in 
suppository form showed a 35% mean reduction in resting anal canal pressure, but there 
was no difference with controls in the pain score at four hours after haemorrhoidectomy. 
The pharmacological action of trimebutine on the IAS, and its potential role in the 
treatment of anal fissures has yet to be defined.
There have been now numerous agents and surgical methods developed that have a role 
in the treatment of chronic anal fissures. Recent evidence in the form of appropriately 
conducted randomized trials has helped to clarify dosages, success rates, complications 
and recurrences. Brown et al. (2002) produced a management algorithm for those with 
persistent and recurrent fissures. It would appear that if initial conservative treatments 
fail surgery with selected use of endoanal ultrasound is appropriate.
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1.8. GUT MOTILITY AND THE INTERNAL ANAL SPHINCTERS
Motility of a particular gut segment depends on its extrinsic and intrinsic innervation. 
The extrinsic innervation is from preganglionic parasympathetic and postganglionic 
sympathetic nerves which constitute the autonomic nervous system. Primary afferent 
neurones through which visceral impulses are conducted into the central nervous system, 
effect reflex connections with preganglionic visceral efferent neurones. Functionally and 
anatomically they are related to the autonomic nervous system. Enteric nerves provide 
the intrinsic innervation. The anal sphincter complex, which controls defaecation, 
consists of an inner ring of smooth muscle (the internal anal sphincter; IAS) and an outer 
ring of skeletal muscle (the external anal sphincter; EAS). The IAS is an involuntary 
muscle that maintains anal tone. It is normally in a state of tonic contraction, due partly 
to the intrinsic myogenic properties of the smooth muscle and partly to extrinsic neural 
influences (Frenckner, 1975; Frenckner and Ihre, 1976). The EAS is a voluntary, 
fatigable muscle, supplied by a somatic nerve that provides short-term augmentation of 
anal pressure to postpone defaecation.
There has been much recent clinical interest in the pharmacological manipulation of the 
internal anal sphincter muscle tone, based on the understanding of the intrinsic 
mechanisms of smooth muscle contraction and of the complex neural control of sphincter 
motility.
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1.8.1. AUTONOMIC TRANSMITTERS AND PHARMACOLOGY
The autonomic nervous system anatomically comprises the craniosacral parasympathetic 
and thoracolumbar sympathetic components, and, with the enteric nervous system, 
constitutes the efferent innervation of every body tissue except skeletal muscle (Kuntz, 
1946; Langley, 1921). Autonomic nerves are predominately efferent, but are associated 
with sensory visceral afferent fibres.
The original classification of the autonomic nerves, as devised by Dale (1911), was based 
on the release of primary transmitters acetylcholine and noradrenaline. Those neurones 
that synthesise and release acetylcholine are termed “cholinergic”. These include almost 
all preganglionic efferent fibres leaving the central nervous system, all parasympathetic 
postganglionic and a few sympathetic postganglionic fibres. Neurones that release 
noradrenaline are termed “adrenergic” or more accurately “noradrenergic”, and include 
most postganglionic sympathetic fibres. It is now known that there are many different 
transmitters in autonomic neurones, these include purines (Hoyle, 1996a), peptides 
(Hoyle, 1996b) and nitric oxide.
Cholinergic receptor subtypes, known as ‘muscarinic’ and ‘nicotinic’ were named after 
the alkaloids originally used in their identification. Dale noted that the cholinergic action 
of muscarine, when directly applied to autonomic effector tissues, was mediated by 
receptors at the effector cells and not by those in the ganglia. Nicotine, by contrast, was
90
found to stimulate autonomic ganglia. Noradrenergic receptors are simpler to define in 
terms of their response to certain catecholamines and are, therefore, known as 
adrenoceptors. Ahlquist (1948) hypothesised that catecholamines act via two distinct 
receptors, a  or P, and this was confirmed with the use of specific antagonists. In most 
smooth muscles a  effects are excitatory and p effects are inhibitory, phenoxybenzamine 
and phentolamine block a-receptors and p-receptors are blocked by propanolol.
The adrenoceptors are further subclassified according to their preferential selective 
response to agonists and antagonists. The subtypes of a-receptors have been identified 
with radiolabelled antagonists that distinguish between ai and 0L2 receptors; for example 
prazocin antagonises a  1-receptors, yohimbine antagonises a 2-receptors, and 
dihydroergocryptine antagonises both ai and a2 receptors. The intracellular effect of ai- 
receptor stimulation is mediated via an increase in inositol-1,4,5- trisphosphate (IP3), but 
a 2-receptor effects are mediated via a decrease in cyclic adenine-3*5’-monophosphate 
(cAMP). pi and P2 receptors are defined by their affinities for adrenaline and 
noradrenaline, pi receptors having equal affinity for both agents, but p2 receptors have a 
higher affinity for adrenaline and they respond to isoprenaline. The intracellular effect of 
p-receptor stimulation is mediated via an increase in cAMP. There are more divisions of 
adrenoceptor subtypes, and in the gut they have roles in secretion and motility, ai- 
adrenoceptors are located postjunctionally on smooth muscle cells and intrinsic neurones, 
while a 2 adrenoceptors may be present both pre- and postsynaptically. pi and P2-
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adrenoreceptors are found mainly on smooth muscle cells, but the former may be present 
on enteric neurons (De Ponti et al., 1996).
1.9. NERVOUS CONTROL OF THE INTERNAL ANAL SPHINCTER
The IAS receives its sympathetic innervation from the hypogastric pelvic plexuses. The 
parasympathetic innervation is from the first, second and third sacral segments via the 
pelvic plexus (Schuster, 1968). There seems to be some continuous excitatory 
sympathetic activity contributing to IAS tone but the precise interactions of the 
parasympathetic and enteric neurones are still poorly defined. Furthermore there is a 
myogenic component which contributes to normal IAS basal tone (Frenckner, 1975; 
Frenckner and Euler, 1975; Frenckner and Dire, 1976; Guiterrez and Shah, 1975).
1.9.1. IN  VIVO STUDIES
Most of the work investigating the adrenergic contribution to internal anal sphincter 
resting tone has been based on ideas introduced by Gaskell (1920). He suggested that the 
sympathetic nerves were excitatory and the parasympathetic inhibitory to the sphincter. 
Learmonth’s (1929) investigations on anaesthetised dogs, a decade later, confirmed 
Gaskell’s initial ideas. In these experiments, electrical stimulation of the lumbar 
sympathetic trunks and hypogastric nerves resulted in a contraction of the IAS. It was 
concluded that the IAS received some motor innervation through the lumbar sympathetic 
outflow. Clinical significance of these observations was given by Rankin and Learmonth 
(1930) who performed a limited sympathectomy in order to treat Hirschsprung’s disease
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and certain types of constipation. In a young anaesthetised woman, stimulation of the 
peripheral end of the cut presacral nerves (pre-ganglionic sympathetic nerves which 
divide into the hypogastric nerves) resulted in “strong clonic contractions of the sphincter 
followed by several weaker clonic contractions”. These findings were the subjective 
comments of a surgical assistant with his gloved finger in the anal canal.
Shepherd and Wright (1968) investigated three normal subjects and eleven patients with 
Hirschsprung’s disease or acquired sigmoid megacolon. They were unable to obtain 
simple or clonic contractions of the IAS with presacral nerve stimulation, as reported by 
Rankin and Learmonth (1930). Instead they demonstrated a clear inhibition of 
contraction of the sphincter with presacral nerve stimulation in all cases, but were unable 
to explain either the mechanism or the neurotransmitter involved.
Electrical stimulation of the hypogastric nerves produced consistent contractile responses 
in animal studies. Carlstedt et al. (1988) observed IAS contraction in cats, and similar 
contractile responses were reported in dogs (Mizutani and Nakayama, 1986) and in 
opossums (Shibamoto et al., 1994). However, in a recent study on human subjects, 
Lubowski et al. (1987) consistently obtained decreases in IAS tone in anaesthetised 
patients which were reproducible using a range of stimulation frequencies and intensities. 
They suggested that this effect was mediated through inhibitory P-adrenergic fibres.
Frenckner and Euler (1975) examined the influence of the autonomic nerves on the IAS 
in man by comparing the anal canal pressure in patients after a high or low spinal
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anaesthetic, or bilateral pudendal nerve blocks. These inhibit respectively autonomic and 
somatic supply to the sphincter complex, the parasympathetic and somatic supply, and the 
somatic motor nerve supply to the external sphincter muscle. They demonstrated a 
decrease in the anal canal pressure of 32mmHg with high spinal anaesthesia but only 
about lOmmHg with low spinal or pudendal nerve block. These findings reaffirm the 
theory that, at rest, there is a tonic excitatory sympathetic discharge to the IAS. The 
contribution of the parasympathetic supply is not as significant.
Penninckx’ group studied the physiological responses of the IAS in cats to various 
pharmacological agents. Adrenergic stimulation was performed by means of successive 
intravenous administration of adrenaline, noradrenaline and isoprenaline, while 
phenoxybenzamine and propanolol were used as a- and (3-adrenoceptor antagonists 
respectively (Kerremans and Penninckx, 1970; Penninckx et al., 1973). Pressure 
recordings were made by means of micro-balloons placed in the rectum and anal canal; 
simultaneous measurements of electrical activity in the internal sphincter and rectum 
were also obtained. They demonstrated two types of pressure waves in the normal anal 
canal; ‘anal pressure waves’ and ‘intestinal-like pressure waves’. The anal pressure waves 
are phasic contractions occurring at a frequency of between 8-30/min. The intestinal-like 
pressure waves are intermittent changes in the baseline pressure occurring at a rate of 2- 
5/min and usually lasting more than 10 seconds. They also showed that the anal pressure 
wave frequency and the level of the baseline pressure were increased by the 
administration of adrenaline and noradrenaline through activity of excitatory a- 
adrenoceptors. Attempts at defining the precise regulatory role of p-receptors were
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variable; an inhibitory effect was observed in 7/16 stimulations with isoprenaline after a- 
receptor blockade, implying that p-receptor stimulation has an inhibitory action on basal 
IAS tone.
Yamato and Rattan (1990) published their findings on the role of a-receptor subtypes, 
based on clinical anorectal physiological measurements in anaesthetised opossums. 
Pancuronium bromide was used to inhibit the external sphincter, whilst the resting 
pressure in the anal canal, representing the IAS tone, was measured by a 7-channel 
catheter assembly. They demonstrated that the ai-agonist phenylephrine caused a dose- 
dependent rise in the resting IAS pressure, with the more-proximal part of the anal canal 
producing a significantly higher response than the distal part. This response was 
antagonised by prazocin, an ai- antagonist. It was not modified by the neurotoxin 
tetrodotoxin (TTX), supporting the concept that cci-adrenoceptors reside on smooth 
muscle cells. Clonidine, an a 2-agonist, caused almost complete inhibition of IAS 
relaxation in response to rectal balloon distension; this response was antagonised by 
yohimbine. The site of action of clonidine was suggested to be proximal to the 
neuromuscular junction. These findings imply that activation of ai-adrenoceptors exerts 
primarily excitatory effects on the IAS smooth muscle, and activation of a 2-adrenoceptors 
exerts an inhibitory modulatory action on the recto-anal inhibitory reflex causing 
suppression of reflex-mediated IAS relaxation.
1.9.2. IN  VITRO STUDIES
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Parks et al (1969) described the effects of noradrenaline, adrenaline, isoprenaline, 
acetylcholine and nicotine on muscle strips obtained from the upper and lower parts of 
the human IAS. Noradrenaline caused contraction of both parts, but caused relaxation 
when given after exposure of the muscle strip to phenoxybenzamine, an a-receptor 
antagonist. This relaxation was attributed to stimulation of residual p-receptors, since 
this effect could be counteracted by pronethalol (a p-receptor antagonist). Isoprenaline 
caused relaxation of both parts of the sphincter, which was inhibited by pronethalol. The 
action of adrenaline on the lower IAS muscle strips was complementary to these 
observations as low concentrations produced relaxation by preferential stimulation of p- 
receptors and higher concentrations produced contractions by successive recruitment of 
a-receptors. Pronethalol antagonised relaxation and allowed a contraction to occur with a 
lower concentration, while phenoxybenzamine prevented the contraction and allowed 
relaxation. Fewer conclusions could be drawn about the action of nicotine and 
acetylcholine. Although nicotine produced relaxation of strips from the upper part of the 
IAS, it had no effect on the lower part and the mechanism of action could not be clarified 
from the data available. Acetylcholine induced contractions in most muscle strips from 
the upper part of the sphincter, whereas the lower part of the IAS was relatively 
insensitive.
Friedmann (1968) made similar observations when investigating the actions of 
catecholamines and nicotine on human isolated IAS muscle strips. Contractions occurred 
in both the proximal and distal parts of the IAS with noradrenaline, whereas there was 
either contraction or relaxation with adrenaline, and only relaxation with isoprenaline.
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Nicotine usually caused muscle relaxation, whereas dimethylphenylpiperazinium 
(DMPP), a nicotinic stimulant, caused contraction. This discrepancy was thought to be 
due to the differing molecular sizes of the drugs; nicotine released noradrenaline close to 
p-adrenoceptors, and DMPP released noradrenaline near to a-adrenoceptors. Both 
proximal and distal segments of the anal sphincter were relatively unresponsive to 
acetylcholine; only minor contractions or relaxations occurred, despite the addition of the 
anticholinesterase physostigmine.
There had been no uniform consensus regarding the action of acetylcholine on IAS tone 
(Bass et al., 1970; Friedmann, 1968; Parks et al., 1969). Burleigh et al. (1979) sought to 
clarify the responses of isolated human IAS to cholinergic and to electrical field 
stimulation. The experiments reported represented data from 408 strips from 55 
operative specimens; they noted that acetylcholine and bethanechol usually relaxed 
muscle strips; this effect was abolished by hyoscine and antagonized to a varying degree 
by tetrodotoxin. Sphincter muscle was also relaxed by electrical field stimulation of 
intrinsic nerves; this response was blocked by tetrodotoxin but unaffected by 
hexamethonium, hyoscine, or propranolol.
The effects of acetylcholine were mediated via by muscarinic receptors on non-adrenergic 
non-cholinergic (NANC) inhibitory enteric neurones [Buckley and Caulfield, 1992]. 
Since the predominant inhibitory transmitter of NANC transmission in the IAS has now 
been identified as nitric oxide, it seems that acetylcholine relaxes the IAS by stimulating 
nitric oxide synthesis. They also demonstrated that bethanecol, a cholinergic agonist that
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selectively stimulates muscarinic receptors, relaxed IAS strips. This is consistent with in 
vivo observations by Gutierrez and Shah (1975) where an infusion of bethanecol lowered 
basal anal pressure by stimulation of inhibitory muscarinic receptors. Electrical field 
stimulation always caused relaxations, by stimulation of these same NANC enteric 
inhibitory nerves. These relaxations were unaffected by hyoscine, propanolol, or 
hexamethonium which prevented relaxations to acetylcholine, isoprenaline, and DMPP 
respectively. However the response was prevented by tetrodotoxin, which blocks nerve 
action potential propagation, demonstrating the neural action of electrical field 
stimulation.
1.10. THE ENTERIC NERVOUS SYSTEM
The enteric nervous system was defined by Langley (1921) as a third division of the 
autonomic nervous system, which receives inputs from the sympathetic and 
parasympathetic divisions. It exists as a separate entity in the gastrointestinal tract and 
comprises the internal and external submucosal plexuses (Meissner’s and Schbadach’s 
plexus respectively), the myenteric plexus (Auerbach’s plexus) and the subserosal plexus 
- all of which are ganglionated (Furness and Costa, 1987). There are also non- 
ganglionated plexuses such as the deep muscular plexus and networks in the submucosa 
and lamina propria of the mucosa. Langley demonstrated histological differences 
between enteric neurones and neurones of other autonomic ganglia. He also showed that 
the connections between fibres from the central nervous system and the enteric neurones
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differ from those between the central nervous system and other peripheral ganglia. 
Specifically he noted the great discrepancy in number between the few fibres in nerves 
running to the intestine and the large populations of enteric nerve cells. In addition he 
pointed out the existence of complex local reflex pathways within the enteric nervous 
system, which function as afferent, efferent or intemeuronal pathways. These constitute 
all the nervous components necessary for co-ordinated activities within the intramural 
plexuses, as exemplified by the recto-anal inhibitory reflex.
Gowers (1877) demonstrated that air injected into the rectum caused a rapid fall in anal 
canal pressure, due to relaxation of the IAS, followed by a steady return to the initial 
resting pressure. This response is now known as the “rectoanal inhibitory reflex” 
(RAIR). A normal reflex is elicited in patients with cauda equina lesions (Denny-Brown 
and Robertson, 1935), and in individuals with spinal cord transection (Burleigh and 
D'Mello, 1983), which clearly indicates that it is entirely intrinsic and independent of 
higher neural centres. The reflex is absent in Hirschsprung’s disease, which is 
characterised by an absence of ganglia in a variable length of the rectum and colon. It 
may be abolished temporarily after restorative rectal resection (Schuster, 1963), but in the 
long term is restored by regeneration of intramural neurones across the anastomosis (Lane 
and Parks, 1977). Sphincter function is often dependent on adjacent gastrointestinal 
movement, and its tone altered through the release of neurotransmitters. These are 
specific for each different gut sphincter (Bennett and Whitney, 1966).
99
Numerous enteric neurotransmitters have now been identified, several of which may be 
released from the same neurone. The release of these transmitters may be affected by pre- 
and post-synaptic neural modulation.
1.10.1. ENTERIC INHIBITORY NEUROTRANSMITTERS
The existence of enteric inhibitory neurones with unknown transmitters which do not rely 
on adrenergic or cholinergic transmitters, labelled non-adrenergic nor non-cholinergic 
(NANC), was first suggested by the work of Langley and Anderson (1896). The 
characterisation of the neurotransmitters involved came nearly seventy years later. 
Bumstock et al (1963) recorded hyperpolarisations in intestinal muscle during 
stimulation of the intrinsic nerves in the presence of atropine and the adrenergic neurone 
blocker bretylium. The block of these hyperpolarisations by tetrodotoxin suggested they 
were inhibitory junction potentials in response to stimulation of NANC nerves 
(Bumstock et al 1964; Bennett and Whitney, 1966). Inhibitory junction potentials are 
electrical events that underlie the relaxation of muscle; they are the hyperpolarising 
response of smooth muscle in response to nerve stimulation and, as such, they cause an 
inhibition of neurotransmission by inhibiting action potential propagation.
Circular muscle strips from the IAS relax via NANC inhibitory nerves when exposed to 
electrical field stimulation. Speakman et al. (1990) found that 4/5 control preparations
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showed a small contraction followed by relaxation. The contraction was abolished by the 
a-adrenoceptor blocker phentolamine.
There has been an extensive search for the intramural NANC transmitter responsible for 
inducing the IAS relaxation seen with rectal distension. The transmitters noradrenaline, 
acetylcholine, prostaglandins E2 and F2«, 5-hydoxytryptamine (5-HT) and dopamine have 
already been discounted as mediators for the RAIR (Burleigh et al. 1979). Over the last 
two decades work has concentrated on the function of adenosine triphosphate (ATP), 
vasoactive intestinal peptide (VIP), and nitric oxide (NO) and their role in mediating the 
RAIR, as they are known to act together in mediating enteric inhibitory co-transmission 
in other areas of the gut.
Adenosine Triphosphate (ATP)
There is evidence to suggest that ATP is a neurotransmitter in the enteric nervous system, 
and the release of ATP through electrical stimulation of enteric nerves has been 
measured. The pharmacological responses to ATP can be blocked by purinoceptor 
antagonists such as suramin or reactive blue 2 (Hoyle, 1996a). Although reliable 
histochemical stains for ATP are not known, a fluorescence technique involving 
quinacrine, which forms complexes with ATP, has been developed. Quinacrine is known 
to bind to compounds with transmitter-like properties, though its efficacy for neurones 
that have a high ATP content is uncertain. Despite its inhibitory action in other parts of 
the gut, there is no evidence of such a role for ATP in the IAS (Burleigh et al. 1979).
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Vasoactive Intestinal Peptide (VIP)
VIP has been identified as an inhibitory transmitter mediating lower 
oesophagealrelaxation (Biancani et al 1984). VIP neurones have been localised in the 
IAS (Alumets et al. 1978), and VIP is released in the venous effluent from the rectum 
following neural stimulation (Andersson et al. 1983). Biancani et al (1985) 
demonstrated that preincubation with VIP-antisera inhibited relaxation of IAS strips in 
response to both exogenously applied VIP and electrical field stimulation. Nurko et al. 
(1989) used specific VIP antagonists to demonstrate VIP as a NANC transmitter. The 
role of other co-transmitters cannot be discounted since VIP antagonists fail to inhibit 
completely IAS relaxation in response to lower levels (0.5Hz) of neural field stimulation.
Nitric Oxide (NO)
From their work on isolated strips of opossum IAS, Rattan and Chakder (1992) suggested 
the possibility of NO as an inhibitory neurotransmitter of NANC nerves in the human 
IAS. First, they showed that NO caused a tetrodotoxin-resistant relaxation in these strips. 
Second, they showed that L-N°-nitro-arginine, a NO synthesis inhibitor, caused a 
stereoselective suppression of the fall in IAS tension due to electrical field stimulation; 
this effect was counteracted by the application of the endogenous precursor of NO, L- 
arginine. This latter finding is consistent with Burleigh’s observations that L-N°-nitro- 
arginine reduced NANC relaxations of the human gut (Burleigh, 1992). Rattan suggested 
that NO worked in conjunction with VIP, since L-N°-nitro-arginine also suppressed the 
fall in resting tension of IAS in response to VIP (Rattan and Chakder, 1992).
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In further work on opossums, Chakder et al. (1993) demonstrated, by 
chemiluminescence, that NO was released in response to NANC stimulation. O’Kelly et 
al. (1993) in similar experiments on isolated human IAS strips, demonstrated a 
concentration dependent inhibition of IAS relaxation to electrical field stimulation by 
application of L-N^nitro-arginine, or the weaker competitive analogue of L-arginine, N- 
monomethyl-L-arginine. However the inhibitory effect of L-NNA was complete, 
disputing the involvement of other transmitters.
Using nitric oxide synthase immunoreactivity, and nicotinamide adenine dinucleotide 
phosphate (NADPH) diaphorase histochemistry, O’Kelly et al. (1994) presented 
morphological data suggesting that, in the human anorectum, NO synthase-containing 
neurones and their processes have the appropriate characteristics to serve as inhibitory 
motor nerves between the rectum and anal canal. Bult et al. (1990) demonstrated release 
of NO from NANC nerves. In a guinea-pig model, Stebbing (1998) using retrograde 
neuronal tracing and enzyme histochemistry, described direct anatomical evidence of an 
efferent descending nitrergic rectoanal pathway appropriate to mediating the motor 
response of the RAIR. NO activates soluble guanylate cyclase, thereby increasing 
production of cyclic guanosine-3’5’-monophosphate (cGMP) and relaxation of smooth 
muscle. NO is important in the RAIR, but other transmitters may have a role.
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1.11. SMOOTH MUSCLE CONTRACTION AND MAINTENANCE OF TONE
Autonomic and enteric neural stimulation regulates smooth muscle contraction in the 
IAS. Contraction of the IAS translates clinically into an increase in anal tone.
Muscle contraction is regulated by changes in cytosolic calcium (Ca2+) levels. Smooth 
muscle differs from striated muscle in the way that its contractile elements are activated. 
The two major contractile proteins in both muscle types are actin and myosin, which are 
structural components of the thin and thick filaments respectively.
In smooth muscle, Ca2+ regulation is affected via the various regulatory proteins 
including the myosin light chains, calmodulin, caldesmon, and calponin. Ca2+ release 
into the myoplasm occurs either by entry through voltage-gated or receptor-operated 
channels or by release from the sarcoplasmic reticulum via inositol triphosphate (fig. 
1.3.). Ca2+ binds to calmodulin which then activates myosin light chain kinase, thus 
inducing phosphorylation of the regulatory light chains of myosin. When actin has been 
activated, by caldesmon, phosphorylated myosin then attaches to actin, this results in the 
production of tension. Dephosphorylation of myosin induces either relaxation or may 
allow cross-bridges to enter the “latch state”, which is defined as a state of prolonged 
contraction in the smooth muscle with a low frequency of cross-bridge cycling. The 
precise mechanisms that are responsible for this maintenance of smooth muscle tone are 
still not entirely known.
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Relaxation of smooth muscle occurs when there is a resulting decrease in cytosolic Ca2+. 
This is effected through cellular mechanisms similar to those for contraction. In vitro 
studies of porcine IAS have shown that tone and spontaneous activity depend on the 
extracellular Ca2+ and flux across the cell membrane, whereas agonist-induced 
contractions were depend mainly on Ca2+ release from the intracellular sarcoplasmic 
reticulum [Cook et al. 1999b]. Understanding the mechanisms that maintain tone and
*  i
muscle contraction in relation to cellular Ca could aid the treatment of smooth muscle 
contractile abnormalities.
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Figure 1.3. Internal anal sphincter (IAS) smooth muscle cell contraction is dependent on a 
rise in cellular calcium (Ca2+). This can be effected by direct influx of calcium through 
mem brane Ca2+ channels or by stimulation of a r adrenoceptors. The latter pathway 
results in release of Ca2+ from the sarcoplasmic reticulum mediated via inositol-1’4’5’- 
triphosphate (IP3). Relaxation is induced by antagonising membrane Ca2+ channels or a i- 
adrenoceptors. Stimulation of p2-adrenoceptors results in a return of Ca2+ to the 
sarcoplasmic reticulum, mediated through cyclic adenine-3’5’-monophosphate (cAMP). 
Stimulation of nitric oxide (NO) containing non-adrenergic non-cholinergic (NANC) 
enteric neurones induces a cyclic guanosine-3’5’-monophosphate (cGMP) mediated 
decrease in cellular Ca2+. M uscarinic nerve stimulation, through the release of 
acetylcholine (Ach) promotes the synthesis of NO.
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CHAPTER TWO 
AIMS OF THESIS
2.1. INTRODUCTION
Idiopathic chronic anal fissures continue to cause significant morbidity in a relatively 
young population. It is generally thought that fissures develop from a traumatic insult to 
the anoderm, commonly in the posterior midline, and the subsequent anal spasm that 
develops compromises the vascular perfusion to this segment. This continued vascular 
ischaemia perpetuates the chronicity of a fissure. It is anal spasm that induces the pain 
patients present with. Whilst traditional therapeutic modalities for treatment of chronic 
anal fissures have been constantly re-evaluated newer non-surgical options have 
developed, with a common underlying objective. This is to effectively reduce maximum 
resting anal canal pressure sufficiently for healing to occur without a permanent 
detrimental effect on sphincter function. Sustained reduction in anal canal pressure after 
therapeutic benefit that is achieved may induce incontinence in the long term.
Accounts of surgical procedures extend from the early nineteenth century; these include 
anal dilatation, lateral sphincterotomy, midline posterior sphincterotomy, fissurectomy, 
and anal advancement flaps. Manual anal dilatation causes uncontrolled tearing of the 
anal sphincter complex and the shearing forces result in fragmentation of the sphincters 
that lead to incontinence in 12.5% of subjects, although not all patients with sphincteric 
defects experience incontinence. Controlled digital dilatation of the anus under 
neuromuscular blockade has been shown to reduce the incontinence rate to 3.8%. The 
midline posterior sphincterotomy with or without fissurectomy has been largely 
abandoned because of the keyhole deformity it creates that is responsible for faecal
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soilage. An advancement flap is reserved for patients with chronic anal fissures 
associated with normal or low resting pressure without anal spasm and after failed lateral 
sphincterotomy. Manometry and endoanal ultrasound are being used more often in 
patient selection.
Farouk et al. (1998) in a retrospective analysis defined the treatment strategy for chronic 
anal fissure between January 1990 and December 1996. Of 221 treated 209 underwent 
surgery. Manual dilatation of the anus was performed in 21 (10%) patients and was 
abandoned in 1995. Lateral internal sphincterotomy, the principal treatment, was 
performed in 183 (88%) patients; five female patients (2%) with a sphincter defect 
identified by anal manometry and endoanal ultrasound examination underwent anal 
advancement flap. Since 1996 15 (7%) were treated by topical GTN as the first line of 
treatment, in nine the fissure healed, three were relieved of pain without healing of the 
fissure, and three proceeded to lateral sphincterotomy.
Nelson et al. (1999) undertook a meta-analysis of operative methods for fissure-in-ano 
that looked at two end points, namely non-healing and flatus incontinence. These 
included anal stretch, open or closed lateral sphincterotomy, posterior midline 
sphincterotomy, and dermal flap coverage of the fissure. There were 17 reports 
encompassing 2727 patients. The authors concluded anal stretch and posterior midline 
internal sphincterotomy should be abandoned and either the open or closed technique of 
lateral anal sphincterotomy was equally efficacious.
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The role of open lateral sphincterotomy under sedation and local anaesthesia after failed 
conservative therapy was investigated in 2108 patients by Argov et al. (2000) with a 
follow up period ranging from 4 to 20 years. The short-term complication rate was 3%; 
this included temporary incontinence to flatus and liquid stool, usually subsiding within 2 
to 3 months; haematoma and wound infection; and urinary retention. There was 1% 
recurrence rate, occurring usually within the first year that necessitated re-sphincterotomy 
on the opposite side. There was not a single case of permanent incontinence.
Since Langley’s (1896) description of the autonomic nervous system much progress has 
been made in defining the neural pathways and their neurotransmitters that has led to 
better understanding of the neuromyogenic properties of the human internal anal 
sphincter and the role of pharmacological agents in the treatment of anal fissures. Nitric 
oxide is the predominant transmitter of the non adrenergic non cholinergic enteric 
neurones. When stimulated this pathway causes marked relaxation of the internal anal 
sphincter. GTN as a nitric oxide donor when applied topically (in a paraffin base at a 
concentration of 0.2%) reduces anal sphincter tone and has been used as a first line agent 
and induces healing of chronic anal fissures in two-thirds of patients. However headache 
has been its main side effect that has influenced patients’ compliance and hence its 
therapeutic use. Isosorbide dinitrate, which acts in a similar manner, has been used with 
equal efficacy although headaches are still common with its use. The contractility and 
maintenance of IAS smooth muscle tone is dependent on calcium. Diltiazem ointment 
(2%) prevents flux of calcium through L-type membrane channels and induces a 
reduction in maximum resting anal canal pressure. This agent is being used in preference
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to topical GTN with comparable results without causing headache or other side effects. 
Botulinum toxin is effective in the treatment of chronic anal fissures. It is believed it acts 
on the IAS by modulating the sympathetic neurones. Its use has been widely evaluated 
but its main drawback is its mode of delivery into the sphincters by injection, which 
besides being unpleasant for patients is a cause of sepsis and bleeding that complicate the 
procedure. The effect of oral indoramin, an a-adrenergic antagonist, and oral salbutamol, 
a p-adrenergic agonist on maximum resting anal canal pressure has been examined. Both 
agents cause a reduction in both patients with chronic anal fissures and healthy 
volunteers. However these observations have not been validated. The relaxant responses 
of these two drugs suggest up-regulation of P-adrenoceptors in patients with chronic anal 
fissures.
The work in this thesis takes into account several unresolved issues with respect to the 
pathophysiology of chronic anal fissures and the therapeutic role of pharmacological 
agents. GTN has been well evaluated in the treatment of chronic anal fissures. Diltiazem 
is emerging as an alternative and safer option and deserves similar scrutiny. While 
botulinum toxin is probably the most effective non-surgical modality its unacceptability 
seems to be related to its mode of delivery that if improved may promote its application. 
The search for the optimal pharmacological agent will continue and the potential effect of 
drugs on the sympathetic adrenergic receptors has not been adequately explored. A 
suitable animal model for human IAS would provide means of exploring the effect of 
pharmacological agents on the IAS.
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2.2. AIMS
Therefore the work presented in this thesis is in two sections: clinical applications and 
experimental work.
2.2.1. CLINICAL APPLICATIONS
1. Topical diltiazem in treatment of anal fissures
Diltiazem is showing promise as an effective agent in the treatment of anal 
fissures. The manometric response to this drug in relation to healing during and 
after cessation of treatment has not been previously investigated. Although some 
studies have attempted to define clinical prognostic indicators there is not 
sufficient evidence to draw out firm conclusions. An open trial with 2% diltiazem 
gel in 33 patients was conducted, and the healing and manometric responses 
measured during a six month period. The relationship of the clinical parameters 
to healing was examined.
2. Novel delivery of botulinum toxin for treatment of anal fissure
There is evidence that Botox (botulinum toxin, Allergan, UK) is effective 
treatment of chronic anal fissures. It is likely that direct injection into the 
sphincter complex may influence its acceptability by both clinicians and patients. 
The needle-less J-tip® syringe uses a prefilled carbon dioxide canister to eject its 
contents through a narrow port at its tip. It was essential to find out whether the 
therapeutic agent reached the target organ. This was indirectly determined by
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estimating the manometric and healing response in 10 patients with chronic anal 
fissures. It was appropriate to conduct studies in porcine anal sphincter to 
establish the optimal angle of injection for the Botox to infiltrate the IAS 
adequately.
3. Sympathetic modulation of the IAS
The effect of oral indoramin and salbutamol on IAS tone was re-examined with 
particular reference to side effects. A topical preparation of whichever drug that 
reduced maximum resting anal canal pressure with least side effects was 
formulated and tested in different doses in healthy volunteers.
2.2.2. IN-VITRO EXPERIMENTAL WORK
1. Validation of an animal model of human IAS tissue
Human IAS is not easily available for investigation of its neuromyogenic features. 
An animal model with physiological similarities was necessary. The physical 
characteristics of guinea pig tissue was initially examined and its responses to 
histamine, atropine, methoxamine, acetylcholine and electrical field stimulation 
(EFS) were quantified. A porcine model was then studied in a similar manner; 
phenylephrine was used to modulate the tone of the muscle. The effects of nitric 
oxide donors and antagonists, purinergic antagonists, a-adrenoceptor antagonists 
and botulinum toxin were also investigated.
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2. Investigation into the properties of porcine IAS muscle 
Most chronic anal fissures are associated with hypertonia, yet a reduction in 
maximum resting anal canal pressure with topical agents in these patients may not 
heal the fissure. The changes in the myogenic behaviour of IAS tissue as its tone 
was increased with phenylephrine was investigated. It was an attempt to find an 
explanation for the ineffectiveness of reduction in tone in the healing of some 
chronic fissures associated with hypertonia.
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CHAPTER THREE
TOPICAL DILTIAZEM IN TREATMENT OF
ANAL FISSURES
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3.1. INTRODUCTION
Lateral sphincterotomy allows healing of chronic anal fissures by reducing the MRP. 
Boulos and Araujo (1984) demonstrated a reduction in MRP after subcutaneous or open 
sphincterotomy. This magnitude of reduction is sustained, as Chowcat et al. (1986) has 
demonstrated in 28 patients one year after surgery. Whilst effective in healing fissures 
Khubchandani et al. (1989) report on long-term clinical sequelae of internal 
sphincterotomy was alarming as 35.1% of 829 patients complained of lack of control of 
gas ranging from “sometimes” to “frequently”, furthermore 56 (6.7%) expressed 
dissatisfaction with the result. Nyam and Pemberton (1999) found a 3% incontinence 
rate among 585 patients after sphincterotomy at a mean follow up of 72 months. While 
these reports and the endosonographic studies that emerged from Sultan et al. (1994) and 
Farouk et al. (1998) called for careful patient selection and precision in technique, 
investigators looking for a safer option explored the feasibility of chemical agents to treat 
chronic anal fissures that would not jeopardise sphincter function.
O’Kelly et al. (1993) discovery that nitric oxide was a significant neurotransmitter that 
induced relaxation in the IAS prompted clinical interest. Initial trials by Loder et al. 
(1994) using 0.5% and 1% GTN and subsequent work by Lund et al. (1996) using 0.2% 
GTN demonstrated the efficacy of GTN in healing fissures. The success with this agent 
was offset by headaches, which is its main side effect reported in at least 20% of patients 
[Gorfine (1995a), Lund and Scholefield (1996)] and alarmingly in 72% of patients 
investigated by Carapeti et al. (1999a). Dorfmann et al. (1999) also reported headaches
115
in 21 (78%) of 27 patients on GTN that were severe in 2 (10%) patients who as a result 
discontinued therapy. Palazzo et al (2000) treated 45 patients treated with GTN, 84% 
had headaches and 11% discontinued treatment. Richard et al (2000) used 0.5% GTN in 
11 and 0.2% GTN in 33 patients. In total, of the 44 patients assigned to GTN, 9 patients 
discontinued GTN because of headaches (8) or significant postural hypotension (1); 5 
(55%) were on 0.5% GTN, and 4 (45%) were on 0.25% GTN.
The healing rates reported in most recent trials ranged from 50 to 75%; in 29 (49.2%) of 
59 patients after a 4 week course of 0.2% GTN [Altomare et al (2000)], in 20 (50%) of 
40 patients by 12 weeks [Hasegawa et a l (2000)] and in 33 (73%) of 45 patients at 6 
weeks, although in this series a higher dose (0.5%) was prescribed [Palazzo et al (2000)].
Pitt et a l (2001a) showed that whilst the recurrence rate of anal fissures after successful 
treatment with GTN varies from 40% to 70%, of 26 (40.6%) of 64 patients with fissures 
healed initially with GTN, 12 (46.2%) recurred within 32 weeks. Graziano et al (2001) 
in a long-term series, of a median follow up of 39 weeks, showed that whilst 0.25% GTN 
healed 75% of chronic fissures and 83% of acute fissures, 67% recurred by 9 months. 
Richard et al (2000) identified among 13 (29.5%) of 44 patients with healed fissures 
with GTN 5 (38%) recurrences by 6 months.
Nifedipine and diltiazem are calcium channel antagonists that prevent calcium influx 
through membrane channels. This diminishes the tone of the IAS, and facilitates the
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healing of anal fissures by reducing the MRP and improves vascular perfusion of the 
anoderm.
Chrysos et al (1996) demonstrated that 20mg oral nifedipine reduced the MRP 
significantly in 10 patients with non prolapsing haemorrhoids and/or anal fissures and 10 
volunteers by 32% and 24% respectively. Antropoli et al. (1999) showed that 0.2% 
topical nifedipine gel healed acute anal fissures in 141 patients after 3 weeks with a 
reduction in MRP of 30% from 72.5 mmHg to 50.5 mmHg. Cook et al (1999a) found an 
oral dose of 20mg nifedipine reduced the MRP significantly by 36% from 102 to 65 
cmH20 in 15 patients with chronic anal fissures, 3 (20%) healed by 6 weeks and 9 (60%) 
after 8 weeks.
Carapeti et al (1998a, 1998b, 1999b) demonstrated that a single dose of oral diltiazem 
significantly lowered the mean MRP by 21%, from 97 to 77 cmP^O, and a topical 
application of 2% diltiazem significantly lowered the mean MRP by 28% from 105 to 76 
cmH20, an effect that lasted 3 to 5 hours after application, without side effects. Higher 
concentrations produced no additional effect. Carapeti et al (2000) treated 15 patients 
with chronic anal fissures with 2% diltiazem gel thrice daily for 8 weeks. The starting 
MRP was elevated in 14 patients (>120 cmH20) and one patient had a normal resting 
pressure. At 8 weeks the fissures healed in 10 (67%) patients, of the remaining 5 with 
unhealed fissures one was asymptomatic and had a normal MRP and 4 had internal anal 
sphincterotomy. There was no significant difference in the pre-treatment MRP between 
responders (median 120; range, 85-156 cmH20) and nonresponders (median 136; range,
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110-140 cmPfeO) or in the post-treatment MRP between responders (median 88; range, 
80-104 cmFhO) and nonresponders (median 94; range, 82-142 cmtbO). In the whole 
group there was an overall significant reduction in mean MRP but the anodermal blood 
flow was unaltered.
Knight et al. (2001) in a prospective study of 71 patients with chronic anal fissures 
treated with 2% topical diltiazem gel noted in 47 (73%) of 64 who attended the first 
review the fissures healed, of the 17 that did not heal 12 had a second course of diltiazem 
of whom 8 healed. At a median follow up of 32 (range 14-67) weeks 27 (66%) of 41 
remained asymptomatic, 7 had mild symptoms without recurrence of the fissure, and 7 
had a fissure recurrence of whom one underwent a lateral sphincterotomy, 3 healed with 
topical GTN, and 3 with further topical diltiazem gel.
Jonas et al (2001b) investigating the role of oral diltiazem as a potential treatment for 
anal fissures randomised 24 patients to oral (60mg) and 26 to topical 2% diltiazem twice 
daily for eight weeks. The mean MRP fell significantly after the first dose in both 
groups; by 15% from 95 to 81 cmffeO in the oral treatment group; and by 23% 102 to 79 
cmfbO in the topical treatment group. At 8 weeks the fissures healed in 9 (38%) patients 
who were treated with oral diltiazem compared with 17 (65%) who had received topical 
treatment.
There have been few studies on the long term results of topical diltiazem treatment. 
DasGupta et al. (2002) followed up 23 patients with fissures using a thrice-daily 2%
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topical diltiazem with symptoms ranging from a median of 6 (range 2-36) months. 
Fissure healing was seen in 11 (48%) of the group by a median follow up of 8 weeks; the 
12 remaining patients either underwent lateral sphincterotomy, used GTN or declined 
further intervention. Griffin et al (2002) in a long-term follow up study of 50 patients 
initially presented by Jonas et al. (2001b) contacted 35 with a median follow-up period of 
31 (range 27-37) months. Of 17 that responded 7 (41%) reported subsequent anal 
symptoms after a median of 6 (range 1 to 35) months.
Kocher et al (2002) randomised 29 patients with chronic anal fissures for treatment with 
GTN and 31 with diltiazem. After 6-8 weeks 21 (72%) of the GTN group experienced 
side effects, the most common being headaches, compared with 13 (42%) of the 
diltiazem group. 3 patients in the diltiazem group discontinued treatment because of 
perianal itching or pruritis. At 8 weeks 25 (86%) of 29 in the GTN group healed or 
improved compared with 24 (77%) of 31 patients in the diltiazem.
A chronic anal fissure is often not clearly defined in the reported results of different 
treatments. The clinical signs associated with chronic anal fissures include visible 
internal sphincter fibres, the presence of a sentinel pile, and a fibroepithelial polyp 
[Keighley and Williams, 1993]. Few studies have addressed the relevance of these 
features to the result of treatment by sphincterotomy or topical agents. Pitt et al (2001a) 
in a Cox model multivariate analysis in 64 patients with chronic anal fissures treated with 
topical GTN to determine prognostic factors for healing demonstrated that a history of a 
fissure exceeding 6 months and the presence of a sentinel pile were associated with
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failure of the fissure to heal. The presence of a sentinel pile was also associated with a 
higher recurrence rate, and therefore poor long-term healing. The authors suggested that 
patients with sentinel piles should be informed that topical GTN therapy was more likely 
to fail, and earlier sphincterotomy was advised.
The aims of this study were to determine in patients with chronic anal fissures the clinical 
and manometric response to topical diltiazem over a six-month period, with reference to 
the manometric patterns in responders and non responders. There have been no clinical 
studies that have assessed manometric responses beyond two months of treatment. The 
significance of duration of symptoms and the clinical features of the fissure in relation to 
the response and healing is also discussed.
3.2. METHODS AND PATIENTS
Thirty three consecutive patients were enrolled for this study. At initial evaluation of the 
patients’ symptoms and their duration, the presence of a fissure, a sentinel pile and anal 
canal spasm were noted. All patients and, for comparison, 10 control subjects in whom 
two measurements were taken at alternate days had anal canal manometry.
The patients were treated with 2% topical diltiazem ointment (SLA Pharma, Herts, UK) 
thrice-daily. They were instructed to apply to the anal verge about one inch expressed 
from the tube for 2 months and this was repeated if the fissure remained unhealed.
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At 2 monthly intervals until 6 months the patients had clinical and manometric 
evaluation. At each visit the presence or absence of symptoms was recorded and clinical 
examination of the anal canal when the patient was pain free and had no anal spasm 
included proctoscopy to assess healing defined as re-epithelialisation of the anal mucosa 
at the site of the fissure. Anal manometry was performed as described in Appendix 7, the 
results expressed in cml-feO and the combined results expressed as a median value with 
ranges. The data is graphically presented (Prism 3.0, Graphpad, San Diego) expressing 
the median values with interquartile ranges. Comparison of the MRP values was 
conducted using the paired or unpaired t test after analysing data for normality.
3.3. RESULTS
The results are shown in Appendices 2-10. There were 17 males and 16 females with 
median age of 33 (range 27-81) years with history of pain in 32 and rectal bleeding in 29 
for a median duration of 5 (1-36) months. On examination in all a fissure was confirmed, 
19 (57.6%) had anal spasm and 22 (66.6%) had sentinel piles. The control group 
included 5 males and 5 females with a median age of 28 (range 21-38) years. The sex 
and age distribution in patients and controls were similar (7>=NS). At the start of the 
study all 33 patients attended and again at 2 months but at 4 and 6 months more patients 
were cured or were reluctant to undergo manometry again {fig. 3.1).
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Pre treatment
The age, sex distribution and MRP are shown in Appendices 2 and 3. The median MRP 
in the 33 patients [110 (77-227)] was significantly higher than in the 20 healthy volunteer 
subject readings [88 (46-175) cmH20 ]  (P<0.05). (fig. 3.2.).
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Figure 3.2. Distribution of the MRP in 20 controls and 33 patients with chronic anal fissures 
prior to treatment with topical 2% diltiazem. The horizontal lines represent the median
values with interquartile ranges.
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Assessment at 2 months
The results are shown in Appendices 4 and 5. The fissures healed in 19 (58%) patients 
and 14 remained unhealed; 18 in the healed group and all o f  the 14 in the unhealed group 
presented with pain on defaecation; and 17 in the healed and 12 in the unhealed group 
presented with bleeding per rectum. After 2 months all with healed fissures were 
asymptomatic while in the unhealed group 4 patients still had pain on defaecation, 3 had 
rectal bleeding and the remaining 7 were asymptomatic. There was a significant 
reduction o f  25 %  in the MRP in all 33 patients [110 (77-227) v 83 (53-147) cm H2O, P  
< 0.0001] (fig. 3.3.).
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Figure 3.3. The median M RP in 33 patients with chronic anal fissures after 2 months 
treatm ent with topical 2%  diltiazem. The horizontal lines represent the median values with
interquartile ranges.
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In the 19 patients that healed the MRP was significantly reduced by 26% [110 (77-195) v 
81 (53-147) cm H20 ,  P<0.0001] (fig. 3.4.). In the 14 patients with unhealed fissures the 
reduction o f MRP was 17%, and this was also significant [111 (77-227) v 92 (56-136) 
cmH20 ,  P<0.01 ] (fig. 3.4.). The MRPs in the groups o f patients with healed and und 
unhealed fissures prior to treatment was not significantly different [110 (77-195) v 111 
(77-227) cmH20 ,  P=NS], in each group the MRP was significantly higher than in 
controls (P<0.05). After treatment the MRP in each group did not differ significantly [81 
(53-147) v 92 (56-136) cmH20 ,  P=NS] and was similar to the MRP in controls.
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Figure 3.4. The median M RP in 19 patients healed and 14 patients who did not heal 
after 2 months treatm ent with 2%  topical diltiazem. Interquartile ranges are displayed.
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The MRP in those with anal spasm and those with sentinel piles is shown in Appendices 6
and  7. The MRP in those with anal spasm (19 o f 33) was higher than those without [124 
(93-227) v 99 (77-142) cmfhO, P<0.01 ] (fig.3.5.); the duration o f  symptoms in both 
groups was similar [4 (1-36) v 5 (2-30) months, P=NS]. O f 19 patients whose fissures 
healed 13 had anal spasm prior to treatment, in these patients the MRP was significantly 
reduced over 2 months by 5% [115 (93-195) v 109 (53-147) cmH20 , P<0.005], while o f  
14 patients whose fissures did not heal 6 had anal spasm before treatment; in this group 
the reduction in MRP o f  16% over 2 months was not significant [133 (93-227) v 112 (56- 
136) cmH20, P=NS]. The number o f  patients with fissures and anal spasm that healed 
and did not heal was not different {Fischer’s exact test, P=  0.17).
14 patients with fissures without anal spasm prior to treatm ent with topical 2%  diltiazem. 
The horizontal lines represent the median values with interquartile ranges.
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Figure 3.5. The median MRP in 19 patients with chronic anal fissures and anal spasm and
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The MRP in those with sentinel piles (22 o f  33) was higher than those without [120 (77- 
227) v 93 (77-144) cml-hO, P<0.005] (fig.3.6.); the duration o f  symptoms in both groups 
was similar [6 (3-36) v 3 (1-12) months, P=NS]. Sentinel piles were present in 11 o f  19 
patients that healed, in whom the MRP was significantly reduced by 30% [115 (77-195) v 
81 (53-136) cml-hO, PO.OOl] and in 11 o f 14 patients that did not heal, in whom the 
MRP was also reduced significantly by 27% [128 (101-227) v 94 (56-136), P<0.005]. 
The MRP in patients with a sentinel pile with healed and unhealed fissures before 
treatment did not significantly differ [115 (77-195) v 128 (101-227) cml-hO, P=0.54]; 
this was also the case comparing MRP after treatment [81 (53-136) v 94 (56-136), 
P=0.64]. The number o f patients with fissures and sentinel piles that healed and did not 
heal was not different (.Fischer’s exact test, P=0.28).
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Figure 3.6. The median MRP in 22 patients with chronic anal fissures and sentinel piles 
and 11 patients with fissures without sentinel piles prior to treatm ent with topical 2%  
diltiazem. The horizontal lines represent the median values with interquartile ranges.
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Assessment at 4 months
The results are shown in Appendices 8 and 9. Twelve patients whose fissures healed at 2 
months remained healed. In this group the MRP was significantly higher than in controls 
[114 (88-195) v 88 (46-175) cmH20 , P=0.02] and was reduced by 16 % at 2 months [114 
(88-195) v 96 (53-147) cmH20 ,  P=0.005], but at 4 months there was no change in the 
MRP [96 (53-147) v 113 (51-142) cmH20  , P=0.19] and was no longer different from the 
pre-treatment level [114 (88-195) v 113 (51-142) cmH20 ,  P=0.07] (fig.3.7. The MRP 
in the 12 patients prior to treatment was significantly higher than in controls [114 (88- 
195) v 88 (46-175) cmH20 , P=0.02]. The MRP achieved at 2 [96 (53-147) cmH20 ]  and 
4 months [113 (51-142) cmH20 ]  did not differ from controls [88 (46-175) cmH20 ,  
P=0.79 and 0.24 respectively].
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Figure 3.7. The median M RP in 12 patients with healed anal fissures that remained healed 
after a 2 month course of topical 2%  diltiazem. The horizontal lines represent the median
values with interquartile ranges.
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In the other 8 patients with unhealed fissures after the initial course o f treatment a 
reduction o f  24% was not significant [106 (77-227) v 81 (56-136) cml-hO, P=0.052] and 
at 4 months after a second course o f  treatment there was no significant change in the 
MRP from pre-treatment levels [106 (77-227) v 109 (47-135), P=0.29] (fig.3.8.). 
However the fissures healed in 6 o f  8 by 4 months; the MRP in this group was unchanged 
over the four months [102 (77-227) v 93 (79-136) v 109 (47-134) crn^O ] and did not 
differ from controls [88 (46-175) crn^O ]. There was no statistical difference between 
pre-treatment MRP in those 8 patients who required and 12 patients who did not require a 
second course o f  diltiazem [114 (88-195) v 106 (77-227) cnft-hO, P=0.92]. There was 
also no significant difference between the pre-treatment MRPs in the 8 patients and 
controls [106 (77-227) v 88 (46-175) cmH20 , /*=0.10].
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Figure 3.8. The median MRP in 8 patients with unhealed fissures at 2 months who required 
a second course of treatm ent with topical 2%  diltiazem. The horizontal lines represent the
median values with interquartile ranges.
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Assessment at 6 months
The results are shown in Appendix 10. O f 14 patients with fissures that had healed by 
four months all remained healed, except one who after initially healing after 2 months 
recurred and one patient who had treatment for 4 months the fissure remained unhealed 
(fig. 3.1.). All patients were asymptomatic. The MRP in the 13 patients that remained 
healed is shown in fig. 3.9. ; there was a significant reduction at 2 months but not at 4 
months compared with pre-treatment values [110 (77-144) v 79 (53-147) v 108 (64-142) 
v 125 (53-161) cml-hO]. At each stage from pre-treatment values to 6 months there was 
no difference from control MRP [88 (46-175) cmH20 ; P=0.11, P=0.67, P=0.21, P=0.09] 
respectively.
P=0.01
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Figure 3.9. The median MRP in 13 patients with chronic anal fissures who had remained 
healed at 6 months after treatm ent with 2%  topical diltiazem. The horizontal lines 
represent the median values with interquartile ranges.
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3.4. DISCUSSION
While there have been several reports in the therapeutic effectiveness of diltiazem in 
chronic anal fissures few have discussed the manometric changes in the long term. 
Carapeti et al (2000) and Jonas et al. (2001b) have included anal manometry in their 
reports with short follow up of 8  weeks, Knight et al. (2001) and Griffin et al (2002) 
have follow up periods of 31 and 32 weeks without manometry. This study combined 
manometry during a six-month follow up that allowed analyses of the clinical response in 
relation to manometric changes.
Carapeti et al. (1999b) demonstrated diltiazem caused a sustained reduction of 28% in the 
MRP that lasted 3 to 5 hours. At present the published data suggests that the healing 
rates after one course of 8  weeks topical treatment with diltiazem have been 67% 
(Carapeti et al 2000), 73% (Knight et al 2001), 65% (Jonas et al 2001b), 26% (Kocher 
et a l 2002), and 48% (DasGupta et al 2002). In this study the healing rate of 19 (58%) 
of 33 is comparable.
The MRP in 33 patients was higher than healthy volunteers [110 (77-227) v 8 8  (46-175) 
cmffeO] and this conforms with other reports [Nothmann and Schuster (1974), Farouk et 
al. (1994)]. Sub group analyses of those that healed and did not heal showed that 19 
responders and 14 non responders had similarly higher [110 (77-195) v 111 (77-227) 
cmFhO, P=NS] MRP than controls [8 8  (46-175) cmFfeO]. Carapeti et al (2000) have 
also found no difference in pre-treatment MRP in responders and non responders [120
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(85-156) v 136 (110-140) cmFkO]. The reduction in MRP of 25% in the whole group of 
33 patients after compares with the 24% reduction [127 (18) v 96 (17) cm H2O, mean 
(sd)] after 8  weeks described by Carapeti et al (2000) and Jonas et al. (2001). In the 19 
that healed the MRP after 8  weeks reduced significantly by 26%, and in the 14 that did 
not heal the MRP also reduced significantly by 17%. In this study like Carapeti et al. 
(2000) the postreatment MRPs in the 19 responders and 14 non responders [81 (53-147) v 
92 (56-136) cmfhO, P=NS] were not different and were similar to the MRPs in controls. 
The reason for those patients with chronic anal fissures that failed to respond to therapy 
despite a reduction in MRPs similar to those fissures that healed and to a level within the 
range in healthy volunteers is unclear. One possible explanation is that treatment failed 
to achieve an anal canal pressure that allows adequate perfusion of the anoderm although 
Carapeti et al. (2000) failed to demonstrate an increase in anodermal blood flow with a 
reduced MRP with 2% topical diltiazem in 15 patients with fissures.
At 4 months 12 patients who healed at 2 months remained healed and whilst their MRP 
reduced during the treatment period it returned to pre-treatment values after cessation. 
There is no long-term manometric data in the literature to support this observation with 
2% diltiazem. Of 8  patients that received a second course of 2% diltiazem although there 
was a trend there was no change in the MRP at any stage of assessment. However 6  
healed by 4 months, and this cannot be explained within our current understanding of the 
pathophysiology of fissures. It can be hypothesised that either the local application of 
diltiazem relaxes the smooth muscles of the anodermal vessels, but this has not been 
corroborated with vascular flux studies; or the diltiazem acts as a placebo, as Altomare et
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al. (2000) demonstrated healing in 29 (49.2%) of 59 patients that received placebo. In 
this series the healing rate at 4 months was 18 (90%) of 20, which includes the 12 that 
received one course and 6  that received a second course.
Evaluation at 6  months in 15 patients demonstrated that although all remained 
asymptomatic 13 (87%) healed. The MRP at 6  months had returned to pre-treatment 
levels [110 (77-144) v 125 (53-161)]. Although 1 (7%) of the 14 that healed by 4 months 
had recurred there is not enough data to reliably support this recurrence rate, though 
Griffin et al. ’s (2002) analysis of patients treated with diltiazem showed that at 31 
(median) months 7 (41%) of 17 described a recurrence of symptoms.
This “reversible” chemical sphincterotomy demonstrated in this study differs from lateral 
sphincterotomy in two respects. Firstly the reduction in MRP is not of the same 
magnitude, being approximately 50% with surgery [Boulos and Araujo (1984)] as 
compared to 16% (in this group). Secondly the effect is not sustained after cessation of 
treatment, as Chowcat et al. (1986) demonstrated that a reduction of about 50% in MRP 
was maintained 1 2  months after surgery.
Whilst manometry does not provide an indication of which patients at the start of therapy 
will heal; as differences in baseline pressure have no statistically significant effect on 
healing rates at 2  months (P=0.51), it does allow tentative conclusions to be made about 
the responses of patients with fissures to topical diltiazem. This study classifies chronic 
anal fissures into those with:
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1: High resting pressures that heal with a reduction o f MRP.
Demonstrated by 19 patients that healed with 2 months treatment in whom the
MRP was significantly reduced by 26% [110 (77-195) v 81 (53-147) cm H2O, 
P<0.0001] to a level similar to controls.
2: High resting pressures that fail to heal despite a reduction in MRP.
Demonstrated by 14 patients that did not heal with 2 months treatment in whom 
the MRP was significantly reduced by 17% [111 (77-227) v 92 (56-136) cmFfeO, 
P<0.01] to a level similar to controls.
3: Normal resting pressures that heal although the MRP is unaltered with treatment.
Demonstrated by the 6  patients who received 4 months treatment and healed, 
where the MRP was not reduced [102 (77-227) v 109 (47-134) cmH2 0 , P=NS].
Few investigators have examined the relationship of the physical signs associated with 
fissures and their healing. Lock and Thompson (1977) noted that the presence of a 
sentinel tag or fibrous anal polyp were significant features of chronicity and of 
conservative treatment. Gough and Lewis (1983) demonstrated that a sentinel tag was 
present in 18 (55%) of 33 patients whose posterior fissures healed on conservative 
therapy compared with 23 (50%) of 46 whose fissure persisted despite treatment. 
Analyses of their results demonstrated that the presence of sentinel piles was not related 
to healing {Fischer’s exact test, P= 0.82). Pitt et al. (2001a) in a Cox model multivariate 
analysis of 7 factors in 64 patients to determine significant factors related to healing 
demonstrated that a history of a fissure exceeding 6  months and the presence of a sentinel
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pile were associated with failure of the fissure to heal. The presence of a sentinel pile 
also predicted higher recurrence rate. Analysis of the data in this study indicates that the 
duration of symptoms did not relate to the presence of anal spasm or sentinel pile, 
although those with spasm had a higher MRP. Important differences between the work in 
this chapter and Pitt et aV s (2001a) study was that the latter study determined factors 
until 12 weeks with treatment, and 0.2% GTN was used instead of 2% diltiazem. 
Furthermore in Pitt et aV  s study, where GTN was used, the recurrence rate of 46% was 
within 32 weeks, and our study, where diltiazem was used, extended to 24 weeks where 1 
(7%) of 14 patients that had healed, recurred.
Diltiazem is an effective agent used to heal chronic anal fissures by causing a reduction 
in MRP in most patients. The IAS of patients with fissures that do not heal may express 
an abnormal physiological behaviour that is yet undefined. Anal canal manometry 
differentiates those with higher MRPs from those with normal resting pressures, in whom 
a reduction with topical agents may not be demonstrated. It is not yet possible to 
determine accurate prognostic factors for healing.
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CHAPTER FOUR
NOVEL DELIVERY OF BOTULINUM 
TOXIN FOR TREATMENT OF 
ANAL FISSURES
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4.1 INTRODUCTION
Botulinum toxin is an endopeptidase which blocks acetylcholine release at the 
neuromuscular junction of alpha motor neurones, at gamma neurones in muscle 
spindles and in all parasympathetic and cholinergic postganglionic sympathetic 
neurones. It is only recently that a study by Jones et al (2002a) described the 
mechanism of action of botulinum toxin on the IAS. The electrically field stimulated 
responses (EFS) to isolated porcine IAS tissue were compared before and after 
incubation with botulinum toxin. It was found that treatment with this agent increased 
myogenic tone by 38%. Whilst the EFS-induced relaxations were unaffected, the 
EFS-induced contractions were significantly reduced. It was concluded that the 
blockade of sympathetic output by botulinum toxin probably outweighed its effect on 
increased myogenic tone and botulinum toxin blocked sympathetic nerves distal to 
their ganglia, by reducing noradrenaline release at the neuromuscular junction, but 
had no effect on nitregic transmission.
Of the different forms of botulinum toxin produced by the bacterium Clostridium 
botulinum, the most commonly used in a therapeutic role is the type A. It has now 
been purified to homogeneity and has been employed in the treatment of various 
neuromuscular disorders. Wright (1955) examined its potency, and demonstrated a 
dose of 0.003 pg of botulinum toxin, administered parenterally, would be lethal to an 
adult human. Although classic absorption, distribution, biotransformation and 
elimination studies on the active substance have not been performed in the human, it 
is believed that little systemic distribution of therapeutic doses of Botox® occurs 
(Allergan, personal communication). There are two commercially available forms of
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botulinum toxin type A, Botox® (Allergan, Irvine, Ca, USA) and Dysport® (Ipsen, 
Dublin, Ireland). One unit of these preparations has the same LD50 but has different 
biological activity: 3-5 units of Dysport® correspond to 1 unit of Botox®. There are 
two reports on the use of Dysport® (see table 4.1), the dosages used range from 20 to 
50 units. Another form of botulinum toxin, type B (Neurobloc, Elan Corporation, 
Dublin, Ireland) has been recently introduced. There have been 14 reports of 
botulinum toxin injection into the IAS for the treatment of anal fissures {table 4.2.), 
one report by Espi et al. (2001) was a long term study. There have been 10 reports of 
injection into the EAS including two reports by Jost and Schimrigk that described the 
complications and effects on the EAS {table 4.1.).
The IAS and EAS maintain the MRP of which 75-85 % is contributed by the IAS 
(Frenckner and Euler, 1975, Schweiger, 1979). Botulinum toxin type A, Botox® in 
different doses injected into the IAS induces reduction in MRP that varied from 16 to 
34 % that is maintained for several weeks and is transient; Borodie et al. (1974) 
indicated that the paralysing effects last for approximately 3 months. There is also a 
reduction in the voluntary anal canal pressure, ranging from 0 to 21 %. Madalinski et 
al. (1999) suggested this apparent reduction of EAS tone may be directly related to 
injection, as botulinum toxin diffuses from the injection point up to a distance of 35- 
40mm. The manometric data for injections into the EAS have not been adequately 
reported but Jost and Schimrigk (1994) stated that, at completion of treatment, the 
sphincter tone was within normal limits. In Jost’s (1997b) later analysis of 100 
patients at 6  months after injection he demonstrated healing and a normal sphincter 
tone in 79 patients.
138
Table 4.1. Effect of injection of botulinum toxin type A injected into the external anal
sphincter in patients with anal fissures
AUTHORS DOSE
(units)
PATIENTS
(number)
REVIEW
(weeks)
HEALING 
RATE (%)
MAXIMUM 
REDUCTION IN 
RESTING 
PRESSURE (%)
MAXIMUM 
REDUCTION IN 
VOLUNTARY 
PRESSURE (%)
Jost&Schimrigk
(1993)
2.5 1 12 100 No data No data
Jost&Schimrigk
(1994)
2.5 12 12 83 No data No data
Jost&Schimrigk
(1995)
5 26 12 81 No data No data
Jost
(1997a)
2 .5 -5 100 12 82 No data No data
Jost & Schrank 
(1999a) *
20
40
50 12 76 (20U) 
80 (40U)
No data No data
Jost & Schrank 
(1999b)
5
10
20
30
12 70 (5U) 
63 (10U)
No data No data
Jost 
(2001)*
200 10 4 70 No data No data
Thompson et al 
(2002)*
50 26 12 -not 
complete
81 No data No data
• * Dysport used for injection
•  * Botulinum toxin type B used for injection
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Table 4.2. Effect of injection of botulinum toxin type A injected into the internal anal
sphincter in patients with anal fissures
AUTHORS DOSE
(units)
PATIENTS
(number)
REVIEW
(weeks)
HEALING 
RATE (%)
MAXIMUM 
REDUCTION IN 
RESTING 
PRESSURE (%)
MAXIMUM 
REDUCTION IN 
VOLUNTARY 
PRESSURE (%)
Giu et al. (1994) 15 10 8 70 25 21
Mason et al. (1996) 0.125- 
1 ng
5 12 60 16 No data
Espi etal. (1998) 10-15 36 24 65 (10U) 
81 (15U)
No data No data
Maria et al. (1998a) 20 15 4 & 8 53 (4 wks) 
73 (8 wks)
28 44
Maria et al. (1998b) 15-20 57 8 44 (15U) 
67 (20U)
29 (15U) 
28 (20U)
17 (15U) 
13 (20U)
Brisinda et al. 
(1999)
20 25 8 96 29 6
Minguez et al. 
(1999)
10-21 69 24 83 (10U) 
78 (15U) 
90 (21U)
5 (10U) 
13 (15U) 
16 (21U)
17 (10U) 
17 (15U) 
35 (15U)
Fernandez et al. 
(1999)
80 76 12 67 No data No data
Maria et al. (2000) 20 50 8 74 32 5
Lysyetal. (2001) 20 ± 
ISDN
30 12 73 (ISDN) 
66
24 (ISDN) 
21
4.8 (ISDN) 
4.4
Madalinski et al 
(2001)
50 13 No data 54 No data No data
Gecim
(2001)
5 27 6 80 No data No data
Brisinda et al. 
(2002)
20-50 150 8 89 (20±30U) 
96 (30±50U)
30 (20±30U) 
34 (30±50U)
0 (20±30U) 
8 (30±50U)
Katory et al. 
(2002)
50 20 6 80 No data No data
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There are few studies that describe complications from injection and no studies to 
indicate patients’ attitude to this form of treatment. Maria et al. (2000) did not 
observe any complications or side effects in 50 patients they treated. Madalinski et al. 
(2002) specifically addressed the side effects of botulinum toxin injection for benign 
anal disorders in 105 patients with anal fissures and 34 patients with functional outlet 
obstruction. Those with fissures complained of incontinence of flatus (n=9), 
incontinence to faeces (n=5), anal haematoma (n=5), flu-like syndrome (n=3), acute 
inflammation of external varices (n=2), epdidymitis (n=l) and haemorrhoidal 
prolapse (n=l). Patients with anismus suffered from intertrigo (n=l), and prolonged 
pain up to 4 days (n=4). However none experienced life threatening side effects. 
Madalinski et al (2001) injected a higher dose of 100 units into the IAS of a male 
patient with an unhealed fissure with a successful outcome and without complication. 
While tachyphylaxis has not been addressed specifically repeated treatment has been 
attempted successfully without side effects. Jost and Schrank (1999b) repeated an 
injection of 5 units in 20 patients with recurrent fissures, 14 (70%) healed by 3 
months. In a second group, comprising of 30 patients with initial therapeutic failure 
of botulinum toxin with 5 units, when administered 10 further units, showed that 19 
(63%) 30 healed at 3 months.
There have been several studies on botulinum toxin injection treatment for chronic 
anal fissures but few have reported on the recurrence rate (table 4.3.). Whilst in 
several series with a mean follow up of at least one year where no recurrences were 
demonstrated; Jost and Schrank (1997b, 1999a) had a recurrence of 8% after injection 
into the EAS at 3 and 6 months and Espi et al. (2001) had a much higher recurrence 
rate of 42% after injection into the IAS at a median follow up of 38 months.
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Table 43. Recurrences after injection of botulinum toxin in the treatment of anal 
fissures
AUTHORS DOSE (units) FOLLOW UP (months) RECURRENCE RATE (%)
Maria etal. (1998b) 15-20 25 ± 6 No recurrences
Maria et al. (2000) 20 18 ±7 No recurrences
20 ±4 No recurrences
Espi etal. (2001) No data 38 (26-45) 42
Brisinda et al. (2002) 20 ±30 21 ± 5 No recurrences
30 ±50 23 ± 4 No recurrences
Jost & Schimrigk (1995) 5 12 No recurrences
Jost(1997b) 2 .5 -5 6 8
Jost & Schrank (1999a) * 20 -40 3 8
•  * Dysport used for injection
Jost (2001) examined the efficacy of another form of botulinum toxin, type B 
(Neurobloc® , Elan Corporation, Dublin, Ireland) in the treatment of 10 patients with 
anal fissures and reported a healing rate of 70% after one month. The only complaint 
was of burning after injection in 4 patients, probably related to the lower pH of this 
preparation. There have been no other reports on this product.
Reluctance for clinicians to use botulinum toxin to treat anal fissures may be related 
to complications of injection. Jost et al (1995) reported perianal thrombosis in 5 of 
26 female patients treated with botulinum toxin injected into the EAS, whereas two of 
ten patients injected into the intersphincteric groove by Tilney et al. (2001) returned 
within a week of injection with perianal haematomas.
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In order to avoid distress to patients and improve compliance, perhaps also to 
minimise the risk of potential complications of direct toxin injection the use of the “J- 
Tip® Needle-less Injection System” (National Medical Products Inc., Irvine, 
California, USA) used by insulin-dependent diabetics seemed an attractive option (fig.
4.1.). The physical characteristics include an ejection pressure of approximately 
3,000 psi, a delivery time of 0.2 s, and a penetration depth of 5-8 mm, which ‘fans 
out’ to cover an area of 1-1.5 cm [Keshtgar and Barker 1999].
The aim of this study was (i) to carry out preliminary work to determine the optimal 
site and method of application of the needle-less syringe to ensure that the injected 
fluid reached the IAS in a porcine anal canal model and (ii) to investigate the efficacy 
of injection of the J-Tip® needle-less injection system in the treatment of chronic anal 
fissures.
The J-Tip® needle-less syringe system has three components (fig. 4.1.):
1. The J-Tip Needleless Injector is a single use, pre-sterilized, disposable unit which 
is similar to the customary syringe in the delivery of medications and contains it's 
own power source (C02) to deliver the medication through the skin into the 
subcutaneous tissue.
2. The J-Tip Adapter is attached to the botulinum toxin bottle enabling the user fill 
the J-Tip Transporter with the appropriate volume dosage.
3. The J-Tip Transporter allows medication to be taken from the botulinum toxin 
bottle and to be filled into the J-Tip injectors.
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(C 0 2 filled)
Figure 4.1. The J-Tip® needle-less syringe 
4.2. PRE-CLINICAL STUDY 
Methods and patients
Twenty-four specimens o f  porcine anal canals were retrieved from the abattoir and 
transported to the laboratory within 3 hours in modified Kreb’s solution. Botox® has 
a molecular weight o f  150 kd and as the colloid eloHAES® (Fresnius) has a similar 
average molecular weight o f  200 kd it was selected to be the carrier for the methylene 
blue. In order to visualise the distribution o f  the injected agent after penetration the 
eloHAES® was mixed with methylene blue (molecular weight o f  373.9 d) (David Bull 
Laboratories, UK). Injections o f  0.25m l volume were delivered at the anal verge in 
six specimens at each angle, ranging from 45° to 90°, in 15° increments from the 
horizontal plane o f  the skin. The sphincter complex was then dissected and the most
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optimal angle that produced consistent penetration into the IAS, as judged visually by 
the investigator, was selected for the clinical study (fig. 4.2.).
Figure 4.2. a) The norm al anatom y of the porcine anal sphincter complex.
b) Injection at 60° to the horizontal plane
c) Injection at 45° to the horizontal plane
Internal
anal
sphincter External
anal
sphincter
Results
The angle that caused consistent infiltration o f  the IAS with all six specimens was 60° 
to the horizontal plane (Fig. 4.2.b.). The other angles o f  injection 45°, 75°, and 90° 
failed to penetrate the IAS adequately with injections. With 75° and 90° injection 
angles the submucosal plane was predominantly penetrated with methylene blue and 
with 45 0 the intersphincteric plane was penetrated (Fig. 4.2.C.).
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4.3. CLINICAL STUDY
Methods and patients
Local Ethical Committee approval for the study was obtained for this study. Ten 
consecutive patients; 5 males, median age 40 (range 22-71) years; with chronic anal 
fissures not previously treated were recruited to have two injections of 25 units of 
Botox® injected either side of the anal fissure at an angle of 60° to the horizontal 
plane of the anal verge in an outpatient setting without anaesthetic. The exclusion 
criteria were as follows:
•  Aged <18 years or > 75 years
•  Inflammatory bowel disease
•  Perianal sepsis or fistula
•  Diabetes, glaucoma or neuromuscular disorders
•  Immunosuppresion
•  Pregnancy and breast feeding
•  Previous significant anal trauma or surgery with residual severe scarring
•  Suspicion o f infective or neoplastic cause for the fissure
Patient assessment included clinical examination, a graduated visual analogue pain 
score, an incontinence score [Vaizey et al. (1999)] (fig. 4.3.), and anal manometry. 
The measurements were repeated at 1,4, 8 and at 12 weeks after treatment, the fissure 
examined and was regarded as healed when it was not tender on palpation and the site 
of the fissure had re-epithelialised. Statistical analyses were conducted with paired t 
tests after Gaussian distribution of the differences in measurements had been 
confirmed.
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Analogue pain score 
>-1-2-3-4-5-6-7-8-10 
> - no pain
|0 = the worst pain imaginable 
ncontinence score [Vaizey et al. (1999)1
Never Rarely Sometimes Weekly Daily
Incontinence for solid stool 0 1 2 3 4
Incontinence for liquid stool 0 1 2 3 4
Incontinence for gas 0 1 2 3 4
Alteration in lifestyle 0 1 2 3 4
No Yes
Need to wear a pad or plug 0 2
Taking constipating medicines 0 2
Lack o f ability to defer defaecation for 15 min 0 4
plever No episodes in the past 4 weeks
barely 1 episode in the past 4 weeks
Sometimes > 1 episode a week in the past 4 weeks < 1 a day
Daily 1 or more episodes a day
\d d  one score from each row:
Minimum score =  0 =  perfect continence 
Maximum score = 24 = totally incontinent
Figure 4.3. Analogue pain score and Incontinence score
Results
Patients did complain o f  discomfort after the injection but were fully mobile after the 
procedure. There were no complications except for one patient who developed a 
3mm haematoma at the injection site. The results are shown in Appendices 11, 12, 13 
and summarised in table 4.4. At 12 weeks 6 patients had complete resolution and 2 
marked improvement o f  pain; 5 o f  whom the fissures healed. One patient remained 
symptomatic and withdrew from the study at 8 weeks and another was symptomatic 
with an unhealed fissure at 12 weeks.
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Time post 
injection (weeks)
Pain score 
(0-10) 
median (range)
Incontinence 
score (0-24) 
median (range)
MRP (cmH20) 
median (range)
Start 6 (3-8) 3.5 (0-9) 99 (71-185)
1 4(1-8) 4 (0-10) 81 (37-166)
4 3 (0-8) 4 (0-14) 93 (70-109)
8 2.5 (0-8) 3 (0-15) 86 (51-110)
12 3 (0-7) 0 (0-15) 101 (74-143)
Table 4.4. The median pain scores, incontinence scores and MRP at 1,4,8 and 12 weeks 
post injection of 50 units of Botox® in 10 patients with chronic anal fissures.
^  P<0.01
10.0 -. P<0.01
P<0.01
P<0.001
7.5-
5.0-
2.5-
0.0J
start 1 4 8 12
Time post injection (weeks)
Figure 4.4. The median pain scores (0-10) over a 12 week period after injection of 50 
units of Botox® in 10 patients with chronic anal fissures. The error bars indicate
interquartile ranges.
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P= NS
1 0 .0  -I
P=NS
P=NS
7.5-
5.0-
2.5-
0.0J
start 1 4 8 12
Time post injection (weeks)
Figure 4.5. The median incontinence scores (0-24) over a 12 week period after injection 
of 50 units of Botox® in 10 patients with chronic anal fissures. The error bars indicate
interquartile ranges.
--------------------- ► P=NS
P< 0.05-►
175-1 P<0.05
P<0.01
150-
125-
100 -
75-
start 1 4 8 12
Time post injection (weeks)
Figure 4.6. The median MRP over a 12 week period after injection of 50 units of Botox® 
in 10 patients with chronic anal fissures. The error bars indicate interquartile ranges.
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At all stages the pain score was significantly decreased, this was reflected in the 8 
patients who had complete resolution (n=6) or improvement (n=2) of pain (fig. 4.4.). 
Although there were no statistically significant changes in incontinence throughout 
the study period one patient described a single episode of urge incontinence at 1-week 
post injection and another patient described a single episode of passive incontinence 
at 8 weeks (fig. 4.5.). The reduction of median MRP after 1,4 and 8 weeks was 18, 6, 
and 13% respectively (fig. 4.6.). These reductions maintained significance until 8 
weeks, but at 12 weeks the MRP did not differ from pre-treatment values. In the 
patient with passive incontinence the MRP had reduced maximally at this stage from 
92 CII1H2O (start) to 66 cmH20 (8 weeks), reflecting a decrease in the MRP of 28%. 
In the patient with urge incontinence the MRP had reduced maximally from the start 
from 91 cmFbO (start) to 85 cmH20 (1 week), reflecting a decrease in the MRP of 
7%. The median MRP for the group had by comparison decreased from 99 cmtbO 
(start) to 81 cmHbO and then to 86 cmt^O (8 weeks). Thus the overall healing rate 
was 5 (50%) of 10 studied.
4.4. DISCUSSION
The experimental studies have demonstrated the need for precise problems relating to 
the unique anatomy of the anal canal and the necessity to inject into the correct 
muscle structures. However as diffusion of the drug is expected over time it would be 
interesting to note the reduction in voluntary squeeze pressure, a manifestation of 
action on the EAS, which was outside the preliminary aim of this study. A similar 
large dose of Botox® is safe to be used as Madalinski et al. (2001) had used a 100 unit
150
dose to treat a patient with a non-healing fissure; also Femandez-Lopez et al. (1999) 
had used 80 units with a 67% healing rate in 76 patients. It is unsure how much of the 
toxin molecule would be denatured as a result of the mode of delivery, however the 
evidence of effect on MRP did demonstrate that some of the toxin had acted until 
three months, which is keeping with duration of action as described by Borodie et al. 
(1974). We were unable to comment on its loss of potency. The maximal reduction 
in the median MRP of 18% in this study was demonstrated at one week; this 
compares favourably with the range of reductions outlined in table 4.2., though 
comparative reductions of 16% were described by Mason et al. (1996) using 0.125-1 
ng of toxin and Minguez et al. (1999) using 21 units of toxin. The healing rate of 5 
(50%) of 10 in this study is lower than expected; this is surprising as a significant 
reduction of the MRP was demonstrated up to 8 weeks post injection. It has been 
shown that though one is able to target the injected solution one cannot determine 
whether the full dose is delivered; this may explain the poor healing rate. Another 
reason for the poor healing rate may be related to the magnitude of the reduction, as it 
was 18% after one week, and may not have been sufficient to allow perfusion of the 
anoderm to allow healing. In Brisinda et a l’s (2002) study healing rates of 89% and 
96% were demonstrated after MRP reductions of 30% and 34% respectively. Dose 
ranging studies with botulinum toxin with the needless syringe would answer this and 
using higher doses could result in improved healing rates. In Madalinski et a l’s 
(2002) study of complications of direct toxin injection 5 (4.7%) of 105 patients with 
anal fissures developed haematomas, compared with 1 patient with the needle-less 
device. It is not possible to equate the initial discomfort of the needle-less device with 
that of direct injection (as no quantitative assessment of discomfort of the direct 
injection method has been made), but patients seem to be unperturbed by the second
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firing of the needle-less syringe. The dose selected did not cause a significant 
disturbance in anal continence in 8 patients. Incontinence would be a reflection of the 
reduction in the resting and/or voluntary squeeze pressures, this is more important for 
botulinum toxin as it has an effect on both the smooth muscle of the IAS and the 
striated muscle of the EAS. Recurrences were not addressed by this study as the 
follow up period of 12 weeks was too short.
This study has demonstrated the feasibility of this mode of delivery of botulinum 
toxin in the treatment of chronic anal fissures. It has limitations as shown by the low 
healing rate, but appears to be safe and patients are able to tolerate the mode of 
delivery. Dose-response studies with higher number of patients with differing doses 
would answer unresolved issues highlighted.
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CHAPTER FIVE
SYMPATHETIC MODULATION OF THE 
INTERNAL ANAL SPHINCTER
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5.1. INTRODUCTION
Current treatments that induce relaxation of the IAS act by promoting the delivery of 
nitric oxide locally (glyceryl trinitrate, isosorbide dinitrate), by inhibiting the transfer 
of calcium across membrane channels (diltiazem, nifedipine) or by modulating the 
sympathetic effect (botulinum toxin). The IAS tone is partly maintained by 
continuous sympathetic input, mediated through excitatory ai adrenoceptors and 
inhibitory P2 adrenoceptors. These ultimately change the intracellular homeostatic 
mechanisms that either promote uptake or release of calcium from the sarcoplasmic 
reticulum. Stimulation of the ai adrenoceptors increases intracellular calcium via 
inositol-r4’5’-triphosphate (IP3), whilst stimulation of p2 adrenoceptors reduces 
intracellular calcium via cylic adenine-3’5’-monophosphate (cAMP).
Ojo-Aromokudo et al (1998) studying the effects of salbutamol, a P2 receptor agonist, 
with indoramin, an a receptor antagonist in volunteers and patients with chronic 
fissures noted that whilst there was no apparent difference in the a-adrenoceptors in 
the IAS of patients with anal fissures compared with controls, as measured by the 
comparative reduction in anal canal pressure after the administration of indoramin, the 
P-adrenoceptors were probably up-regulated in patients with anal fissures, as the 
reduction in anal canal pressure was greater in fissure patients than in controls. The 
up-regulated p-adrenoceptors have also been demonstrated by in vitro studies by 
Regadas et al (1993) where supersensitivity to relaxation by isoproterenol, a P- 
adrenoceptor agonist, was demonstrated in IAS strips removed from patients 
undergoing lateral sphincterotomy, as compared with IAS strips removed from 
patients with third-degree haemorrhoids and normal anal canal pressures.
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Pitt et a l (2000) reported the effect of a single 20mg oral dose of indoramin, <xi 
adrenoceptor antagonist on MRP in 7 patients with chronic anal fissures, mean age 38 
(range 24-48) years and 6 healthy volunteers, mean age 52.2 (range 30-71) years. 
Anal manometry was performed using a water-filled microballoon by the station pull- 
through method at 1 cm intervals, with equilibration of the pressure before a reading 
was taken. In the patient group the mean MRP was reduced significantly from 106.9 
to 68.6 cmH20, a 35.8% reduction, at 1 hour. In volunteers the MRP was also 
significantly reduced from 84.2 to 52.2 cml^C), a 39.9% reduction. These significant 
reductions were maintained at 2 and 3 hours in both groups. No adverse 
cardiovascular or other effects were experienced by any subject in the study. The 
MRP in both controls and patients with anal fissures was measured at 1 to 2 cm from 
the anal verge; this profile was not altered by indoramin. This initial study prompted 
further investigation into indoramin as a therapeutic agent to treat chronic anal 
fissures.
Pitt et al (2001b) then conducted a double-blind randomised placebo-controlled trial 
of oral indoramin to treat chronic anal fissure in 23 patients; 14, mean age 37 years, 
received 20mg oral indoramin; and 9, mean age 39 years received placebo. Seven 
patients in the indoramin group and two patients in the placebo group withdrew due to 
side effects within the first two weeks of treatment. The side effects included fatigue, 
dizziness, headache, dry mouth, nasal congestion, and retrograde ejaculation; and 
overall there were more side effects in the indoramin group. Pain was reduced in the 
placebo group but not in the indoramin group. At six weeks only 1 (7%) fissure 
healed in only 1 (7%) compared with 2 (22%) in the placebo group. The fissure that
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healed with indoramin recurred at 3 months. On the basis of this disappointing result 
the investigators felt it was unethical to continue with the study due to ethical reasons.
The aim of the study was (i) to validate the effects that manipulation of IAS tone with 
indoramin, an ai adrenoceptor antagonist, and salbutamol, a p2 adrenoceptor agonist 
have on IAS tone and (ii) to examine the pharmacological potential of topical 
formulations of these agents for the treatment of anal fissures.
5.2. EFFECT OF ORAL INDORAMIN AND ORAL SALBUTAMOL ON 
ANAL CANAL PRESSURE.
5.2.1. PATIENTS AND METHODS
There were 10 patients (median age 35.5, range 28-65 years, 6 females) with chronic 
anal fissures and 10 healthy volunteers (median age 28, range 21-38 years, 5 females) 
that were studied after local ethical committee approval was obtained. The MRP, 
pulse and blood pressure were measured before a single oral dose of 20mg indoramin 
or 4mg salbutamol in a cross over manner. Both the investigator and the participants 
were blinded as to the nature of the drug administered. The MRP, pulse and blood 
pressure were measured hourly post ingestion of the drugs until 3 hours; noticeable 
side effects were also recorded. A minimum “washout period” of 24 hours before the 
next drug could be given was observed. This was considered a sufficient period as the 
elimination half lives of indoramin and salbutamol are 5 [Pierce, 1990, Volans et a l 
(1982)] and 1-2 hours [Janson, 1991] respectively. Whilst 20mg indoramin is a dose
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that is safely used to treat hypertensive patients, 4mg oral salbutamol is a considerably 
higher dose than that inhaled (200-400pg) for the treatment of asthma. However the 
agents and the doses were selected as they were those employed in the studies by Pitt 
et al. (2000) and Ojo-Aromokudo et al (1998), and it was felt that employing the 
same doses were essential if any meaningful comparisons from this study were to be 
made. The differences within each dose were calculated with the paired t test after 
testing differences in MRP for normality.
5.2.2. RESULTS
The data are shown in Appendices 14 to 19, and in table 5.1. The hourly effect up to 
three hours of indoramin and salbutamol on the MRP in volunteers and patients with 
chronic anal fissures are shown. Also shown are the % reductions of the median MRP 
at each hour. At the start of the study patients with fissures had a significantly higher 
MRP than volunteers [131 (94-227) v 88 (46-175) cmH20, median (range), P < 
0.0001] (fig. 5.1.). In all 4 groups the MRP reduced significantly after one hour and 
this reduction was observed over the 3 hours studied (table 5.1, figs 5.2-5.5.). The 
reductions of the median MRP at 1 hour for indoramin in the patient group was 32.6 
% and in the volunteer group was 25.4%; and there was no difference in the 
magnitudes of reduction of the MRP [52 (18-69) v 17 (4-121) cmH20, median 
(range), P=NS]. The reduction of the median MRP at 1 hour for salbutamol in the 
patient group was 29.6% and in the volunteer group was 30.4 %; again there was no 
difference in the magnitudes of reduction of the MRP [20 (7-81) v 25 (-1-105) 
cmH20, median (range), P=NS]. Whilst in 3 of the groups there was no further 
reduction in the MRP from 1 to 3 hours in the 10 volunteers that had received
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indoramin there was a further significant reduction in the MRP from 2 to 3 hours [55 
(46-114) v 53 (33-112), median (range), P < 0.05] (fig. 5.2.).
There was no difference in the pulse rate in the subjects that had received indoramin 
(fig. 5.6.). There was a transient significant increase in the pulse rate at 1 hour in 
volunteers and at 2 hours in patients that had received salbutamol (fig. 5.7.). There 
were no differences in systolic blood pressure in any group during the study period 
(figs. 5.8. & 5.9.). Four volunteers and five patients experienced tremors after 
salbutamol, three patients complained of light-headedness with indoramin, and none 
of the volunteers had any side effects with indoramin.
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Figure 5.1. The median maximum resting anal canal pressure (MRP) in 10 patients with 
chronic anal fissures as compared with 10 healthy volunteers. The horizontal lines 
represent the median values with interquartile ranges
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Table 5.1. The effect of 20mg oral indoramin and 4mg oral salbutamol on the maximum 
resting anal canal pressure
MRP (cmH20 ) at start (0), and 1, 2 
and 3 hours after ingestion of drug
PATIENTS WITH ANAL 
FISSURES
HEALTHY
VOLUNTEERS
INDORAMIN SALBUTAMOL INDORAMIN SALBUTAMOL
o Mean (S.E.) 147.0(14.1) 144.5(11.9) 87.4(10.1) 101.1 (11.0 )
Median (Range) 130.5 (94-227) 143.5 (97-194) 84.5 (46-136) 93.5 (47-175)
1 Mean (S.E.) 101.1 (12.3) 111.6 (11.2 ) 66.3 (8 .6 ) 72.1 (6 .6 )
Median (Range) 88 (57-169) 101 (78-181) 63 (36-117) 65 (44-101)
% Reduction Of Median 
MRP Compared With Start
32.6 % 29.6 % 25.4 % 30.4 %
2 Mean (S.E.) 96.5 (7.8) 97.5 (7.9) 66.9 (7.8) 75.8 (6.7)
Median (Range) 96 (61-140) 90 (72-142) 55(46-114) 76(47-118)
% Reduction Of Median 
MRP Compared With Start
26.4 % 37.2 % 34.9 % 18.7 %
3 Mean (S.E.) 85.9 (8.1) 91.0 (8.9) 59.3 (7.6) 67.8 (9.7)
Median (Range) 91 (57-120) 92 (53-132) 53 (33-112) 68 (34-128)
% Reduction Of Median 
MRP Compared With Start
30.2 % 35.8 % 37.2 % 27.3 %
159
Figure 5.2. Effect of 20mg oral indoramin on the median maximum resting anal canal
pressure (MRP) in 10 healthy volunteers over a 3 hour period.
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Figure 53. Effect of 4mg oral salbutamol on the median maximum resting anal canal 
pressure (MRP) in 10 healthy volunteers over a 3 hour period.
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Figure 5.4. Effect of 20mg oral indoramin on the median maximum resting anal
canal pressure (MRP) in 10 patients with chronic anal fissures over a 3 hour period.
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Figure 5.5. Effect of 4mg oral salbutamol on the median maximum resting anal 
canal pressure (MRP) in 10 patients with chronic anal fissures over a 3 hour period.
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Figure 5.6. Effect of 20mg oral indoramin on the pulse rate (/minute) in 10 patients with
chronic anal fissures and 10 control subjects measured over a 3 hour period.
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Figure 5.7. Effect of 4mg oral salbutamol on the pulse rate (/minute) in 10 patients with 
chronic anal fissures and 10 control subjects measured over a 3 hour period.
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Figure 5.8. Effect of 20mg oral indoramin on the systolic blood pressure (mmHg) in 10
patients with chronic anal fissures and 10 control subjects measured over a 3 hour
period.
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Figure 5.9. Effect of 4mg oral salbutamol on the systolic blood pressure (mmHg) in 10 
patients with chronic anal fissures and 10 control subjects m easured over a 3 hour 
period.
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5.3. EFFECT OF TOPICAL INDORAMIN ON ANAL CANAL
PRESSURE
Analysis of the results from the oral trial presented in this chapter was aimed at 
determining the safety of salbutamol and indoramin before investigating the 
therapeutic potential of using a topical formulation. Salbutamol was excluded from 
further analysis due to the high incidence of side effects demonstrated in 9 (45%) of 
20 subjects. Since indoramin caused side effects in 3 (15%) of 20 subjects and there 
was no change in systolic blood pressure it was felt that a topical formulation should 
be investigated.
5.3.1. PATIENTS AND METHODS 
Pilot Study
An initial pilot trial attempted to determine if a topical formulation of indoramin 
lowered the MRP. Indoramin is not freely soluble in water, but in paraffin. A topical 
preparation of indoramin was not commercially available; therefore pilot formulations 
of 30mg indoramin were mixed with paraffin/wool fat similar to the carrier used for 
GTN to a total volume of 1.2ml (fig. 5.10.). These were applied to the anal verge in 2 
subjects, a 36 year old female and 24 year old male, to determine whether this 
formulation like the oral preparation caused any tentative effect on the MRP by 1 
hour. At 1cm from the anal verge the MRP reduced by 19% and 23%, and at 2cm 
from the anal verge the MRP was reduced by 34% and 40%. Since the highest anal 
canal pressures are in the lower anal canal and a topical formulation was being used 
the resting pressure measurements at 1 and 2cm from the anal verge was deemed
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sufficient for analysis. These results prompted a randomised blinded trial was to 
determine the effect o f  topical indoramin in varied concentrations on the MRP. 
Measurements o f  MRP were made by a station manometry technique described in 
Appendix 1.
Figure 5.10. Indoram in (30 mg/ 1.2 ml) in a paraffin / wool fat base (for topical
application)
Randomised Trial
Eight healthy volunteers (median age 29.5, range 20-39 years, five males) were 
selected. Local ethical committee approval was obtained. Four topical preparations 
o f  indoramin (lOmg, 20mg, 30mg, 40mg) were added and made up to a volume o f  0.6 
ml o f  paraffin/wool fat. A placebo preparation, o f  0.6 ml o f  paraffin/wool fat, made a 
total o f  5 doses each for 8 volunteers. This volume was selected at it was more 
manageable to apply to the anal verge. Each preparation was randomly allocated to a 
subject to make a total o f  five day-visits, with a minimum washout period o f  18 hours, 
representing 3 half lives o f  indoramin. The participants and the investigators were 
blinded to the doses o f  the preparations. On each occasion the MRP was measured
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prior to and then at 1 and 3 hours after the application of the agent. When a response 
was noted at either 1 or 3 hours the measurements were continued at 2-hourly 
intervals until the MRP returned to the pre-treatment level. If, by 7 hours post 
application there appeared to be a sustained reduction, the study was terminated. It 
was difficult to recruit more healthy volunteers. The differences within each dose 
were calculated with the paired t test after testing differences of MRP for normality. 
Any effect of formulated dose over placebo was determined with a one-tailed analysis 
of variance (ANOVA).
5.3.2. RESULTS
The data are shown in Appendix 20 and table 5.2. with the mean (s.e.) and median 
(range) MRP shown, and the % reductions of median MRP. The results for each dose 
are also presented graphically as medians (interquartile ranges) (fig. 5.11). At 1 hour 
placebo, lOmg and 20mg caused a significant reduction in the MRP. At 3 hours the 
placebo, 20mg and 30mg showed a significant reduction in MRP. At 5 hours placebo 
and 30mg achieved significant reduction in MRP. Because of the blinded nature of 
the study there was little effect on MRP at 5 hours of the lOmg, 20mg and 40mg 
doses and of all doses at 7 hours; as such there was insufficient data. Whilst these 
results appear to demonstrate effects from certain doses, comparison of the 
differences for each dose-effect at 1 hour and then at 3 hours showed no difference for 
any dose or an overall effect of any doses of topical indoramin over placebo (P= NS, 
ANOVA) (figs. 5.12 & 5.13).
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Table 5.2. The effect of placebo, lOmg, 20mg, 30mg and 40mg topical indoramin in a
paraffin base on the MRP in 8 healthy volunteers.
0
Mean (s.e.) 
Median (range)
110.0 (6.3) 
113 (74-135)
104.8 (9.9) 
102 (78-159)
114.4(12.2)
113(79-182)
105.6 (8 .8 ) 
105 (73-147)
105.5 (7.7) 
102 (77-147)
1 Number Mean (s.e.) 
Median (range) 
% Reduction O f 
Median MRP 
Compared With 
Start
8
95.8 (8.1) 
93 (69-125) 
17.7 %
8
88.3 (9.9) 
95 (49-124) 
6.8 %
8
87.5 (8.1) 
82 (52-122) 
27.4 %
7
91.1 (11.8) 
9 7  (47-144) 
7.6 %
8
97.4 (9.9) 
90 (58-151) 
11.7 %
3 Number Mean (s.e.) 
Median (range) 
% Reduction O f 
Median MRP 
Compared With 
Start
6
8 8 .8  (6 .0 ) 
93 (68-109) 
17.7 %
8
96.5 (10.4) 
92 (62-143) 
9.8 %
7
79.7 (9.2) 
88  (35-109) 
22.1 %
7
91.0(12.1) 
83 (51-127) 
20.9 %
7
102  (6 .0 )
100 (83-132) 
1.9 %
5 Number Mean (s.e.) 
Median (range) 
% Reduction Of 
Median MRP 
Compared With 
Start
6
85.8 (8.4) 
89 (56-111) 
21.2 %
2
83.5(11.5) 
84 (72-95) 
17.6 %
5
96.4 (6.4) 
89 (82-117) 
21.2 %
6
72.7 (8.7) 
70 (46-109) 
33.3 %
2
76 (8.0)
76 (68-84) 
25.4 %
7 Number Mean (s.e.) 
Median (range) 
% Reduction Of 
Median MRP 
Compared With 
Start
3
108.3 (19.3) 
115 (72-138) 
-1.7%
3
85.0(15.3) 
82 (54-123) 
19.6 %
3
90.3 (12.7) 
101 (65-105) 
10.6 %
4
70.3 (9.5) 
70 (48-94)
33.3 %
2
88  (4.0)
88  (84-92) 
13.7 %
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Figure 5.10. The effect of 
placebo, lOmg, 20mg, an 30mg 
and 40mg topical indoram in in 
0.6ml paraffin base on the 
median MRP in 8 healthy 
volunteers. The e r ro r  bars 
indicate the in terquartile  ranges 
and w here shown assessment of 
significance can be determ ined. 
When no e rro r  bars are 
displayed the number of patients 
re turn ing  for assessment, judged 
by cessation of effect at the 
previous reading, was too few to 
determ ine a meaningful effect of 
the dose on MRP.
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Figure 5.12. Effect of placebo and lOmg, 20mg, 30mg, and 40mg topical indoram in and 
the response of M RP of 8 volunteers at 1 hour post application [median (interquartile 
range)]. The “s tart value” indicates the M RP [median (interquartile range)] of the 
whole group pre-treatm ent. There was no effect of any dose of indoram in over placebo 
(P = m ,  ANOVA).
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Figure 5.13. Effect of placebo and lOmg, 20mg, 30mg, and 40mg topical indoram in and 
the response of MRP of 8 volunteers a t 3 hours post application [median (interquartile 
range)]. The “s ta rt” value indicates the M RP [median (interquartile range)] of the 
whole group pre-treatm ent. There was no effect of any dose of indoram in over placebo
(P  = NS, ANOVA).
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5.4. DISCUSSION
The results with indoramin from the oral trial seem to validate the effects described by 
Pitt et al (2000) who described a significant reduction in the MRP by 1 hour, which 
was sustained over the 3 hour study period. Whilst Ojo-Aromokudo et al (1998) 
described a greater reduction with salbutamol in patients as compared to controls, this 
was not substantiated in this study. The magnitude of reductions in the MRP with 
salbutamol in patients compared with volunteers was no different at one hour. In this 
study the number of subjects was larger and dedicated anorectal manometric water 
perfused catheter assemblies were used as opposed to microballoons.
However while a reduction in MRP both patients and controls was observed Acheson 
et a l (2002) failed to show any effect of salbutamol over placebo on MRP in 15 
healthy volunteers or offer an explanation for this observation. Regadas et al (1993) 
observations have not been validated, they failed to explain why there is no 
upregulation of the P adrenoceptors in patients with haemorrhoids given that patients 
with haemorrhoids also have higher anal canal pressures that are also sustained. 
Furthermore it is not clear why there should be supersensitivity of the p adrenoceptor 
group alone as in animal hypertensive models it is the a adrenoceptors that are up 
regulated [Weishar et al. 1991].
While salbutamol reduced the MRP it was associated with side effects in nearly half 
of the subjects and in this respect indoramin was the preferred option for the
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therapeutic trial. Whilst Pitt et al (2000) did not describe any side effects in 13 
subjects (including 6 volunteers) a subsequent oral trial in 14 patients with chronic 
anal fissures who were given 20mg indoramin showed side effects that included 
fatigue, dizziness, headache, dry mouth, nasal congestion and retrograde ejaculation 
[Pitt et al. 2001b].
Indoramin topical preparation did not differ from placebo in demonstrating an 
effective reduction in the MRP. This could be explained by the large sympathetic 
drive to the IAS not counteracted by increasing doses of indoramin. Indeed Frenckner 
and Euler (1975) demonstrated significant sympathetic contribution in maintaining 
the resting anal canal pressure. This was shown by comparing the anal canal pressure 
in patients after a high or low spinal anaesthetic, or bilateral pudendal blocks. 
Yamato and Rattan (1990) demonstrated that the ai-agonist phenylephrine caused a 
dose-dependent rise in the resting IAS pressure, with a significantly higher response 
in the proximal part than in the distal part of the anal canal. This response was 
antagonised by prazocin, an ai-antagonist. It is plausible that topical indoramin failed 
to affect the distal IAS tissue, where a reduction of IAS pressure is required to treat 
fissures.
The results presented so far indicate that whilst a 20mg dose of oral indoramin 
reduces MRP, it is not effective in the treatment of chronic anal fissures. Furthermore 
a topical preparation of indoramin, in a dose ranging from 10 to 40mg in a paraffin 
base, is not different from a placebo in reducing MRP. Oral salbutamol causes too 
many side effects to be considered as an effective agent for treatment of anal fissures.
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CHAPTER SIX
VALIDATION OF AN ANIMAL MODEL OF 
HUMAN INTERNAL ANAL SPHINCTER
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6.1. INTRODUCTION
Our understanding of the neurophysiology of the IAS is based on human and animal 
studies. In vivo work by Gaskell (1920) and Learmonth (1929) defined an excitatory 
sympathetic and inhibitory parasympathetic supply to the IAS. Stimulation of the 
hypogastric nerves in cats by Carlstedt et al. (1988), in dogs by Mizutani and 
Nakayama (1986) and in opposums by Shibamoto et al (1994) led to adrenergically 
mediated contractile responses of the IAS. Yamato and Rattan (1990) studied the role 
of a-receptor subtypes in the opossum and concluded that ai adrenoceptors exert 
important neuromodulatory influences on rectoanal inhibitory reflex, while ai 
adrenoceptors may exert modulatory effects on the resting IAS tone. Early in vitro 
studies by Friedmann et al (1968) and Parks et al (1969) identified the a- 
adrenoceptor mediated contraction and P-adrenoceptor mediated relaxation of human 
IAS when investigating the action of noradrenaline, adrenaline, isoprenaline and 
acetylcholine. Later Burleigh et al (1979) examined the relaxant response in human 
IAS muscle strips to electrical field stimulation (EFS). The identification of nitric 
oxide (NO) as an enteric inhibitory transmitter was made possible by Rattan and 
Chakder (1992) and Chakder et al (1993), with work on opossum IAS muscle strips. 
Stebbing et al (1998) used a guinea-pig model to demonstrate evidence of an 
inhibitory enteric pathway. Whilst studies on human IAS have evolved, the 
introduction of stapling techniques advanced restorative rectal excision which has 
impinged on the demand for human tissue. Interest in the pharmacological 
manipulation of smooth muscle tone of the IAS, for the treatment of anal fissures, has 
prompted search for suitable models for human IAS.
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Rat Anococcygeus
The rat anococcygeus muscle was initially considered as Gibson and Gillespie (1973) 
demonstrated its contractility was sympathetically mediated. However Gillespie 
(1972) had previously shown that the rat does not have an anatomically definable 
IAS, and as Creed and Gillespie (1974) and Creed et al (1975) showed that the rat 
anococcygeus does not have spontaneous myoelectrical activity and as such is an 
unsuitable model for investigation of the pharmacological properties of the IAS
Guinea-Pig IAS
Lim and Muir (1985) defined the mechanisms underlying the electrical and 
mechanical responses of the guinea-pig IAS to electrical field stimulation (EFS) and 
drugs. The IAS developed its own tone (3-4g), following initial stretch (lg) and 
spontaneous spike potentials were evident. In the absence of spike potentials, tone 
declined and disappeared. EFS (l-20Hz, 0.5ms, supramaximal voltage) produced 
inhibitory junction potentials and relaxed tone. These inhibitory junction potentials 
and relaxations were inhibited by apamin, tetrodotoxin but not atropine, phentolamine 
and hexamethonium. These results suggested work that could examine the 
relationship between the basal tone and the effects of EFS on relaxation of the IAS 
muscle strips could be undertaken.
Sheep IAS
Mundey et a l (2000) investigated the sheep IAS and demonstrated that muscle strips 
of sheep IAS develop intrinsic contractile tone following the application of stretch
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tension. On EFS (1-20  Hz, 10 V pulse strength, 0.5 ms pulse width, 1 s every 180 s) 
transient relaxations were observed. The amplitude of the relaxations were 
frequency-dependent reaching a maximal response at 10-20 Hz and were inhibited by 
tetrodotoxin (0.3 pM). Neither atropine (0.3 pM) nor phentolamine (1 pM) affected 
control responses. The nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl 
ester (L-NAME, 100 pM) and the selective inhibitor of soluble guanyl cyclase ODQ, 
(lH-[l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one) (1 pM) completely inhibited the 
neurogenic relaxations and uncovered contractions that were abolished by 1 pM 
phentolamine and 0.1 pM prazosin. The effect of L-NAME, but not that of ODQ, was 
partially reversed by the addition of L-arginine (1 mM), a substrate for nitric oxide 
synthesis. Sodium nitroprusside (10 nM - 10 pM) caused concentration-dependent 
inhibition of myogenic tone and this effect was significantly reduced by ODQ. 
Calcium-free Krebs-Henseleit solution also reduced myogenic tone by 85%. The 
authors concluded that EFS of sheep IAS muscle strips caused a transient relaxation 
of myogenic tone that appeared to involve NO from non-adrenergic, non-cholinergic 
nerves and, to a lesser degree, noradrenaline from sympathetic nerves. Griffin et al 
(2001), using the same model, demonstrated that L-arginine did not affect either the 
resting tone or magnitude of electrically induced contractions; furthermore they 
showed that L-arginine prevented L-NAME-induced inhibition of electrically evoked 
relaxations. These studies provided adequate validation that sheep IAS muscle strips 
could be substituted for human IAS muscle strips in pharmacological investigation. 
Jonas et al. (2001c) used this model to show that whilst glyceryl trinitrate and 
diltiazem each caused a reduction of sheep IAS tone by 70%, a combination of these 
drugs caused abolition of IAS tone irrespective of the order in which they were added.
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Porcine IAS
O’Kelly et al. (1992) investigated the possibility of the porcine IAS as a suitable 
animal model of the human IAS. Porcine IAS muscle strips from Landrace pigs were 
mounted for isometric tension, with an initial load of lg applied to provide tone. 
Electrical stimulation (10V, 0.5ms duration and 8  pulses per second) of the NANC 
(non adrenergic, non cholinergic) inhibitory nerves produced terodotoxin sensitive 
relaxations. Sodium nitroprusside also relaxed the muscle strips in a concentration- 
dependent manner; after which the tone could be re-established with histamine. The 
inhibitory NANC responses were partially inhibited by L-N-monomethylarginine (L- 
NMMA) (5x1 O' 5 M) and abolished by oxyhaemoglobin as well as L-nitroarginine (L- 
NOARG) (1 O'6-10"4 M). The effects of L-NMMA and L-NOARG were reversed by 
equimolar concentrations of L-arginine but not D-arginine. Cook et a l (1999b) 
determined, in a similar experimental manner, that tone and spontaneous activity were 
dependent upon extra-cellular calcium and flux across the cell membrane, through L- 
type calcium membrane channels, whilst agonist-induced contractions were 
dependent mainly on release of calcium from the intracellular sarcoplasmic reticulum. 
Furthermore the addition of nifedipine, an L-type calcium channel antagonist which 
blocks entry of calcium into smooth muscle cells, abolished tone and spontaneous 
activity.
It has been established that nitric oxide is the predominant neurotransmitter that 
induces non-adrenergic non-cholinergic induced relaxation of the internal anal 
sphincter (IAS). What is not clear is how the effect of other neurotransmitters or 
intracellular messengers that may be less important in this response modulate this
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relaxation. To explore these interactions it was therefore proposed to investigate the 
actions of purinergic and alpha adrenoceptor antagonists on the relaxant induced 
responses to electrical field stimulation. ATP is commonly a co-transmitter with 
vasoactive intestinal polypeptide and nitric oxide in enteric inhibitory neurones 
[Hoyle, 1996a]. To date the effect of an inhibition of the IP3 induced cellular 
contraction through ai-adrenoceptor antagonism and its modulation had not been 
investigated.
Botulinum toxin is an endopeptidase which blocks acetylcholine release at the 
neuromuscular junction of alpha motor neurones, at gamma neurones in muscle 
spindles and in all parasympathetic and cholinergic postganglionic sympathetic 
neurones. Jones et al (2002a) recently described the mechanism of action of 
botulinum toxin on the IAS. The electrically field stimulated responses (EFS) to 
isolated porcine IAS tissue were compared before and after incubation with botulinum 
toxin. It was found that treatment with this agent increased myogenic tone by 38%. 
Whilst the EFS-induced relaxations were unaffected, the EFS-induced contractions 
were significantly reduced. It was concluded that the blockade of sympathetic output 
by botulinum toxin probably outweighed its effect on increased myogenic tone and 
that botulinum toxin blocked sympathetic nerves distal to their ganglia, by reducing 
noradrenaline release at the neuromuscular junction, but had no effect on nitregic 
transmission.
The aims of studies presented here were to determine if the physiological parameters 
of guinea-pig and porcine IAS muscle strips are comparable to human IAS in order to
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affirm if these tissues could be substituted satisfactorily for human IAS in further 
studies.
6.2. METHODS
Male guinea pigs (Dunkin Hartley, Charles River; weight 275-375g) were killed by 
cervical dislocation. The abdomen was opened, internal viscera excised, and the 
pelvic floor structures were removed and transported in modified Kreb’s solution to 
the laboratory where the IAS tissue was dissected free. The sphincter complexes of 
female Landrace pigs (live weights 80-120kg) killed at the abbatoir in accordance 
with approved methods (captive bolt stunning, and exsanguination) were transported 
en bloc in modified Kreb’s solution to the laboratory where the IAS tissue was 
dissected free.
Muscle strips of IAS (guinea-pig: 4mm x 1mm, porcine 5-10mm x 2mm) were 
suspended in organ-baths containing modified Krebs’ solution. One end of the 
preparation was attached to a rigid support and the other, using silk thread, to an 
isometric force-displacement transducer (Biopac TSD 125 C). The data were 
presented with “Acquire software (Acqknowledge 2.0)” computer software, through a 
MPW100 data acquisition system (Biopac). Preparations were preloaded with 0.5- 
2.0g and were allowed to equilibrate for at least 50 min before any drugs were added. 
Where tissues were electrically stimulated (Experimetria S02 stimulator) the 
following stimulation parameters were used: pulse width (0.3 ms, biphasic);
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frequency (0.5 - 32 Hz); train length (10 s); interval between trains (110 s) and 
voltage (supramaximal, 60 V).
The concentration-response curves in each specimen were constructed by addition of 
the following drugs: histamine, phenylephrine, isoprenaline, GTN, acetylcholine, L- 
NAME, ATP, and suramin. The organ-bath concentrations are shown in the results. 
Relaxant or contractile responses were allowed to plateau before the concentrations 
were increased. The contractile responses in the guinea pig preparations were 
measured as percentage increase above basal tone, and the contractile responses in the 
porcine tissues were measured as percentages of total maximal contraction. The 
relaxant responses were measured as percentages of basal levels. The results for the 
effects of L-NAME on the EFS-induced relaxation of tissue are represented in 
absolute relaxant amplitudes. The effects of the purinoceptor antagonist, suramin on 
the relaxant response to EFS were investigated and the results and were expressed as 
percentages of basal levels. Regadas et al (1993) investigated the actions of 
adrenoceptor antagonists on the human IAS, and it was appropriate to study the 
responses to similar agents in the porcine model. The effects of prazosin and 
indoramin on histamine and phenylephrine response curves were investigated. The 
results were expressed as percentages of total maximal contraction. The role of 
botulinum toxin exerted on the acetylcholine-induced relaxation of porcine IAS was 
investigated, as in botulinum toxin inhibits the release of acetylcholine at the motor 
nerve ending striated muscle. Similarities of action in the smooth muscle of the IAS 
were sought. These results were expressed as the extent of relaxation from basal 
levels. Statistical analysis was conducted using the paired t test for paired 
observations.
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6.3. RESULTS
GUINEA PIG IAS
The results are shown in Appendices 21 to 23 and figures 6.1. to 6.3. When placed 
into the organ bath, the IAS had no tone as measured with the force transducer. The 
preparation was then subjected to a tension of lg by stretching the tissue. The tone 
was maintained at this level throughout the experiments. In 6 preparations the tone 
was significantly raised by histamine (lx  10'5, 3 x 10'5, lx lO^M) (fig.6.1.). There 
was no significant difference in the basal tone in 6 different muscle strips after the 
application of atropine (lx 10’6M; 0.25 ± 0.08 g versus 0.30 ± 0.09 g, mean ± s.e.). 
Furthermore there was no significant effect of the adrenoceptor agonist methoxamine 
(lx  lO^M) when applied to 4 muscle strips (0.23 ± 0.04 g versus 0.39 ± 0.1 lg).
The response to EFS (8Hz) was initial relaxation followed by rebound excitation 
(fig. 6.2.). There was a linear relationship between tension (increased by histamine) 
and relaxant response (indicated here by the area of relaxation) at levels of tone up to 
1 g (y=8.08x-3.64, ^=0.98, d.f.=2) (fig.6.3.).
PORCINE IAS
The results are shown in Appendices 24 to 36 and figures 6.4. to 6.17. Histamine 
(1 x 1 0 '7M -1 x 1 0 ‘3M) induced a concentration-dependant contraction (fig. 6.4.); the 
mean maximal contraction was 2.4 ± 0.5g (mean, s.e.mean) above basal tones. 
Phenylephrine (an ai-adrenoceptor agonist) induced a concentration-dependent 
contraction of the tissue in (lx l0 '8 -  lxlO'4 M) (fig. 6.5.). The mean maximal
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contraction was 4.0 ± 0.6g (mean, s.e.mean). Agonism of the [3-receptors with 
isoprenaline (lxl O'7 -  lxl O'3 M) resulted in relaxation (fig. 6.6.). The addition of GTN 
also caused relaxation of the IAS in a dose-dependent manner (2.2x1 O'4, 6.6x1 O'4, 
2.2xl0'3 M) (fig.6.7.). Acetylcholine (1 x 1 0 '3M) induced a rapid decrease in basal tone 
that was transient (fig. 6.8A.) and in the presence of L-NAME (lxlO^M) this response 
was significantly decreased (P<0.05, paired t test) (fig.6.8B.). ATP (1 x 1 0 '3M) 
induced a sustained decrease in basal tone (fig.6.9A.). In the presence of suramin 
(3x1 O^M), this response was significantly increased (P<0.05,paired t test) (fig.6.9B.).
EFS produced an initial rapid relaxation followed by a rebound excitation. This 
response was demonstrated across a broad range of frequencies (0.5-32Hz) 
(fig.6.10.), with a notable increase in the relaxant response as the frequency of 
stimulation was increased (fig. 6.11.). L-NAME (lxlO^M) abolished the EFS-induced 
relaxation, that was less notable at lower stimulation frequencies (fig. 6.12.). Suramin 
(3x10"* M) did not significantly effect the relaxant response to EFS (0.5-32 Hz) (P = 
NS, paired t test) (jig. 6.13.). The effect of prazosin (lxlO'7 M) on the relaxant 
response to EFS (0.5-32 Hz) demonstrated a significant increase as compared with 
the control preparation for the frequencies above 0.5 Hz (P < 0.05, paired t test) (jig. 
6.14.).
For the experiment investigating the effect of prazosin (lxlO'6 M) on the histamine 
induced contraction an initial load of 2 g was applied, and after equilibration (45 min), 
by which time the tone had dropped to 0.8 ± 0.3 g (n = 3, mean ± s.e. mean), 
histamine was added cumulatively to provide a bath-concentration from 1x10' M - 
lxlO*4 M. Prazosin (lxlO'6 M) resulted in a shift of the histamine dose response curve
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(fig. 6.15.) to the right. This effect was more demonstrable in concentrations of 
histamine above lx l O'6 M.
For the experiment investigating the effect of indoramin (lxlO'7 M) on the 
phenylephrine induced contraction initial load of 2 g was applied, and after 
equilibration (45 min), by which time the tone had dropped to 1.1 ± 0.2 g (n = 7, mean 
± s.e. mean), phenylephrine was added cumulatively to provide a bath-concentration 
from lxlO'8 M - lxlO-4 M. Indoramin (lxlO'7 M) reduces the phenylephrine induced 
contraction of the IAS across the concentrations (lxl 0‘8 M - lxl O'4 M). For this 
antagonism the effect is indicated by the following relationship: pKs = 8.3 ± 0.33. 
(fig-6.16.)
Incubation of IAS muscle strips with one unit of botulinum toxin for one hour did not 
significantly alter the relaxant response induced by acetylcholine (1x10 M) (P = NS, 
paired t test) (fig. 6.17.). The relaxant response prior to incubation with botulinum 
toxin was 43.9 ± 8.1 % (n=3, mean, s.e.mean.), and after incubation was 44.3 ± 9.2 % 
(n=3, mean, s.e.mean.).
6.4. DISCUSSION
The aim of the work presented in this chapter was to investigate the suitability of an 
animal model with physiological similarities to human IAS tissue.
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Guinea pig IAS muscle strips maintain an applied tone, as demonstrated after 
preloading with lg. It was not possible to confirm in the in vitro environment 
Frenckner and Hire’s (1976) observations of the existence of a tonic sympathetic 
discharge to the guinea pig IAS as isolated IAS muscle strips are devoid of a 
sympathetic input. Lim et al (1985) demonstrated that adrenergic nerves in this 
species play little part in maintaining sphincteric tone and showed that it was 
maintained by fast action potentials, unlike that of human tissue. Histamine caused a 
dose dependent increase in basal tone which is in contrast to Burleigh et al (1979) 
and Burleigh and D'Mello’s (1983) observations in human IAS tissue where histamine 
caused a relaxant response. Rae and Muir (1996) investigated the neuronal mediators 
of inhibitory junction potentials and relaxation in the guinea-pig IAS and showed that 
EFS produced similar relaxations, and that nitric oxide was probably a transmitter that 
was responsible in part for this, the other being ATP or a closely related analogue.
In the porcine IAS a spontaneous tone could be maintained for a considerable time 
after loading. Histamine, through Hi receptors, and phenylephrine, through ai- 
adrenoceptors, induced a concentration dependent contractile response in porcine IAS 
muscle strips. Whether these receptors are located on the smooth muscle membrane 
can be determined by studying the effect of ai, Hi and H2 antagonists, such as 
indoramin, mepyramine, and ranitidine respectively. Alpha-adrenergic mediated 
cellular contraction results in the release of calcium from the intracellular 
sarcoplasmic reticulum, mediated via IP3 [Cook et al, 1999b]. From these data it is 
not possible to determine which of the two receptors are more potent at inducing 
contraction. In the human IAS, histamine induced a relaxant response, and was
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believed to be responsible for NANC mediated relaxation of the IAS [Burleigh et al., 
1979], but has since been discounted.
The non-specific p-adrenoceptor agonist, isoprenaline, induced a relaxant response, 
which is similar to observations by Parks et al. (1969). This is mediated through 
cAMP with the resultant return of calcium to the sarcoplasmic reticulum. The effect 
of GTN on isolated muscle strips were investigated by in sheep IAS muscle strips by 
Jonas et a l (2001c) who identified dose dependent relaxations after addition of GTN. 
In the porcine model the dose dependent relaxations were similar as doses 2.2x10*4, 
6.6X10-4 and 2.2xl0'3 M caused a mean relaxation of 14.9%, 28.7% and 35.3% 
respectively. Burleigh et al (1979) demonstrated that acetylcholine in human tissue 
induced a relaxant response, and in porcine a rapid transient decrease in tone was 
noted with 1x10' M. The abolition of the acetylcholine mediated relaxation by L- 
NAME suggests that the muscarinic relaxant pathways involve NO as a transmitter. 
The effect of ATP on the human IAS is negligible. However, in the porcine IAS it 
induced a sustained relaxation, which was enhanced by the purinoceptor antagonist 
suramin. The reason for this is unclear, but suramin is an inhibitor of ecto-ATPase 
and is also an antagonist of some P2 receptors. However, while suramin potentiated 
the responses to applied ATP in this study, it had no signifcant effect on responses to 
EFS, implying that under these conditions ATP does not contribute significantly to 
the inhibitory neuromuscular transmission
Nitric oxide plays a significant role in the relaxant response of the human IAS and 
this was similar in porcine tissue, demonstrated by the action of GTN, and the 
inhibitory effect of L-NAME on the relaxant amplitude induced by EFS. Although
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nitric oxide is the predominant neurotransmitter in the porcine IAS, it is not solely 
responsible for inducing relaxation, as there was still some relaxation on EFS after the 
addition of L-NAME.
The rightward shift of indoramin on the concentration-response curve of 
phenylephrine suggests that indoramin acts through ai adrenoceptors as indoramin 
reduces the phenylephrine induced contraction of the IAS. Prazosin also reduces the 
histamine induced contraction of the IAS. Furthermore the increase in the relaxant 
response to EFS of frequencies greater than 0.5 Hz up to 32 Hz indicate that addition 
of ai adrenoceptor antagonists with nitric oxide donors may have a synergistic effect 
reducing IAS tone in the human IAS muscle strips.
The failure of botulinum toxin to reduce acetylcholine induced relaxation of porcine 
IAS muscle strips may be due to several reasons. Firstly the incubation period may 
not be long enough. Mackenzie et al. (1982) demonstrated a reduction in the twitch 
response of guinea-pig ileum, which is mediated by acetylcholine, after only two 
hours of incubation with botulinum toxin. However in humans the reduction of anal 
canal pressure after injection of botulinum toxin into the IAS is not demonstrable until 
after a few days. Secondly the dose may not be sufficient to counteract acetylcholine 
induced relaxation of the IAS. Work by Jones et al. (2002a) has since eluded to the 
effect of botulinum toxin on the porcine IAS, through blockade of sympathetic nerves 
distal to their ganglia.
This work shows that with the exception of histamine, causing contraction and ATP 
inducing relaxation, the neural properties of the porcine IAS showed similar features
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to human tissue, as presented in the introduction of this thesis. Furthermore the 
porcine anal sphincter complex is structurally similar to the human, and pigs are 
phylogenetically more closely related to humans than rodents (rats) or hystricomorphs 
(guinea pigs). Hence the porcine IAS was regarded a suitable model of human IAS to 
pursue the aims of this work.
Figure 6.1. Effect of histamine on the basal tone of guinea-pig IAS isolated muscle 
strips. Points represent the mean and the vertical lines s.e.mean.
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Figure 6.2. D iagram atic representation of the initial relaxant effect of electrical field 
stim ulation (EFS 0.3 ms, 8 Hz, 60 V, tra in  length 10 s, interval 110 s) on the tone of 
isolated guinea pig IAS muscle strip.
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Figure 6.3. Representation of the dependency of the relaxant response on background tone in 
guinea pig internal anal sphincter (IAS) a fte r electrical field stim ulation (EFS: 0.3 ms, 8 Hz, 60 V, 
tra in  length 10 s, interval 110 s). There is a linear relationship between tension (increased by 
histamine) and relaxant response (indicated here by the area of relaxation) a t lower levels of tone 
for the tissue.
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Figure 6.4. Histamine concentration-response curve in porcine internal anal sphincter
(IAS). Points represent the mean and vertical lines s.e.mean.
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Figure 6.5. Phenylephrine concentration-response curve in porcine internal anal
sphincter (IAS). Points represent the mean and vertical lines s.e.mean.
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Figure 6.6. Isoprenaline concentration-response curve in porcine internal anal
sphincter (IAS). Points represent the mean and vertical lines s.e.mean.
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Figure 6.7. Relaxant effect of glyceryl trinitrate (GTN) (2.2xl(T4-2.2xl0'3 M) on the 
basal tone of porcine internal anal sphincter (IAS) at differing basal tones (0.72-8.73g) 
as raised by phenylephrine (lxlO -^lxlO*4 M). Points represent the mean and vertical 
lines s.e.mean.
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Figure 6.8A. Effect of acetylcholine (1x10'3M) on the basal tone of porcine internal anal
sphincter (IAS). Note the transient relaxant effect of the drug on the tissue.
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Figure 6.8B. The effect of L-NAME (lXlO^M) on the acetylcholine (lXlO^M) induced 
relaxation of porcine internal anal sphincter (IAS) (n=7). Points represent the mean and 
vertical lines s.e.mean. L-NAME (1X1 O^ M) caused a significant reduction in the 
relaxant response of acetylcholine (lXlO^M) induced relaxation (P<0.05, paired t test).
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Figure 6.9A. Effect of ATP (1x10'3M) on the basal tone of porcine internal anal
sphincter (IAS). Note the sustained decrease in basal tone in the tissue.
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Figure 6.9B. The effect of suramin (3X1 O^ M) on the ATP (1X10'3M) induced relaxation 
of porcine internal anal sphincter (IAS) (n=7). Points represent the mean and vertical 
lines s.e.mean. Suramin (3X1 O^ M) caused a significant increase in the relaxant response 
of ATP (1X10'3M) (P<0.05, paired t test).
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Figure 6.10. Effect of frequency of stim ulation on relaxant and contractile response of 
porcine internal anal sphincter (IAS). (EFS: 0.3 ms, 0.5-32 Hz, 60 V, tra in  length 10 s, 
interval 110 s).
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Figure 6.11. Effect of electrical field stimulation (EFS: 0.3 ms, 0.5-32 Hz, 60 V, train
length 10 s, interval 110 s) on the relaxant amplitude of the porcine internal anal
sphincter. The points represent mean values and the vertical bars s.e.mean. (n=9). Note
that the abscissae are on a logarithmic scale.
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Figure 6.12. Effect of L-NAME (lxlO^M) on the EFS-induced (EFS: 0.3 ms, 0.5-32 Hz, 
60 V, train length 10 s, interval 110 s) relaxant amplitude of the porcine internal anal 
sphincter. The points represent mean values and the vertical bars s.e.mean.
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Figure 6.13. Effect of suramin (3XHT4 M) on the relaxant response of porcine internal 
anal sphincter tissue (IAS) due to EFS (EFS: 0.3 ms, 0.5-32 Hz, 60 V, train length 10 s, 
interval 110 s) (n=5). There was no significant change in the relaxation response for the 
control preparation (■) compared with suramin (▲) for each of the frequencies 
examined (P = NS, paired t test).
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32.0 15.2 4.2 17.4 4.1
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Figure 6.14. Effect of prazosin (lxlO'7 M) on the relaxant response of porcine internal 
anal sphincter tissue (IAS) due to EFS (EFS: 03 ms, 0.5-32 Hz, 60 V, train length 10 s, 
interval 110 s) (n=7). There was a significant increase in the relaxation response with 
prazosin (A) as compared with the control preparation (■) for the frequencies above 0.5 
Hz (P < 0.05, paired t test).
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Figure 6.15. Effect of prazosin (lxKT6 M) (A) on the histamine (■) dose-response curve 
of porcine internal anal sphincter (IAS) (n=3). The dose-response curve is shifted to the 
right indicating a reduction of the contractile effect of histamine.
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Figure 6.16. Effect of the ai-antagonist indoramin (lxlO'7 M) (A) on the phenylephrine 
dose-response curve (■) in porcine internal anal sphincter (IAS). The pK, = 8.3±0.33, 
which is agreement for the pK» in other tissues. This indicates that phenylephrine- 
induced contraction of the IAS is mediated through ai-adrenoceptors.
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Figure 6.17. Effect of one-hour incubation of one unit of botulinum toxin (Botox®) on 
the acetylcholine (Ixl0-3M) induced relaxation of porcine internal anal sphincter (IAS). 
There is no difference in the relaxant response seen after incubation with botulinum 
toxin (P = NS, paired t test).
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CHAPTER SEVEN
RELATIONSHIP BETWEEN INTERNAL ANAL 
SPHINCTER TONE AND NEUROGENICALLY 
OR PHARMACOLOGICALLY MEDIATED
RELAXATION
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7.1. INTRODUCTION
From the observations by Nothmann and Schuster (1974), Hancock (1977), Lin (1989), 
and Farouk et al. (1994) it is generally accepted that most patients with chronic anal 
fissures have a higher MRP than normal subjects believed to be hypertonia of the IAS. 
Whilst lateral internal anal sphincterotomy results in a high healing rate for chronic anal 
fissures Boulos and Araujo (1984) demonstrated a sustained reduction in the MRP. This 
has the disadvantage that in the long term this reduction of MRP may lead to disturbances 
in continence as reported by Khubchandani and Reed (1989). Topical agents, namely 
GTN and Diltiazem, heal anal fissures with a transient reduction of MRP. Lund and 
Scholefield (1997) and Carapeti et al. (1999) showed fissures in two-thirds of patients 
heal, although the healing rates are lower in recent studies by Pitt et al. (1999), Jonas et 
al. (1999) and Altomare et al. (2000). There is a group of patients in whom the fissures 
do not heal despite experiencing an adequate reduction of the MRP with treatment. This 
was demonstrated in chapter three where 14 (33%) of 33 patients with chronic anal 
fissures failed to heal with topical diltiazem after a two month course despite a significant 
reduction in MRP. The reasons for failure of some anal fissures with high internal anal 
sphincter tones despite significant reduction in MRP is unclear.
There is evidence to suggest that the physiological behaviour of the IAS in anal fissures 
is altered. Hancock (1977) demonstrated the presence of ultraslow waves in 10 of 12 
patients with chronic anal fissures, compared with 2 of 40 control subjects. Similarly 
Schouten and Blankensteijn (1992) observed these waves in 29 of 58 patients with
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fissures as compared with 2 of 20 control subjects. Ojo-Aromokudo et al (1998) 
demonstrated an up regulated p adrenoceptor response to the p2-agonist salbutamol in 
patients with fissures compared with controls as compared with relaxant effects of the ai- 
antagonist indoramin. Regadas et al. (1993) compared the responses to the a- 
adrenoceptor agonist phenylephrine and the p2-agonist isoproterenol of the IAS from 7 
patients with chronic anal fissures and increased anal canal pressures and in 5 control 
patients with haemorrhoids and normal resting anal canal pressures. The sensitivity to 
phenylephrine in both groups was similar but a significant difference in sensitivity in the 
experimental group undergoing relaxation using isoproterenol. Though this up regulation 
has not been validated in the work presented in this thesis an explanation for altered 
physiology of the IAS in fissures needs clarification.
Jonas et a l (2001c) investigated in an in vitro setting with isolated sheep internal anal 
sphincter whether GTN and diltiazem have an additive effect. Maximal concentrations of 
GTN and diltiazem each decreased sheep IAS tone by approximately 70%. The 
combined effect of GTN and diltiazem was complete abolition of IAS tone irrespective of 
the order in which they were added.
The aim of this study was to investigate the effect of EFS, GTN and diltiazem on an 
increasing tone of porcine IAS muscle strips in order to explain why some 
pharmacological agents may not heal anal fissures associated with high IAS tone.
7.2. METHODS
Female Landrace pigs (live weights 80-120kg) were killed at the abbatoir in accordance 
with approved methods, and the sphincter muscles complexes were removed en bloc and 
transported in modified Kreb’s solution to the laboratory where the IAS tissue was 
dissected free.
Muscle strips of IAS (guinea-pig: 4mm x 1mm, porcine 5-10mm x 2mm) were suspended 
in organ-baths containing modified Krebs’ solution. One end of the preparation was 
attached to a rigid support and the other, using silk thread, to an isometric force- 
displacement transducer (Biopac TSD 125 C). The data were presented with “Acquire 
software (Acqknowledge 2.0)” computer software, through a MPW100 data acquisition 
system (Biopac). The porcine muscle strips had an initial load of 2 g applied, and after 
equilibration (45 min), phenylephrine was added in increasing doses to provide a bath- 
concentration from lxlO^M - 1x10‘3m.
Electrical field stimuli (EFS) was applied at the maximal frequency of 8-16 Hz, using 0.3 
ms biphasic pulses at supramaximal voltage for 30 s, and induced maximum relaxations 
of 0.7 ± 0.13 g. After electrical field stimulation (EFS) of the muscle strips at a specified 
frequency the tissue responses were allowed to stabilise before the relaxant responses of 
the contracted porcine strips to GTN (2.2x1 O^M, 6.6x10^M, 2.2xlO'3M) and diltiazem 
(lxlO^M) were measured.
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The relaxant responses for EFS, GTN and diltiazem were measured as tone (as a 
percentage o f  maximal tone) vs. residual tone (as a percentage o f  maximal tone). The 
“maximal tone” is the end tone achieved after cumulative addition o f phenylephrine to 
the highest concentration used (1 x 1 0 '3m ). The “residual tone” is the tone achieved at the 
point o f  maximal relaxation after the application o f  EFS, GTN or diltiazem (JigJA.).
Figure 7.1. Diagrammatic representation of the response of isolated porcine internal anal 
sphincter (IAS) tissue suspended in oxygenated modified K reb’s solution to electrical field 
stimulation (EFS: 0.3 ms, 0.5-32 Hz, 60 V, train length 10 s, interval 110 s). Note the 
contraction of the tissue in response to phenylephrine and the subsequent starting tone 
prior to stimulation. After stimulation a relaxant response is produced with an ensuing 
rebound excitation. The residual tone refers to the tone within the preparation at the end of 
the relaxant response.
Stimulation
Rebound
Excitation
Relaxant
Response
(Nitric
Oxide)
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Residual Tone
t
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7.3. RESULTS FOR PORCINE IAS MUSCLE STRIPS
Electrical Field Stimulation
The porcine muscle strips had an initial load of 2 g applied, and after equilibration (45 
min), by which time the tone had dropped to 1.7 ± 0.2 g (n = 9, mean ± s.e. mean), 
phenylephrine was added in increasing doses to provide bath-concentration from 1x 10'6m  
- 1x 10'3M. A s tone in the porcine IAS was raised by phenylephrine (lxlO^M - 1x 10'3m ), 
the relaxant response to the same frequency of EFS (8 Hz or 16 Hz) increased (fig. 7.2). 
The regression of this relationship was exponential (r?=0.16', d.f=118) (fig.7.3.). The 
results for 10 muscle strips are shown in Appendix 37. Phenylephrine evoked 
concentration-dependent sustained contractions that reached a clear maximum level (4.8 
± 0.9 g) within this range. The residual tone, i.e. the level of tone to which the 
preparation relaxed during EFS, was proportional to the level of tone at which EFS was 
applied (fig. 7.4.). The results for 10 muscle strips are shown in Appendix 38. The 
regression of residual tone on level of tone was linear and showed a statistically 
significant correlation (r2 = 0.90, P «  0.001, d.f. = 120).
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Figure 7.2. The increase in the relaxant response in porcine internal anal sphincter (IAS) as the 
starting tone of the tissue prior to electrical field stimulation is increased (EFS: 0.3 ms, 8 Hz, 60 V, 
train length 10 s, interval 110 s).
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Figure 7.3. Increase of the relaxant response of porcine internal anal sphincter (IAS) to electrical field 
stimulation (EFS: 0.3 ms, 16 Hz, 60 V, train length 10 s, interval 110 s) on tone raised by phenylephrine 
(1 pM-1 mM). There is an expontential relationship between the two variables (r2=0.16, d.f.=118).
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Figure 7.4. Residual tone of response to electrical field stimulation (EFS: 0.3 ms, 16 Hz, 60 V, train 
length 10 s, interval 110 s) on tone raised by phenylephrine (1 pM-1 mM) in the porcine internal anal 
sphincter (IAS). There is statistically significant linear relationship between starting tone and residual 
tone after EFS (y=0.88x-3.64, r2=0.90, d.f.=120). These are the same data as represented in figure 7.3.
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The results for 21 muscle strips are shown in Appendix 39. The relaxant responses to GTN 
in different concentrations (2.2x1 O^M, 6.6x10 '4M, 2.2x1 0 '3m ) were quantified. An initial 
load of 2 g was applied, and after equilibration (45 min), by which time the tone had 
dropped to 1.3 ±  0.3 g (n = 8, mean ± s.e. mean), phenylephrine was added in increasing 
doses to provide bath-concentrations from 1x 10'6M - 1x 10'3m . Phenylephrine evoked 
concentration-dependent sustained contractions that reached a clear maximum level (4.51 ± 
0.9  g) within this range. For each of the concentrations of GTN the residual tone, i.e. the 
level of tone to which the preparation relaxed during GTN, was proportional to the level of 
tone at which GTN was applied. For this the regression of residual tone on level of tone 
was linear and again showed a highly statistically significant correlation (fig.7.5., fig.7.6., 
fig-7-7.).
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Figure 7.5. Relationship of tone (% maximum) to residual tone (% maximum) for porcine 
internal anal sphincter (IAS) relaxation induced by glyceryl trinitrate (GTN: 2.2xlO'4M). 
There is a linear relationship between the starting tone and residual tone after addition of 
GTN y=1.04x-10.96, r2=0.95, d.f.=21).
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Figure 7.6. Relationship of tone (% maximum) to residual tone (% maximum) for porcine 
internal anal sphincter (IAS) relaxation induced by glyceryl trinitrate (GTN: 6.6xl0'4 M). 
There is a linear relationship between the starting tone and residual tone after addition of 
GTN y=0.92x-11.01, r2=0.87, d.f.=20).
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Figure 7.7. Relationship of tone (% maximum) to residual tone (% maximum) for porcine 
internal anal sphincter (IAS) relaxation induced by glyceryl trinitrate (GTN: 2.2xlO~3M). 
There is a linear relationship between the starting tone and residual tone after addition of 
GTN y=0.72x-9.68, r2=0.72, d.f.=20).
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DILTIAZEM
The results for 6 muscle strips are shown in Appendix 40. An initial load of 2 g was 
applied, and after equilibration (45 min), by which time the tone was 2.2 ± 0.3 g (n = 7, 
mean ± s.e. mean), phenylephrine was added in increasing doses to provide a bath-
s' ^
concentration from 1x10 M -  1x10'M. Phenylephrine evoked concentration-dependent 
sustained contractions that reached a clear maximum level (2.8 ± 0.6 g) within this range. 
For diltiazem ( lxlO'4 M) the residual tone, i.e. the level of tone to which the preparation 
relaxed during diltiazem, was proportional to the level of tone at which diltiazem was 
applied. For this the regression of residual tone on level of tone was linear and again 
showed a statistically significant correlation (fig. 7.8.).
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Figure 7.8. Relationship of tone (% maximum) to residual tone (% maximum) for porcine 
internal anal sphincter (IAS) relaxation induced by diltiazem (lxlO'4 M). There is a linear 
relationship between the starting tone and residual tone after addition of diltiazem 
(y=0.91x-0.36, r2=0.90, d.f.=25).
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7.4. DISCUSSION
This discussion relates the relaxant responses of contracted isolated IAS muscle strips to 
EFS, GTN and diltiazem and proposes a possible theory for failure of some chronic anal 
fissures with sphincter hypertonia to respond to topical pharmacological therapy despite 
significant reduction in resting anal canal pressure. In order to extrapolate the 
pharmacological model to the clinical situation similarities are drawn between the in vitro 
and in vivo setting. These are based on evidence that neural ly mediated relaxation of the 
IAS in vitro, through EFS, and in vivo with GTN, is modulated through release of nitric 
oxide; GTN being a nitric oxide donor. The effect of the relaxant response to diltiazem is 
described separately. Schouten et al. (1994) identified the concept of the “ischaemic 
threshold” which is the IAS muscle tone above which the anoderm is inadequately 
perfused, and within this “ischaemic zone” chronic anal fissures do not heal. It is 
proposed the ischaemic threshold varies between individuals.
A hypertonic IAS is reproduced in vitro by cumulative addition of the a-adrenoceptor 
agonist phenylephrine. The “maximal tone” is the end tone achieved after the addition of 
increasing doses of phenylephrine. The “residual tone” is the tone achieved at the point 
of maximal relaxation after the application of EFS, GTN or diltiazem (fig 7.7.).
The residual tone after EFS, which is the tone achieved from activation of the enteric 
nerves, also increases as the basal tone of the tissues is increased by phenylephrine, and
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followed a linear pattern (figs. 7.2. & 7.3.). This indicates at very high tones the resultant 
residual tone achieved is also high.
Similar observations are made with the three concentrations of GTN and diltiazem. 
There is a linear relationship between the starting tone and resultant residual tone 
achieved after relaxation. The importance of the linear relationship of starting tone to the 
residual tone after either EFS or pharmacological relaxation is relevant to the vascular 
pathogenesis of anal fissures (Schouten et al., 1996a). Schouten et al. (1996b) have 
demonstrated that the perfusion of the posterior commissure of the anal canal, where the 
majority of idiopathic chronic anal fissures occur, is strongly related to the anal canal 
pressure. There is an inverse relationship between the maximal anal canal pressure and 
the flux (vascular perfusion) of the anal canal. Current hypotheses indicate that chronic 
anal fissures do not heal because of the persistent vascular ischaemia of the fissure [Lund 
and Scholefield, 1996]. Therefore reduction of the anal canal pressure below a critical 
level will allow the fissure to heal.
The results presented in this chapter show as the tone of the IAS is increased the relaxant 
response increases (see fig. 7.9.). There is a point above which the tone of the IAS 
(which is translated clinically into the maximal anal canal pressure) means that the anal 
canal is not adequately vascularly perfused. This is termed the “ischaemic threshold”. 
The residual tone achieved after EFS above this point may or may not result in perfusion 
of the anal canal. Points A, B, C in fig. 7.9. are explained as follows:
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(A) This starting tone of the muscle strip and resultant residual tone achieved after 
EFS both lie below the “threshold level” for adequate perfusion. Relating this 
to the clinical situation means that fissures with low pre-treatment MRP and 
the resultant relaxant stimuli applied will mean that the anoderm is perfused 
throughout.
(B) This starting tone of the muscle strip lies above the “ischaemic threshold” but 
resultant residual tone achieved after EFS lies below the “threshold level” for 
adequate perfusion. Relating this to the clinical situation means that fissures 
with high pre-treatment MRP may have an inadequately perfused anoderm but 
after application of relaxant stimuli the anoderm is perfused. Fissures that 
display this physiological response will heal.
(C) The starting tone here is very high, above the “ischaemic threshold” (clinically 
analogous to some chronic anal fissures associated with higher resting anal 
canal pressures). As such they lie in the zone where the anoderm is 
inadequately perfused. Even with EFS (nitric oxide transmission) the residual 
tone is not sufficiently low to provide an adequate perfusion of the anal canal. 
Therefore using nitric oxide donors will not result in an adequate reduction of 
tone to allow adequate perfusion of the anal canal and fissures that experience 
this behaviour will not heal. Note also as the starting tone is increased the 
amplitude of the relaxant response increases.
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Figure 7.9. Representation of the relationship increasing tone on of the result of EFS (and indirectly 
pharmacological relaxation) on the response of isolated IAS muscle strips and its relevance to the 
“ischaemic” threshold.
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It would be ideal if one could relate the MRP of the anal canal and suggest whether a 
particular dose of an agent will cause healing.
Consider the “ischaemic threshold” which has been defined as the point at which anal 
canal pressure just allows for adequate perfusion of the anal canal. Above this the anal 
canal pressure is associated with chronic anal fissures (fig. 7.10.).
Lei “Z”, an arbitrary figure be termed the “ischaemic index” indicated by the equation:
Z = X /Y  [1]
Where:
X = the maximal anal canal pressure for adequate perfusion of the anal canal. 
Y= the anal canal pressure associated with chronic anal fissures, which is 
assumed to be when the smooth muscles of the internal anal sphincter are 
maximally contracted.
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Figure 7.10. Diagram demonstrating the relationship between anal canal pressure and 
anodermal blood flow (flux) (Schouten et a l 1994). According to Schouten’s hypothesis of 
the importance of ischaemia in the development of chronic anal fissures there is an anal 
canal pressure (as indicated by “X”) above which the anal canal will not be adequately 
perfused and a chronic anal fissure may not heal. The point “C” indicates the mean MRP 
in healthy volunteers.
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C X
Maximal anal canal pressure
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We can calculate the value of Z from Schouten et al. ’s (1994) demonstration from 9 
patients with chronic anal fissures. Their the mean maximal anal canal pressure was 125 
± 26 mmHg, and that in 31 control subjects was 66 ± 19 mmHg. For this group the 
ischaemic Z, the “ischaemic index” is calculated by the equation:
Z = [MRP in control subjects + s.d. (mean)] / MRP in patients with fissures
= (66+19)/125 
= 0.7 (to one decimal place)
Thus if the IAS in patients with chronic anal fissures at maximal tone the residual tone 
(% maximally contracted tone) above which the tissue are not adequately perfused is Z 
xlOO % = 70 %.
Figures 7.11 & 7.12. depicts the starting tone ,T, above which the relaxation of the 
tissues by either EFS of pharmacological intervention will not be adequate for perfusion 
of the anal canal.
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Figure 7.11. The concept of the “ischaemic index”, “Z”, the figure beyond which the anal 
canal is inadequately perfused “X” which is the relationship demonstrated in the following 
equation:
Z = X/Y
X = the maximal anal canal pressure for adequate perfusion of the anal canal. 
Y= the anal canal pressure associated with chronic anal fissures, which is 
assumed to be when the smooth muscles of the internal anal sphincter are 
maximally contracted.
“C” is the anal canal pressure associated with healthy volunteers.
“T” indicates the MRP above which relaxation of the muscle through either 
neural stimulation or pharmacological manipulation will not reduce the MRP to 
below point “X”.
▲
T ™
Anal Canal Pressure
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Figure 7.12. Diagram representing the relationship between the residual tone of the 
internal anal sphincter after relaxation (as a fraction of the maximal tone), the staring tone 
(as a percentage of maximal tone) prior to this relaxation, and the concept of ischaemia of 
the anal canal.
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tone
Ischaemia
Normal
Perfusion
T
Tone 
(%  Maximum)
“T” is the tone of the smooth muscle, as a percentage of the maximal tone achieved by 
contraction, above which relaxation of the smooth muscle for the value interpolated by “Z” 
relates to inadequate perfusion of the anal canal.
Because o f  the linear relationship between the starting tone and residual tone, for the EFS 
frequency denoted and the drug concentrations used, T can be calculated.
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For example for EFS (16Hz) the regression equation is:
y = 0.88 x -  3.64
If y = 70, x = T
T = (70+ 3.64)/0.88 
T = 84
Therefore if the IAS is contracted to beyond 84 % of its maximal contacted tone, the 
stimulation of the enteric nerves will not be enough to allow adequate vascular perfusion 
of the anal canal.
Application of these results for the pharmacological agents used shows varying values for 
T :
T (The % of maximally contracted tone 
Above this % use of the [drug] stated will 
be
Ineffective in reducing the tone to below X 
(see/fe. 7.11)
GTN (2.2 x lO^M), T = 78 %
GTN(6.6x K T ' m ) T = 88 %
GTN (2.2 x 10'JM) T = 97 %
Diltiazem (1 x lO^M) T = 77 %
These results indicate that if the ischaemic index is equivalent to a residual tone of 70 %, 
one can interpolate the IAS tone at which GTN becomes ineffective. The results
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demonstrate there is concentration dependence for GTN, with higher concentrations 
proving possibly more effective. If one takes into account of the amount and 
concentration of GTN in biophase following topical application the reduction noted 
might not be great enough to allow vascular perfusion in any case, therefore the effect of 
concentration may not be important.
In conclusion these results would suggest that in the clinical setting those patients with 
chronic anal fissures in whom GTN and diltiazem reduces the MRP significantly but still 
fail to heal may be related to the failure of these agents to reduce the MRP sufficiently to 
allow adequate perfusion of the anoderm. The amplitude of the relaxation is dependent 
on the starting MRP and may be dose dependent. This chapter has provided direct 
evidence in the in vitro setting for this hypothesis.
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CONCLUSION
The evolution of alternative therapeutic strategies over the last decade has enabled 
clinicians to treat chronic anal fissures more effectively. The increasing interest in 
conservative therapies has arisen because of concerns over the long term functional 
effects of surgical division or dilatation of the IAS.
The management of chronic anal fissures was investigated by Karandikhar et al. (2002) 
in a postal survey. Among 357 (78%) responders of 452 members of the Association of 
Coloproctology of Great Britain and Ireland, 70% regarded GTN as the treatment of 
choice. Fissures that did not heal after 6-12 weeks of treatment were deemed as a failure. 
The extent of surgical division of the IAS varied, as 42% divided the entire length of the 
IAS. Anal dilatation was selectively practiced by 37.6%. The authors then explored the 
treatments offered for a 40 year old continent male and continent postpartum female. In 
the male patient 90.6% would perform lateral sphincterotomy; 5% would perform 
endoanal ultrasonography, and 3.6% would perform anorectal physiology. In the female 
patient 76.6% would perform lateral sphincterotomy, but 89% would evaluate the 
sphincter preoperatively. 33% by endoanal ultrasound, 30% by anorectal physiology and 
26% by both. The results suggest that in patients who fail to respond to conservative 
treatment lateral sphincterotomy is the surgical procedure of choice and in females 
preoperative evaluation of the IAS is recommended.
The first-line treatment of chronic anal fissures with topical agents has led to 
management algorithms that can be effectively employed under the supervision of nurse
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specialists. Porrett et al (2002) examined the outcome of 135 patients with chronic anal 
fissures over a 3-year period. Patients were initially treated with a single course of 0.2% 
GTN, and those that failed were offered 0.2% GTN again, 0.4% GTN or surgery. 
Surgical treatment included anoplasty in all females, and in those males with normal or 
low resting anal canal pressures, and lateral sphincterotomy in males with high anal canal 
pressures. At a median follow up of 9 months, 66 (49%) healed with resolution of 
symptoms after a single course of 0.2% GTN (62% acute, 41% chronic fissures). 74% 
healed after a second course of 0.2% GTN (100% acute, 71% chronic fissures) with no 
advantage in using 0.4% GTN. In 20 (15%) patients the fissures healed by surgical 
treatment (10 anoplasty, 10 lateral anal sphincterotomy) and one patient suffered soiling 
after surgery. This approach was effective in that a clear protocol was followed with 
good effect.
Brown et al (2002) also used algorithms with particular reference to the management of 
persistent and recurrent chronic fissures. They highlighted that with GTN as initial 
treatment, fissures persist in 32-54% of cases [Kennedy et al (1999), Altomare et al
(2000), Lund and Scholefield (1997b)]. Furthermore Dorfmann et al. (1999) had shown 
that fissures recurred in upto 63%. Irrespective of the mode of therapy these persistent or 
recurrent fissures pose a particular challenge.
Failure of GTN therapy may be related to non-compliance due to headaches, or 
inadequate length of treatment. Pitt et al (1999), Richard et al (2000) and Skinner et al
(2001) stated that approximately 20% of patients cease treatment because of side effects.
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Salgado and Berman (1999) showed that the use of a slotted applicator tip (Apthorp 
Pharmacy, New York, USA) reduced many of the side effects experienced from digital 
application. Whilst Watson et al. (1996) suggested that the minimum length of period of 
treatment with GTN is 4 weeks; there is no consensus over the optimal period of 
treatment for GTN, as the duration of treatment reported has varied from 4 to 12 weeks.
Whilst botulinum toxin is an effective modality for initial treatment, Brisinda et al.
(1999) successfully treated 9 patients with fissures that persisted after GTN. Jost et al. 
(1999b) also used a repeat injection of botulinum toxin to treat fissures that persisted. 
There is evidence of the use of alternative agents that do not heal with initial 
pharmacological therapy. Jonas et al. (2002) showed topical diltiazem heals fissures that 
failed with GTN therapy and Cook et al. (1999a) reported healing in 4 patients with 
nifedipine who failed treatment with GTN. Most would advocate surgery in those that 
have failed to heal with repeat pharmacological therapy. Nevertheless Richard et al.
(2000) showed that in their randomized trial comparing lateral sphincterotomy with GTN, 
no recurrences occurred following surgery, but 45.4% of 44 patients who were initially 
treated with GTN subsequently required sphincterotomy. Whilst lateral sphincterotomy 
is the procedure of choice for the majority, alternative surgical modalities such as 
anoplasty is advocated in those with lower anal canal pressures.
In those that fail to respond or recur after surgery secondary causes which include 
Crohn’s disease, HIV infection, tuberculous disease or malignancy must be considered 
before further surgery or pharmacological therapy, particularly when fissures are multiple
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or not in the midline. Lewis et al. (1988) found that 5 (24%) of 21 patients with 
persistent fissures following lateral sphincterotomy had Crohn’s disease. Sweeney et al. 
(1988) showed that many fissures associated with Crohn’s disease heal with conservative 
treatment alone, though of those that do not approximately 80% will heal with 
immunosuppressive treatment. Whilst most fissures associated with Crohn’s disease are 
painless, Fleshner et al. (1995) still advocated a lateral sphincterotomy. Barrett et al. 
(1998) noted that of 260 patients with anorectal disease 32% had anal fissures. Not all 
fissures associated with HIV infection are associated with sphincter hypertonia and in 
these cases sphincterotomy should be used with caution. In the management of the 
tuberculous fissure Candela et al. (1999) and Whalen et al. (1980) have reported healing 
with anti tuberculous therapy.
Nyam et al. (1999) showed that conservative management with high fibre and fluid 
intake will heal upto two-thirds of patients with unhealed idiopathic fissures. Of 11% of 
fissures that recurred in a series of 549 patents reported by Garcia-Aguilar et al. (1996), 
30% of these were reoperated on and the remainder were treated successfully with 
conservative therapy. In a larger series of 2030 patients Argov et al. (2000) reported a 
1% incidence of recurrent or persistent fissures. Sphincterotomy on the contralateral side 
in those with high resting anal canal pressures resulted in healing in all patients. Nyam et 
al. (1995) used anal advancement flap successfully in 7 patients whose fissures did not 
heal or recurred following lateral sphincterotomy.
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This thesis has sought to re-explore and clarify issues raised in the literature since the 
introduction of pharmacological agents almost a decade ago.
The use of topical 2% diltiazem is an effective alternative to topical 0.2% GTN as first 
line therapy for the treatment of chronic anal fissures without risk of potential headaches 
and poor compliance. Manometric evaluation confirmed higher MRP in patients with 
fissures compared with volunteers, and in those with anal spasm. A healing rate of 58% 
was comparable to that seen with other topical pharmacological agents, and those fissures 
that heal do so with a significant reduction the MRP. Of note there was also a reduction 
in the MRP in fissures that did not heal and this may be explained by the vascular 
pathogenesis of chronic anal fissures due to failure to attain the ischaemic threshold. The 
results in this thesis imply that it is not possible to use pretreatment MRP as a prognostic 
indicator to determine success with topical diltiazem as the MRP is similar in responders 
and non responders. Furthermore it was not possible to use the presence of a sentinel pile 
and/or anal spasm as a prognostic indicator. All patients that had healed were 
asymptomatic. After cessation of treatment the MRP in 12 patients initially healed at two 
months revealed a return to pretreatment MRPs by 4 months, this is the “reversible 
chemical sphincterotomy”. The use of a second course in persistent fissures failed to 
decrease the MRP in the patients studied at 4 months, yet 6 healed. This healing may be 
related to the direct effect of topical diltiazem in the vasculature of the anal canal. The 
response to the application of topical diltiazem may be classified into three groups: 
patients with high MRP that heal with a reduction of MRP; patients with high MRP that
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fail to heal despite a reduction in MRP; and patients with low MRPs in whom the MRP is 
unaltered with treatment.
The reluctance of clinicians to directly inject botulinum toxin into the anal sphincter 
complex led to the feasibility studies that used the J-tip needless injection system to 
deliver the agent. After initial animal studies to determine an optimal angle of penetrance 
10 patients with chronic fissures were recruited, treated with 50 units, and evaluated until 
12 weeks. Despite the size of the injected molecule it was effective in reducing the MRP 
at least to 2 months, with an effective reduction in median pain scores, and without a 
detrimental effect on continence. The poor healing rate of 5 (50%) of 10 may be related 
to the inadequate dosages used.
Both oral indoramin and oral salbutamol acting on the sympathetic receptors on the IAS 
smooth muscle cell decrease MRP in both volunteers and patients over the three hours 
studied. Whilst 3 patients experienced light headedness with indoramin, 9 subjects 
experienced tremors with salbutamol. Furthermore there was a transient tachycardia 
experienced in subjects taking salbutamol. It was felt that salbutamol would not be a 
suitable agent to continue to investigate. The subsequent study conducted, investigation 
of a topical pharmacological preparation of indoramin at doses ranging from lOmg to 
40mg failed to have any superior effect over placebo. This may be related to the paraffin 
based delivery substance, or the superior local action of the sympathetic drive. The 
unsuitability of oral indoramin to treat chronic anal fissures was examined by Pitt et al.
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(2000). In this trial many more patients experience side effects which included fatigue, 
dizziness, headache, dry mouth, nasal congestion and retrograde ejaculation.
The necessity to validate an animal model of human IAS tissue was bom out of O’Kelly 
et a l ’s (1992) and Cook et al.9s (1999b) investigations to examine the pharmacological 
responses of porcine IAS. Whilst Mundey et al. (2000) has subsequently validated the 
responses of sheep IAS muscle, it was felt that this needed to be conducted with porcine 
tissue. Porcine IAS muscle strips maintained their own muscle tone, contracted in 
response to histamine and phenylephrine. The muscle strips relaxed in response to 
isoprenaline and glyceryl trinitrate, and acetylcholine, and ATP. The relaxant response to 
acetylcholine was abolished by L-NAME, and suramin potentiated the relaxant response 
of ATP. The relaxant responses to electrical field stimulation were reduced with L- 
NAME, unaffected by suramin, and potentiated by prazosin. Furthermore prazosin 
reduced the contractile response of histamine, whilst indoramin reduced the contractile 
response of phenylephrine. These studies confirmed the similarities of the neural 
properties of porcine and human IAS, and as the tissue was structurally similar it was felt 
that this tissue could be suitably used for further investigation.
The final series of experiments investigated the reasons for why in some patients a 
reduction of MRP is not equated with healing of chronic anal fissures. There was a linear 
relationship between the residual relaxant tone after electrical field stimulation and the 
starting tone. Similar effects were seen for relaxant responses demonstrated with 
glyceryl trinitrate and diltiazem. One can conclude from this that in patients with very
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high MRPs healing may not be observed as the relaxation of the IAS that is induced may 
not be sufficient to permit adequate perfusion of the anoderm. This conclusion may 
explain why 14 of 33 patients treated with topical diltiazem in chapter 3 failed to heal 
despite demonstrating a significant reduction in their MRP.
This thesis has sought to investigate current controversies in the treatment of chronic anal 
fissures. Before appropriate treatment can be instituted it is imperative that the nature of 
the fissure is identified, as related to the history and the examination findings; and the 
appropriate consequences of treatment should be discussed with the patient. There is 
much scope for tailoring pharmacological therapy for the management of chronic anal 
fissures.
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APPENDICES
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Appendix 1: GENERAL METHODS
CLINICAL PHYSIOLOGICAL WORK 
Anorectal physiological equipment
The equipment used to obtain the measurements of the resting pressure of the IAS was a 
continually water-perfused eight-channel catheter assembly (Lewis Medical, 
Hertfortshire and Mui Scientific, Ontario) (figs.l. & 2.). The measurements of resting 
anal canal pressure were obtained by advancing the manometiy catheter into the anal 
canal from the external anal verge. At each point the catheter was not advanced until a 
steady reading had been observed. This method is similar to that used by Arabi et al. 
(1977) who deemed the maximal resting anal canal pressure (MRP) to be the highest 
mean pressure at any of these sites. This method is different from the mean value of 
different pressures measured throughout the anal canal, which was used in Hancock’s 
study (1977); the single point manometry which was used in the assessment of 
salbutamol in a smaller number of subjects (Ojo-Aromokodo et al, 1998), and differs 
from pull-through manometry which is used where vector volume manometry is routinely 
employed. The data was presented with “MMS” computer software package (version 
7.0), with a NEC Cyrix 686 MX processor. When required pulse and blood pressure 
were measured by the author using a manual syphgmometer (Branchburg, New Jersey).
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Drugs and solvents used
The following pharmacological agents were used in the clinical trials involving human 
subjects:
INDORAMIN SMITHKLINE BEECHAM PHARMACEUTICALS
SALBUTAMOL APPROVED PRESCRIPTION SERVICES
BOTULINUM TOXIN ALLERGAN LTD.
DILTIAZEM SLA PHARMA
Continuously water-perfused 
8 -channel manometer 
(Mui Scientific. Ontario'!
Figure 1. Anorectal physiology suite at the Middlesex Hospital.
Anal
Canal
External 
anal “  
sphincter
Internal 
anal /  
sphincter
Figure 2. Eight channel catheter assembly and diagram showing advancement of catheter
into anal canal
LABORATORY EXPERIMENTAL WORK 
Physiological solutions
For all experiments performed on mammalian tissues a modified Krebs’ solution was 
used, o f  the following compostion (mM): NaCl, 133; KC1, 4.7; NaH2P0 4 , 1.4; NaHC0 3 , 
16.3; M gS04, 0.6; CaCh, 2.5; Glucose, 7.7 (Bulbring, 1953). The solution was gassed 
with 95% 0 2 / 5% C 02, and after equilibrium the pH was 7.3-7.4.
Animals used
The guinea pigs were male Dunkin Hartley, (Charles River, weight 275-375g). The 
guinea pigs were sacrificed by cervical dislocation and the pigs were stunned and bled. 
The pigs were male and female Landrace (live weights 80 -120kg). The pigs were culled 
in accordance with approved methods.
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Organ-bath apparatus
Organ-baths were 5ml or 10ml in volume, side-arm gassed and made o f  glass 
(Linton,Norfolk, UK). The baths and reservoirs o f  the Krebs’ solution were maintained at 
36.5 ±  0.5°C (unless otherwise stated), and were continually gassed (fig.3.).
Isometric force transducer 
(Biopac TSD 125C)
Oxygenated 
Modified Kreb’s 
Solution
Porcine IAS
Figure 3. Organ Bath Apparatus 
Preparations for organ-bath studies
Guinea-pig internal anal sphincter: The abdomen was opened, internal viscera removed, 
and the pelvic floor structures were removed. The internal sphincter was dissected free. 
Porcine internal sphincter: The isolated sphincteric complex was removed from the
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abattoir and transported in Kreb’s solution. In the laboratory the internal sphincter tissue 
was dissected free.
Segments of internal anal sphincter (5-10mm x 2mm) were suspended in organ-baths 
containing Krebs’ solution. One end of the preparation was attached to a rigid support 
and the other, using silk thread, to an isometric force-displacement transducer (Biopac 
TSD 125 C). The data was presented with “Acquire software (Acqknowledge 2.0)” 
computer software, through a MPW100 data acquisition system (Biopac). Preparations 
were preloaded with 0.5-2.0g and were allowed to equilibrate for at least 50 min before 
any drugs were added. If required the tissues were electrically stimulated (Experimetria 
S02 stimulator) the following stimulation parameters were used: pulse width (0.3 ms, 
biphasic); frequency (0.5 - 32 Hz); train length (10 s); interval between trains (110 s) and 
voltage (supramaximal, 60 V).
Drugs and solvents used
ACETYLCHOLINE CHLORIDE 
ADENOSINE 5’-TRIPHOSPHATE 
ATROPINE SULPHATE 
BOTULINUM TOXIN 
DILTIAZEM HYDROCHLORIDE
SIGMA
(ATP) SIGMA
SIGMA
ALLERGAN LTD. 
SIGMA
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ELO H A E S FR E S N IU S
GLYCERYL TRINITRATE (GTN) FAULDING DBL
S-NITROSOGLUTATHIONE (GSNO) SIGMA
GUANETHEDINE MONOSULPHATE SIGMA
HISTAMINE SIGMA
INDORAMIN HYDROCHLORIDE SMITHKLINE BEECHAM PHARMACEUTICALS
NORADRENALINE BITARTARATE SIGMA
Nw-NITRO-L-ARGININE METHYL ESTER 
(L-NAME) HYDROCHLORIDE SIGMA
METHOXAMINE HYDROCHLORIDE SIGMA
L-PHENYLEPHRINE HYDROCHLORIDE SIGMA
PRAZOSIN HYDROCHLORIDE SIGMA
PROPANOLOL HYDROCHLORIDE ZENECA PHARMA
SURAMIN (SODIUM SALT) SIGMA
KREB’S SALTS WERE ALL ANALYTICAL GRADE
Most drugs were made up into stock solutions using distilled water. Noradrenaline was 
dissolved in ascorbic acid at 0.01 times the molar concentration of noradrenaline.
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ANALYSIS OF RESULTS
Statistical analysis of results was carried out using “SPSS” (statistical packages for social 
sciences) computer software (version 7.5) and “Prism” (version 3.0). Comparison of 
MRP was conducted after testing for normality. Graphs were drawn using “Prism” 
version 3.0. A level of probability, if considered in the statistical analysis, of P< 0.05 was 
considered significant.
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TOPICAL DILTIAZEM IN TREATMENT OF ANAL FISSURES
Appendix 2: Maximum Resting Anal Canal Pressure (cml^O) in patients analysed over 
a 6 month period
START
2
MONTHS
4
MONTHS
6
MONTHS
No. Sex Age
1 Male 38 77 83 47
2 Female 40 77 55 53
3 Male 36 83 68
4 Male 81 88 75 77 76
5 Female 35 88 90
6 Female 68 93 64 100 76
7 Female 28 93 75
8 Female 29 93 103 101 125
9 Female 59 98 96
10 Female 28 101 79 100 98
11 Female 27 101 68
12 Male 35 102 79 117 161
13 Female 29 103 61
14 Male 40 108 111 110 134
15 Female 27 109 66 51
16 Male 37 110 53 120 137
17 Female 35 110 107 134
18 Male 27 110 83
19 Female 30 112 69 88
20 Male 28 112 94
21 Female 42 115 119 132 120
22 Female 28 124 123 96 137
23 Male 33 128 56 64 113
24 Female 39 129 79 135 120
25 Male 28 131 81 115 125
26 Female 27 137 120
27 Male 33 141 109
28 Male 31 142 124
19 Male 29 143 125 134 130
30 Male 31 144 147 142 140
31 Male 38 161 124
32 Male 36 195 136 129
33 Male 28 227 136 128
Minimum 77 53 47 53
25% Percentile 96 69 92 98
Median 110 83 113 125
75% Percentile 134 119.5 130.5 137
Maximum 227 147 142 161
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Appendix 3: Maximum
Resting Anal Canal Pressure 
(cmtfeO) In 20 Volunteers 
compared With 33 Patients 
with chronic anal fissures
VOLUNTEE RS PATIENTS
Sex Age MRP
Female 23 46 77
Male 31 47 77
Male 25 54 83
Male 23 63 88
Female 24 67 88
Female 23 77 93
Female 33 82 93
Female 33 86 93
Female 38 87 98
Male 31 88 101
Female 24 88 101
Male 33 89 102
Male 23 98 103
Male 21 105 108
Female 35 111 109
Female 35 121 110
Male 21 130 110
Female 38 135 110
Male 33 136 112
Male 25 175 112
115
124
128
129
131
137
141
142
143
144
161
195
227
Number of values 20 33
Minimum 46 77
25% Percentile 72 96
Median 88 110
75% Percentile 116 134
Maximum 175 227
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Appendix 4: Maximum Resting Anal Canal 
Pressure (cmFhO) after two months in 19 
patients successfully treated after a 2 month 
course
START 2 MONTHS
Sex Age
Female 40 77 55
Male 36 83 68
Male 81 88 75
Female 68 93 64
Female 28 93 75
Female 59 98 96
Female 29 103 61
Male 40 108 111
Female 27 109 66
Male 37 110 53
Male 27 110 83
Female 30 112 69
Female 42 115 119
Female 28 124 123
Male 28 131 81
Male 33 141 109
Male 29 143 125
Male 31 144 147
Male 36 195 136
Minimum 77 53
25% Percentile 93 66
Median 110 81
75% Percentile 131 119
Maximum 195 147
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Appendix 5: Maximum Resting Anal Canal 
Pressure (cmPfeO) after two months in 14 
patients who failed to heal after being treated 
after a 2 month course
START 2 MONTHS
Sex Age
Male 38 77 83
Female 35 88 90
Female 29 93 103
Female 28 101 79
Female 27 101 68
Male 35 102 79
Female 35 110 107
Male 28 112 94
Male 33 128 56
Female 39 129 79
Female 27 137 120
Male 31 142 124
Male 38 161 124
Male 28 227 136
Minimum 77 56
25% Percentile 97 79
Median 111 92
75% Percentile 139.5 122
Maximum 227 136
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Appendix 6: Maximum Resting Anal Canal 
Pressure (cmtfeO) in 19 patients who had anal 
spasm at presentation compared with 14 patients 
who did not
SPASM
NO
SPASM
93 77
93 77
103 83
108 88
110 88
110 93
112 98
112 101
115 101
124 102
128 109
131 110
137 129
141 142
143
144
161
195
227
Number of 
values 19 14
Minimum 93 77
25% Percentile 110 85.5
Median 124 99
75% Percentile 143 109.5
Maximum 227 142
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Appendix 7: Maximum Resting Anal Canal 
Pressure (cmH20) in 22 patients who had 
sentinel piles at presentation compared with 
11 patients who did not
SENTINEL
PILES
NO PILES
112 98
109 93
93 88
110 83
195 103
124 110
77 108
115 144
141 88
143 93
131 77
129
227
101
101
112
161
128
110
102
142
137
Number of 
values
22 11
Minimum 77 77
25% Percentile 106 88
Median 120 93
75% Percentile 142 108
Maximum 227 144
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Appendix 8: Maximum Resting Anal 
Canal Pressure (cmTfeO) in 12 patients 
who healed at two months after one 
course of topical diltiazem and remained 
healed at four months
START
2
MONTHS
4
MONTHS
Sex Age
Male 81 88 75 77
Female 68 93 64 100
Male 40 108 111 110
Female 27 109 66 51
Male 37 110 53 120
Female 30 112 69 88
Female 42 115 119 132
Female 28 124 123 96
Male 28 131 81 115
Male 29 143 125 134
Male 31 144 147 142
Male 36 195 136 129
Minimum 88 53 51
25% Percentile 108.5 67.5 92
Median 114 96 113
75% Percentile 137 124 130.5
Maximum 195 147 142
Appendix 9: Maximum Resting Anal 
Canal Pressure (cmFfeO) in 8 patients who 
had not healed after two months of 
therapy with topical diltiazem. These 
patients received a second course of 
diltiazem. The results in bold italics 
represent the 2 patients that had not 
healed.
START
2
MONTHS
4
MONTHS
Sex Age
Male 38 77 83 47
Female 29 93 103 101
Female 28 101 79 100
Male 35 102 79 117
Female 35 110 107 134
Male 33 128 59 64
Female 39 129 79 135
Male 28 227 136 128
Minimum 77 56 47
25% Percentile 97 79 82
Median 106 81 109
75% Percentile 128.5 105 131
Maximum 227 136 135
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Appendix 10: Maximum Resting Anal 
Canal Pressure (cmtbO) in 15 patients 
over a 6 month period with topical 
diltiazem. The results in bold italics 
represent the 2 patients that were unhealed 
at six months.
START
2
MONTHS
4
MONTHS
6
MONTHS
Sex Age
Female 40 77 55 53
Male 81 88 75 77 76
Female 68 93 64 100 76
Female 29 93 103 101 125
Female 28 101 79 100 98
Male 35 102 79 117 161
Male 40 108 111 110 134
Male 37 110 53 120 137
Female 42 115 119 132 120
Female 28 124 123 96 137
Male 33 128 59 64 113
Female 39 129 79 135 120
Male 28 131 81 115 125
Male 29 143 125 134 130
Male 31 144 147 142 140
Minimum 77 53 64 53
25% Percentile 93 64 98 98
Median 110 79 113 125
75% Percentile 129 119 133 137
Maximum 144 147 142 161
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NOVEL DELIVERY OF BOTULINUM TOXIN FOR TREATMENT 
OF ANAL FISSURES
Appendix 11: Pain scores (range 0, no pain -10, extreme pain) in patients with chronic 
anal fissures assessed over 12 weeks in 10 patents who received two 25-unit injections 
into the internal anal sphincter
Sex, age (years) START 1 week 4 weeks 8 weeks
12
weeks
Female, 32 3 1 2 1 1
Female, 44 4 2 3 2 3
Male, 38 7 6 3 1 3
Female, 43 5 4 0 0 4
Female, 26 5 4 3 3 1
Male, 22 8 5 7 8
Male, 71 6 3 4 4 3
Male, 42 6 4 2 0 0
Male, 52 7 6 7 5 6
Female, 28 8 8 8 8 7
Minimum 3 1 0 0 0
25% Percentile 4.5 2.5 2 0.5 1
Median 6 4 3 2.5 3
75% Percentile 7.5 6 7 6.5 5
Maximum 8 8 8 8 7
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Appendix 12: Incontinence scores (range 0, perfect continence -  24, totally incontinent) 
in patients with chronic anal fissures assessed over 12 weeks in 10 patents who received 
two 25-unit injections into the internal anal sphincter
Sex, age(years) START 1 week 4 weeks 8 weeks
12
weeks
Female, 32 1 4 6 3 6
Female, 44 9 10 14 15 15
Male, 38 0 0 8 3 0
Female, 43 7 9 4 6 4
Female, 26 0 0 0 0 0
Male, 22 4 4 8 4
Male, 71 7 4 4 4 0
Male, 42 4 4 2 3 0
Male, 52 3 3 3 2 3
Female, 28 0 1 0 0 0
Minimum 0 0 0 0 0
25% Percentile 0 0.5 1 1 0
Median 3.5 4 4 3 0
75% Percentile 7 6.5 8 5 5
Maximum 9 10 14 15 15
Appendix 13: Maximum Resting Anal Canal Pressure (cmtfeO) in patients with chronic 
anal fissures assessed over 12 weeks in 10 patents who received two 25-unit injections 
into the internal anal sphincter
Sex, age (years) START 1 week 4 weeks 8 weeks
12
weeks
Female, 32 105 87 80 89 95
Female, 44 77 68 81 62 91
Male, 38 170 123 105 107 107
Female, 43 91 85 104 110 108
Female, 26 80 62 76 82 74
Male, 22 129 105 105 101
Male, 71 185 166 108 108 126
Male, 42 92 72 80 66 101
Male, 52 141 77 109 54 143
Female, 28 71 37 70 51 94
Minimum 71 37 70 51 74
25% Percentile 78.5 65 78 58 92.5
Median 99 81 93 86 101
75% Percentile 155.5 114 106.5 107.5 117
Maximum 185 166 109 110 143
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SYMPATHETIC MODULATION OF THE INTERNAL ANAL 
SPHINCTER
Appendix 14: Hourly maximum Resting Anal Canal Pressure (cmH20) in 10 patients 
with chronic anal fissures and 10 volunteers who received an oral 20mg dose of 
indoramin over 3 hours
PATIENTS START 1 hour 2 hours 3 hours
Sex, Age -years
Female, 65 149 127 117
Male, 35 227 169 114 115
Male, 38 135 98 71 92
Male, 37 195 145 140 120
Female, 30 126 67 92 91
Female, 33 198 129 111 98
Female, 28 119 65 71 57
Male, 40 117 57 100 85
Female, 36 110 78 88 58
Female, 29 94 76 61 57
Minimum 94 57 61 57
25% Percentile 113.5 66 71 57.5
Median 130.5 88 96 91
75% Percentile 196.5 137 115.5 106.5
Maximum 227 169 140 120
VOLUNTEERS START 1 hour 2 hours 3 hours
Sex, Age -years
Male, 33 136 117 96 75
Female, 35 121 114 112
Male, 25 54 40 46 56
Male, 23 63 49 47 39
Female, 24 67 63 46 33
Female, 38 87 59 81 66
Male, 21 130 92 82 76
Male, 31 88 63 51 38
Female, 23 46 36 47 50
Female, 33 82 78 59 48
Minimum 46 36 46 33
25% Percentile 58.5 44.5 46.5 38.5
Median 84.5 63 55 53
75% Percentile 125.5 85 89 75.5
Maximum 136 117 114 112
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Appendix 15: Hourly maximum Resting Anal Canal Pressure (cmH20) in 10 patients
with chronic anal fissures and 10 volunteers who received an oral 4mg dose o f
salbutamol over 3 hours
PATIENTS START 1 hour 2 hours 3 hours
Sex, Age -years
Female, 65 191 110 115 127
Male, 35 172 117 126 95
Male, 38 161 92 97 82
Male, 37 173 166 142 132
Female, 30 97 82 83 92
Female, 33 194 181 113 92
Female, 28 109 92 78 57
Male, 40 121 114 72 85
Female, 36 126 84 74 53
Female, 29 101 78 75 96
Minimum 97 78 72 53
25% Percentile 105 83 74.5 69.5
Median 143.5 101 90 92
75% Percentile 182 141.5 120.5 111.5
Maximum 194 181 142 132
VOLUNTEERS START 1 hour 2 hours 3 hours
Sex, Age -years
Male, 33 89 63 86 70
Female, 35 111 90 85 77
Male, 25 175 101 118 128
Male, 23 98 57 58 64
Female, 24 88 89 85 51
Female, 38 135 87 67
Male, 21 105 92 68
Male, 31 47 44 56 47
Female, 23 77 53 47 34
Female, 33 86 65 64 71
Minimum 47 44 47 34
25% Percentile 81.5 55 57 49
Median 93.5 65 76 68
75% Percentile 123 89.5 89 74
Maximum 175 101 118 128
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Appendix 16: Hourly pulse rate ( /minute) in 10 patients with chronic anal fissures and
10 volunteers who received an oral 20mg dose of indoramin over 3 hours
PATIENTS START 1 hour 2 hours 3 hours
Sex, Age -years
Female, 65 72 72 68
Male, 35 70 65 68 72
Male, 38 68 66 60 54
Male, 37 60 64 78 90
Female, 30 84 78 84 75
Female, 33 84 75 84 80
Female, 28 60 54 60 66
Male, 40 66 60 66 66
Female, 36 66 72 72 60
Female, 29 68 72 72 66
Minimum 60 54 60 54
25% Percentile 63 62 63 63
Median 68 69 70 66
75% Percentile 78 73.5 81 77.5
Maximum 84 78 84 90
VOLUNTEERS START 1 hour 2 hours 3 hours
Sex, Age years
Male, 33 68 64 68 64
Female, 35 66 60 60
Male, 25 84 72 68 72
Male, 23 78 78 84 76
Female, 24 60 66 66 66
Female, 38 60 60 84 84
Male, 21 66 72 78 78
Male, 31 76 84 84 84
Female, 23 70 72 74 70
Female, 33 66 72 70 74
Minimum 60 60 60 60
25% Percentile 63 65 67 65
Median 67 72 72 73
75% Percentile 77 75 84 81
Maximum 84 84 84 84
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Appendix 17: Hourly pulse rate ( /minute) in 10 patients with chronic anal fissures and
10 volunteers who received an oral 4mg dose of salbutamol over 3 hours
PATIENTS START 1 hour 2 hours 3 hours
Sex, Age -years
Female, 65 64 66 68 84
Male, 35 78 74 84 78
Male, 38 75 80 78 66
Male, 37 72 84 82 78
Female, 30 78 86 82 78
Female, 33 72 85 105 90
Female, 28 66 60 72 72
Male, 40 60 92 84 66
Female, 36 84 78 90 90
Female, 29 66 78 72 66
Minimum 60 60 68 66
25% Percentile 65 70 72 66
Median 72 79 82 78
75% Percentile 78 85.5 87 87
Maximum 84 92 105 90
VOLUNTEERS START 1 hour 2 hours 3 hours
Sex, Age -years
Male, 33 60 84 68 66
Female, 35 56 60 66 68
Male, 25 70 74 85 65
Male, 23 60 72 60 66
Female, 24 72 84 78
Female, 38 84 76 80 82
Male, 21 72 60 66
Male, 31 84 84 90 84
Female, 23 60 72 78 78
Female, 33 68 80 66 72
Minimum 56 60 60 65
25% Percentile 60 72 63 66
Median 69 76 73 68
75% Percentile 78 84 82.5 80
Maximum 84 84 90 84
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Appendix 18: Hourly systolic blood pressure (mmHg) in 10 patients with chronic anal
fissures and 10 volunteers who received an oral 20mg dose of indoramin over 3 hours
PATIENTS START 1 hour 2 hours 3 hours
Sex, Age -years 185 175 175
Female, 65 120 118 120 118
Male, 35 128 126 122 114
Male, 38 122 118 118 126
Male, 37 138 134 126 128
Female, 30 142 150 144 144
Female, 33 108 102 110 112
Female, 28 129 128 122 114
Male, 40 112 115 114 112
Female, 36 108 118 118 108
Female, 29
Minimum 108 102 110 108
25% Percentile 110 116.5 116 112
Median 125 122 121 114
75% Percentile 140 142 135 127
Maximum 185 175 175 144
VOLUNTEERS START 1 hour 2 hours 3 hours
Sex, Age -years
Male, 33 112 110 108 105
Female, 35 118 112 112
Male, 25 114 114 106 110
Male, 23 132 128 116 114
Female, 24 120 134 118 134
Female, 38 130 118 114 112
Male, 21 134 116 118 104
Male, 31 108 110 112 108
Female, 23 108 104 112 118
Female, 33 110 120 114 112
Minimum 108 104 106 104
25% Percentile 109 110 110 106.5
Median 116 116 113 112
75% Percentile 131 124 117 116
Maximum 134 134 118 134
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Appendix 19: Hourly systolic blood pressure (mmHg) in 10 patients with chronic anal
fissures and 10 volunteers who received an oral 4mg dose of salbutamol over 3 hours
PATIENTS START 1 hour 2 hours 3 hours
Sex, Age -years 165 155 170 165
Female, 65 124 110 118 112
Male, 35 138 140 138 132
Male, 38 124 134 128 130
Male, 37 132 128 118 122
Female, 30 142 154 152 138
Female, 33 108 106 106 110
Female, 28 134 122 124 122
Male, 40 122 116 120 118
Female, 36 108 128 132 120
Female, 29
Minimum 108 106 106 110
25% Percentile 115 113 118 115
Median 128 128 126 122
75% Percentile 140 147 145 135
Maximum 165 155 170 165
VOLUNTEERS START 1 hour 2 hours 3 hours
Sex, Age -years
Male, 33 110 122 118 112
Female, 35 108 111 120 115
Male, 25 114 122 124 116
Male, 23 124 120 114 132
Female, 24 132 130 128
Female, 38 128 134 124 122
Male, 21 118 116 114
Male, 31 122 118 122 128
Female, 23 114 116 118 114
Female, 33 110 110 120 116
Minimum 108 110 114 112
25% Percentile 110 113.5 117 114
Median 116 120 120 116
75% Percentile 126 126 124 125
Maximum 132 134 128 132
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Appendix 20: Maximum Resting Anal Canal Pressure (cmPfcO) in eight volunteers who 
received varying doses of topical indoramin (placebo, lOmg, 20mg, 30mg, 40mg)
Placebo
start 1 hour 3 hours 5 hours 7 hours
135 125 94 111 115
99 78 68 68 72
119 116 109 88 138
108 82 95 102
115 120
120 104 92 90
74 72
110 69 75 56
10 mg
start 1 hour 3 hours 5 hours 7 hours
159 124 118 95 123
79 49 62 54
118 97 74 95
79 62 87
104 104 125
122 118 143
78 60 67
99 92 96 72 68
20 mg
start 1 hour 3 hours 5 hours 7 hours
182 122 109 117 105
79 52 77
138 112 105
83 85 88
123 102 97 89
113 73 88
112 79 64 89 101
85 75 35 82 65
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30mg
start 1 hour 3 hours 5 hours 7 hours
147 105 124 109
87 67 51 63 94
126 97 127
111 100 83 77 67
121 144 117
73 63 72
98 78 80 78
82 47 55 46 48
40mg
start 1 hour 3 hours 5 hours 7 hours
147 151 132
77 58 83
114 123 100
99 90 89
105 90 108
120 96 106 84 92
90 89 68 84
92 82 96
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LABORATORY EXPERIMENTS
Appendix 21: Effect of histamine (lx 10'5, 3 x 10‘5, lx 10^M) on the basal tone (g) of 
guinea-pig isolated IAS muscle strips.
basal new tone significance
lx  10^M 0.21 2.5
0.04 0.83
0.27 1.87
0.44 2.4 P =  0.014
3 x 10°M 0.27 0.73
0.47 1.38
0.09 0.72
0.24 0.93
0.36 1.95
0.38 2.12 P =  0.006
lx  10°M 0.4 0.99
0.35 1.04
0.38 2.12
0.45 1.97 P =  0.030
Appendix 22: Effect of atropine (1 x 10"6 M) on basal tone (g) of guinea-pig isolated IAS 
muscle strips.
basal new tone significance
1 xlO ^M 0.36 0.41
0.48 0.61
0.07 0.05
0.4 0.47
0.17 0.22
0.04 0.06 P =  0.058
Appendix 23: Effect of methoxamine (1 x 10"4 M) on basal tone (g) of guinea-pig 
isolated IAS muscle strips.
basal new tone significance
1 x lO^M 0.27 0.26
0.27 0.14
0.11 0.54
0.27 0.62 P =  0.324
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Appendix 24: Effect of histamine on tone in 3 isolated porcine IAS muscle strips
[Histamine]
M
Contraction (% of maximal 
response)
1x10' 3.3 11.3 6.1
3x1 O'7 5.7 24.1 11.7
lxlO* 15.4 39.6 24.2
3X10* 25.2 51.9 35.2
lxlO'5 42.3 68.9 51.1
3x10° 64.2 82.1 62.5
1x10^ 85.4 83.5 79.2
3x1c4 88.6 92.0 86.7
lxlO'J 100 100 100
Appendix 25: Effect of phenylephrine on contractile response of porcine IAS muscle 
strips.
[Phenylephrine]
M
Contraction (% of maximal response)
lx l  O'* 6.7 2.7 2.9 8.2 4.6 11.6 7.0
3x10-* 9.0 4.4 5.2 17.4 4.6 14.2 8.7
1x10' 10.4 10.2 10.2 23.2 8.3 21.1 13.1
3x10'7 23.9 20.7 16.1 28.9 11.0 22.4 17.8
lx l  O'6 32.1 35.3 29.7 41.4 22.0 31.9 27.7
3x10* 53.7 59.7 49.5 80.3 37.6 45.3 44.0
lxlO'5 69.4 76.3 66.9 94.6 61.5 65.9 62.4
3x10° 84.3 93.9 83.6 98.5 72.5 84.1 86.3
1x1c4 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Appendix 26: Effect of isoprenaline on the relaxant response of porcine IAS muscle 
strips
[Isoprenaline]
M
Relaxation (% of basal tone)
lx l  0'7 6.5 14.8 5.7
lx l  O'6 4.4 17.6 3.3
lx l  0'5 7.6 20.2 6.2 9.1
lx l  O'4 29.6 68.2 8.6 20.6 6.9
X o u 22.0 48.3 6.1 14.1 4.7
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Appendix 27: Effect of GTN on the relaxant response of porcine IAS muscle strips
[GTN]
M
Relaxation (% of basal tone)
2.2x1 O'4 44.4 0.4 1.2 1.9 7.5 66.9 3.7 4.8
6.6x1 O’4 56.9 0.4 7.6 6.4 3 73.4 3.5 22.1
2.2xl0'3 63.9 10.5 17.3 5.1 76.6 10.2 17.9 43.6
2.2x10"* 11 3.4 58.1 3 18.2 26.2 1.3 1.5
6.6x10"* 13.7 76.5 15.3 34.6 52.5 23.8 16.2 16.4
2.2xl0'3 7.7 5.3 76.8 22.1 58.4 51.1 25.5 29
2.2x10"* 0.7 23 2.6 49.4 3 1.7 7.7
6.6xl04 32.2 11 63.7 46 32.5 22.9
2.2x1 O’3 38.3 34.5 8.4 58.4 57.7 52.3 41.1
Appendix 28: Effect of L-NAME on the acetylcholine induced relaxation of porcine IAS 
muscle strips.
Relaxation (% of basal tone)
Ach (1x10-*^ 11.0 2.0 32.4 26.6 60.9 66.6 17.9
Ach (lx l0‘4M,+ L-Nameclx,u^ M) 0.6 1.1 0.6 0.3 0.7 1.8 2.1
Appendix 29: Effect of suramin on the ATP induced relaxation of porcine IAS muscle 
strips.
Relaxation (% of basal tone)
ATP (lx l0‘JM) 24.0 5.2 3.4 4.6 24.2 8.7 21.3
A T T J  (lX lO -^ M ) i • (3 x 10-ATPv ' + suraminv
4 M )
23.6 7.2 17.2 14.8 33.2 15.9 30.1
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Appendix 30: Effect of electrical field stimulation (EFS: 0.3 ms, 0.5-32 Hz, 60 V, train 
length 10 s, interval 110 s) on the relaxant amplitude of porcine IAS muscle strips.
Stimulation
frequency
(Hz)
Relaxant Amplitude (g)
0.5 0.7 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1
1 1.2 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.1
2 2.0 0.2 0.2 0.1 0.1 0.3 0.5 0.2 0.1
4 2.7 0.4 0.3 0.2 0.1 0.4 1.0 0.3 0.3
8 2.9 0.9 0.5 0.2 0.1 0.6 1.6 0.3 0.5
16 3.2 1.3 0.5 0.2 0.2 0.6 1.9 0.3 0.5
32 2.8 1.4 0.5 0.2 0.1 0.6 1.9 0.2 0.6
Appendix 31: Effect of L-NAME (1x10 V) on the EFS-induced (EFS: 0.3 ms, 0.5-32 
Hz, 60 V, train length 10 s, interval 110 s) relaxant amplitude of the porcine IAS muscle 
strips.
Stimulation
frequency
(Hz)
Relaxant Amplitude (g)
0.5 0.2 0.1 0.1 0.1
1 0.2 0.2 0.2 0.1
2 0.2 0.2 0.2 0.1
4 0.2 0.1 0.3 0.2
8 0.2 0.2 0.5 0.3
16 0.2 0.2 0.6 0.3
32 0.3 0.2 0.7 0.4
Appendix 32: Effect of suramin PXIO^M) on the relaxant response of porcine IAS 
muscle strips due to EFS (EFS: 0.3 ms, 0.5-32 Hz, 60 V, train length 10 s, interval 110 s).
Stimulation
frequency
(Hz)
control relaxation (g)
0.5 2.0 1.7 5.5 3.2 5.3
1 6.2 2.5 8.9 4.0 4.1
2 9.9 5.0 14.1 5.6 3.3
4 16.5 7.5 21.6 8.6 6.5
8 24.0 9.9 26.3 12.5 6.9
16 21.8 10.2 29.1 12.1 4.1
32 20.4 8.6 28.8 13.1 5.3
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Stimulation
frequency
(Hz)
with suramin (g)
0.6 2.7 2.6 3.6 1.3 2.1
1 6.7 4.5 5.9 2.4 4.4
2 14.5 9.5 9.7 4.5 4.4
4 22.9 17.4 15.5 7.1 4.6
8 30.2 23.9 19.8 9.6 3.2
16 32.5 25.6 21.4 11.5 5.0
32 29.3 19.9 20.7 10.7 6.2
Appendix 33: Effect of prazosin (lxlO"7 M) on the relaxant response of porcine IAS 
muscle strips due to EFS (EFS: 0.3 ms, 0.5-32 Hz, 60 V, train length 10 s, interval 110 s).
Stimulation
frequency
(Hz)
control relaxation (g)
0.5 4.2 14.1 12.8 14.3 3.3 10.8
1 5.9 15.7 8.6 21.4 10.2 19.3
2 11.8 26 10.7 31.7 15.9 26.5
4 17.4 29.1 17.1 40.5 26.3 38.6
8 19.9 30.7 21.4 45.2 34.4 39.8
16 8.5 9.4 22.5 46 36.6 18.1
32 3.8 7.9 25.1 42.9 35.8 9.6
with prazosin (g)
0.5 5.5 16.9 9.8 20.7 8.1 9.8
1 9.7 36.4 12.8 25.2 21.3 23.6
2 19.8 40.3 20.4 36 33.4 39
4 34.5 52.6 22.3 43.2 44.5 56.1
8 65.4 57.8 24.2 50.4 50 63.4
16 34.1 48.7 23 46.8 49.8 60.2
32 31.3 33.8 30.2 38.7 49.6 56.1
Appendix 34: Effect of prazosin (lxl O'6 M) on the histamine dose-response curve of 
porcine IAS muscle strips.
[Histamine]
M
Contraction (% maximum) with prazosin
1x10' 1.0 22.4 8.7 10.8 6.8 1.5
3x10 7 6.9 37.0 16.0 25.5 16.1 1.9
1x10-° 8.8 54.2 32.0 33.3 21.4 10.2
3x10* 34.3 69.3 46.1 47.1 24.0 18.4
1x10° 59.8 84.9 67.0 59.8 42.7 35.9
3x10° 73.5 97.4 81.6 69.6 65.1 49.5
lxlO4 100.0 100.0 100.0 78.4 82.3 68.9
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Appendix 35: Effect of the a i -antagonist indoramin (lxlO"7 M) on the phenylephrine 
dose-response curve in porcine IAS muscle strips.
[Phenylephrine]
M
Tone (% of maximally raised tone)
lxlO'8 6.7 2.7 2.9 8.2 4.6 11.6 7.0
3xl0'8 9.0 4.4 5.2 17.4 4.6 14.2 8.7
1x10" 10.4 10.2 10.2 23.2 8.3 21.1 13.1
3x10" 23.9 20.7 16.1 28.9 11.0 22.4 17.8
lxlO-6 32.1 35.3 29.7 41.4 22.0 31.9 27.7
3x10* 53.7 59.7 49.5 80.3 37.6 45.3 44.0
1x10* 69.4 76.3 66.9 94.6 61.5 65.9 62.4
3x10° 84.3 93.9 83.6 98.5 72.5 84.1 86.3
lxlO-4 100.0 100.0 100.0 100.0 100.0 100.0 100.0
with indoramin
1x10'^ 0.7 0.3 0.3 0.7 3.7 1.3 0.6
3x1c8 4.5 0.7 1.0 0.7 3.7 2.6 0.3
1x10" 4.5 3.7 1.6 0.2 5.5 5.6 0.6
3x10" 5.2 3.4 1.0 0.9 1.8 8.2 2.6
1x10* 11.2 7.1 2.9 0.4 4.6 20.7 8.5
3x10* 12.7 10.8 4.4 3.3 7.3 40.5 15.2
1x10* 17.9 26.8 13.8 7.4 14.7 67.2 33.5
3x10* 29.9 53.2 30.2 17.6 51.4 94.4 69.1
lx l O'4 36.6 73.6 50.3 29.7 68.8 112.9 97.1
Appendix 36: Effect of one-hour incubation of one unit of botulinum toxin (Botox®) on 
the acetylcholine (Ixl0-3M) induced relaxation of porcine IAS muscle strips.
Relaxation (% basal tone)
Ach 23.9 60.5 50.9 25.2 59.0
Ach + Botox 25.0 57.6 56.0 19.0 64.0
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Appendix 37: Increase of the relaxant response of porcine internal anal sphincter (IAS) 
to electrical field stimulation (EFS: 0.3 ms, 16 Hz, 60 V, train length 10 s, interval 110 s) 
on tone raised by phenylephrine (1 pM-1 mM).
Tone
(%
maximal
tone)
Relaxation
(%
maximal
tone)
Tone
(%
maximal
tone)
Relaxation
(%
maximal
tone)
Tone
(%
maximal
tone)
Relaxation
(%
maximal
tone)
29.8 6.4 98.7 3.6 99.0 10.3
26.1 6.0 91.6 3.4 97.2 8.4
34.2 10.7 93.1 3.4 94.9 8.7
45.7 12.1 38.2 3.3 92.1 8.3
61.1 13.6 43.4 4.7 60.3 5.6
74.9 13.6 48.6 5.5 65.3 6.1
91.7 12.2 49.1 7.6 68.3 5.9
98.2 10.7 58.1 9.2 77.3 6.9
100.0 9.4 64.7 11.8 83.5 7.5
33.8 7.4 69.2 12.6 90.7 7.2
36.3 4.2 71.1 12.6 93.1 8.3
45.8 6.0 78.7 12.1 97.3 8.0
51.8 7.0 88.9 14.5 95.5 7.2
61.3 10.6 90.5 12.6 100.0 8.8
68.3 13.0 94.1 14.5 81.2 18.8
74.3 16.2 98.8 13.7 86.8 24.8
75.4 17.6 100.0 12.3 86.3 22.6
78.5 16.9 17.6 6.7 93.6 25.6
83.1 19.4 20.6 6.8 95.7 24.4
90.1 21.8 22.7 7.6 99.1 26.1
94.7 24.6 22.6 7.5 96.6 26.1
97.5 25.7 31.4 8.9 100.0 28.2
97.9 25.0 38.9 10.6 97.9 26.9
100.0 26.1 39.7 10.0 100.0 26.1
99.6 26.1 54.8 14.5 42.9 16.8
15.7 2.1 63.7 15.2 46.8 16.1
15.0 1.7 69.4 12.2 55.5 21.0
14.2 1.1 85.6 15.1 60.3 22.9
15.0 1.3 84.5 13.3 61.6 26.1
65.2 2.6 85.8 12.1 64.5 22.6
68.2 3.0 92.0 11.4 73.2 27.4
76.6 2.6 95.6 9.6 79.7 27.7
82.1 2.8 96.5 7.8 89.4 27.1
87.7 2.6 96.7 8.3 91.9 25.2
92.3 3.2 100.0 9.1 96.1 25.5
95.1 3.2 81.9 15.2 98.7 26.5
95.7 3.0 96.1 19.4 95.8 25.5
99.1 3.2 98.4 18.8 100.0 26.8
99.6 3.6 97.7 18.4 63.8 8.1
100.0 3.4 100.0 20.4 75.4 12.3
81.6 16.2 81.2 14.6
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Appendix 38: Residual tone of response to electrical field stimulation (EFS: 0.3 ms, 16 
Hz, 60 V, train length 10 s, interval 110 s) on tone raised by phenylephrine (1 pM-1 mM) 
in the porcine internal anal sphincter (IAS).
Tone (% 
maximal 
tone)
Residual 
tone (% 
maximal)
Tone (% 
maximal 
tone)
Residual 
tone (% 
maximal)
Tone(% 
maximal 
tone)
Residual 
tone (% 
maximal)
29.8 23.5 98.7 95.1 99.0 88.7
26.1 20.1 91.6 88.2 97.2 88.8
34.2 23.5 93.1 89.7 94.9 86.2
45.7 33.7 38.2 34.8 92.1 83.8
61.1 47.5 43.4 38.6 60.3 54.7
74.9 61.3 48.6 43.1 65.3 59.2
91.7 79.5 49.1 41.5 68.3 62.4
98.2 87.5 58.1 48.8 77.3 70.4
100.0 90.6 64.7 52.8 83.5 76.0
33.8 26.4 69.2 56.6 90.7 83.5
36.3 32.0 71.1 58.5 93.1 84.8
45.8 39.8 78.7 66.6 97.3 89.3
51.8 44.7 88.9 74.4 95.5 88.3
61.3 50.7 90.5 78.0 100.0 91.2
68.3 55.3 94.1 79.6 81.2 62.4
74.3 58.1 98.8 85.1 86.8 62.0
75.4 57.7 100.0 87.7 86.3 63.7
78.5 61.6 17.6 10.9 93.6 67.9
83.1 63.7 20.6 13.8 95.7 71.4
90.1 68.3 22.7 15.1 99.1 73.1
94.7 70.1 22.6 15.1 96.6 70.5
97.5 71.8 31.4 22.5 100.0 71.8
97.9 72.9 38.9 28.3 97.9 70.9
100.0 73.9 39.7 29.8 100.0 73.9
99.6 73.6 54.8 40.2 42.9 26.1
15.7 13.6 63.7 48.4 46.8 30.6
15.0 13.3 69.4 57.2 55.5 34.5
14.2 13.1 85.6 70.4 60.3 37.4
15.0 13.6 84.5 71.3 61.6 35.5
65.2 62.6 85.8 73.7 64.5 41.9
68.2 65.2 92.0 80.6 73.2 45.8
76.6 74.0 95.6 86.0 79.7 51.9
82.1 79.3 96.5 88.7 89.4 62.3
87.7 85.0 96.7 88.4 91.9 66.8
92.3 89.2 100.0 90.9 96.1 70.6
95.1 92.0 63.8 55.7 98.7 72.3
95.7 92.7 75.4 63.1 95.8 70.3
99.1 95.9 81.2 66.7 100.0 73.2
99.6 96.1 81.6 65.4
100.0 96.6 81.9 66.7
97.7 79.3 96.1 76.7
100.0 79.6 98.4 79.6
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Appendix 39: Relationship of tone (% maximum) to residual tone (% maximum) for
porcine internal anal sphincter (IAS) relaxation induced by glyceryl trinitrate (GTN: 
2.2x1 O'4 M, 6.6xl04 M ,2 .2 x 10‘3M ).
2.2xb 6.6x
2to
2 .2 x 10 '3 M
Tone(% 
maximum)
Residual 
tone (% 
maximal)
Tone(% 
maximum)
Residual 
tone (% 
maximal)
Tone(% 
maximum)
Residual 
tone (% 
maximal)
17.5 9.8 17.5 7.6 17.5 6.3
56.6 55.6 56.6 55.6 56.6 50
100 98.8 100 92.4 100 82.7
18 17.6 18 16.8 100 95.4
100 83.5 100 89.3 22.5 5.3
22.5 7.5 22.5 6 69.1 60.3
69.1 64.7 69.1 64.9 28.5 23.4
100 95.2 100 77.9 100 56.4
33.3 29.7 33.3 28.8 65.3 60.3
100 91.8 44.9 10.6 100 95
44.9 18.8 82.1 69.6 44.9 10.4
82.1 79.7 100 65.4 82.1 64
100 80.9 52.4 24.9 100 41.6
52.4 38.7 88.8 67.7 52.4 25.7
88.8 87.7 80.3 68 88.8 66.2
80.3 74.7 100 83.6 80.3 53.9
100 99.3 47 31.9 100 71.7
47 36.2 100 90.8 47 30.8
100 81.1 30.6 8.6 100 84.3
30.6 11.9 91.1 49.2 30.6 9.8
91.1 88.4 72.5 48.9 91.1 38.5
72.5 71.3 100 82.6 72.5 34.6
100 98.8 100 63
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Appendix 40: Relationship of tone (% maximum) to residual tone (% maximum) for 
porcine internal anal sphincter (IAS) relaxation induced by diltiazem (lxlO'4 M).
Tone (% 
maximum)
Residual 
tone (% 
maximal)
100.0 86.2
93.1 86.2
72.4 62.9
69.8 64.7
89.7 87.1
100.0 74.0
44.6 37.3
27.9 24.5
52.8 45.6
88.2 86.6
90.0 78.0
97.4 94.4
100.0 97.0
81.6 69.6
100.0 84.3
82.9 77.4
85.7 81.1
83.9 81.6
82.0 69.1
100.0 82.9
83.9 80.6
84.3 80.2
60.1 54.0
84.8 77.8
78.8 74.7
92.4 88.4
100.0 93.9
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